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Resumo 
Os Líquidos Iónicos (LIs) são uma classe de compostos que se popularizaram em 
meados da década de 90 do século XX. Apesar de os LIs serem definidos por uma 
propriedade física (ponto de fusão), muitas das suas aplicações actuais baseiam-se nas 
suas propriedades biológicas. Com efeito, o uso de um fármaco na forma líquida é 
susceptível de evitar alguns dos problemas inerentes ao polimorfismo, responsável por 
influenciar a solubilidade da droga e a sua dosagem. Adicionalmente, o arranjo de um 
catião ou anião com um fármaco pode: a) alterar a classificação biofarmacêutica do 
fármaco; b) influenciar o processo de formulação do fármaco; e c) alterar as 
propriedades biológicas do Ingrediente Farmacêutico Activo (IFA).  
A presente Tese tem como objectivo a síntese e o estudo das propriedades físico-
químicas e biológicas de LIs como IFAs a partir de antibióticos beta-lactâmicos 
(ampicillina, penicilina G e amoxicilina) e a partir do anti-fúngico anfotericina B. Os 
IFAs usados foram combinados, através de métodos de neutralização tamponados, 
com adequados catiões hidróxidos. Os catiões hidróxido foram obtidos a partir de 
halogenetos através troca iónica na resina de Amberlite (na forma OH). Os estudos das 
propriedades biológicas destes novos compostos foram feitos usando os métodos 
colorimétricos e de microdiluição. 
No total, foram sintetizados 19 LIs (6 LIs baseados na ampicilina, 4 LIs baseados na 
amoxicilina, 6 LIs baseados na penicilina G, e 4 LIs baseados na anfotericina B) 
caracterizados por métodos espectroscópicos e analíticos para confirmar a sua 
estrutura e pureza. O estudo das propriedades biológicas dos LIs sintetizados 
demonstrou que estes possuem actividade antimicrobiana em bactérias e fungos, 
inclusive em bactérias resistentes. Este trabalho permitiu, ainda, verificar que os LIs 
baseados na ampicilina poderiam funcionar como agentes anti-tumorais. Estes 
resultados confirmam que a escolha do contra-ião pode provocar alterações nas 
propriedades físico-químicas e biológicas dos IFA-LIs com grande impacto, tendo em 
conta as suas aplicações. 
Palavras-chave: Ingrediente Farmacêutico Activo, Líquidos Iónicos; Agentes 
antimicrobianos, Resistência a antimicrobianos; Actividade anti-tumoral.  
 
VIII 
 
  
 
IX 
 
Abstract 
Ionic Liquids (ILs) are class of compounds, which have become popular since the mid-
1990s. Despite the fact that ILs are defined by one physical property (melting point), 
many of the potential applications are now related to their biological properties. The 
use of a drug as a liquid can avoid some problems related to polymorphism which can 
influence a drug´s solubility and thus its dosages. Also, the arrangement of the anion 
or cation with a specific drug might be relevant in order to: a) change the 
correspondent biopharmaceutical drug classification system; b) for the drug 
formulation process and c) the change the Active Pharmaceutical Ingredients’ (APIs). 
The main goal of this Thesis is the synthesis and study of physicochemical and 
biological properties of ILs as APIs from beta-lactam antibiotics (ampicillin, penicillin 
G and amoxicillin) and from the anti-fungal Amphotericin B. All the APIs used here 
were neutralized in a buffer appropriate hydroxide cations. The cation hydroxide was 
obtained on Amberlite resin (in the OH form) in order to exchange halides. The 
biological studies of these new compounds were made using techniques like the micro 
dilution and colorimetric methods.  
Overall a total of 19 new ILs were synthesised (6 ILs based on ampicillin, 4 ILs, based 
on amoxicillin, 6 ILs based on penicillin G and 4 ILs based on amphotericin B) and 
characterized by spectroscopic and analytical methods in order to confirm their 
structure and purity. The study of the biological properties of the synthesised ILs 
showed that some have antimicrobial activity against bacteria and yeast cells, even in 
resistant bacteria. Also this work allowed to show that ILs based on ampicillin could be 
used as anti-tumour agents. This proves that with a careful selection of the organic 
cation, it is possible to provoke important physico-chemical and biological alteration in 
the properties of ILs-APIs with great impact, having in mind their applications. 
 
Keywords: Active pharmaceutical ingredients, Ionic Liquids; Antimicrobial agents, 
Antimicrobial resistance; Anti-tumoral activity.  
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Objectives and General Plan 
 
 
1.1 Study Approach 
Ionic Liquids (ILs) are a new type of compounds, which have become a hot topic since 
the mid-1990s1. A literature search in Web of Science® database has revealed that the 
term “Ionic Liquids” in 1990 only had 3 results, in 2002, it had 485 results and in 2012, 
it had 3461 results (Figure 1.1). ILs have been attracting a great interest in the last 
decade. At the same time, there has been a growing awareness of the range of 
properties that ionic liquids can possess2.  
 
Figure 1.1 Publication frequency of the term “Ionic Liquids” obtained from Web of Science® 
database. 
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The definition of ILs, although ambiguous, is generally defined as salts with melting 
points below 100 oC (many are liquid at room temperature), and composed only by 
discrete cations and anions3. ILs are not new compounds, they have been known for 
over a century, but just quite recently they have become under intense worldwide 
scrutiny, not only due to the implications of their use as solvents3,4, but mainly because 
of the biological applications of ILs. Biologically active ions have been used to make 
new ILs. However, the primary driver for these materials has been the use of ions of 
known low toxicity to obtain the IL physical property set5. They have been used as 
potential alternatives to the classical volatile organic solvents2,6-9. 
Recently, the attention for ILs came from other areas like biology and medicine. 
Despite the fact that ILs today are defined by one physical property (melting point), 
many of the potential applications are now using combinations of chemical or 
biological properties, such as in the study of energetic materials or pharmaceutical ILs9-
11. ILs are indeed tuneable, multipurpose materials for a variety of applications, rather 
than just solvents12 (Figure 1.2). 
 
Figure 1.2 Examples of some applications of ILs (adapted from Plechkova Seddon13). 
Chapter 1 Objectives and General Plan 
5 
As described below, the present work was designed in order to develop new methods 
of producing ILs based on Active Pharmaceutical Ingredients (API) and the study of 
their biological applications. This approach could be particularly useful for the 
pharmaceutical industry because ILs can offer new and distinctive properties 
compared to the solid pharmaceutical forms.  
The selected pharmaceutical drugs were divided in two classes: 1) beta-lactam 
antibiotics 2) anti-fungal (Amphotericin B). For all the cases, the drugs were used as 
anion combined with organic cations based on imidazolium, ammonium, 
phosphonium and pyridinium structures. 
The organic cations such as cetylpyridinium, choline and imidazolium structures were 
selected based on their biocompatibility and recent applications in the pharmacy field9. 
Cetylpyridinium is a cation and is used as an antiseptic, present in most toothpastes14-
16. Choline is an available metabolite of phosphatidylcholine and has an important 
contribution in both proliferative growth and programmed cell death17. Imidazolium 
cations are one of the most common cations in ILs field and they are being applied as 
antibacterial18-21, antifungal22 and anti-tumour23. There are also some studies about the 
toxicological effect of these cations24,25. 
A more sustainable synthetic strategy was explored for all the Active Pharmaceutical 
Ingredients – Ionic Liquids (API-ILs) according with the final interest and the API 
stability. The most conventional synthetic method for the preparation of ILs involves a 
metathesis reaction step by the anion exchange of halide salts with adequate metal 
salts. The pure IL can be obtained by the elimination of undesired inorganic salts 
(mainly sodium, potassium or lithium chloride or bromide) using a precipitation 
followed by filtration or other efficient separation processes such as ultra or 
nanofiltration methods. This work further explores ion exchange resin methods 
recently developed by Fukumoto et al26. 
After the synthesis and purifications of ILs, based on beta-lactam antibiotics, it was 
necessary to understand their biological behavior. We intended to study their 
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antibacterial activity against sensitive Gram-negative bacteria Escherichia coli ATCC 
25922 and Klebsiella pneumonia (clinically isolated), as well as Gram-positive 
Staphylococcus aureus ATCC 25923, Staphylococcus epidermidis and Enterococcus faecalis. 
The arising resistance developed by bacteria to antibiotics is a serious public health 
threat and needs new and urgent actions such as the development of new drugs that 
show an efficient antimicrobial activity. In this context, we also intended to study the 
antibacterial activity of these new compounds against a panel of resistant bacteria 
(clinically isolated strains): E. coli CTX M9, E. coli TEM CTX M9, E. coli TEM1, E. coli 
CTX M2, E. coli AmpC Mox227-29.To better understand the behaviour of these drugs in 
human cell line and to explore the dual activity (antibacterial and anti-tumour) of the 
ILs with ampicillin anion [Amp]23,30,31, we also studied anti-proliferative activity against 
five different human cancer cell lines, in particular T47D (breast), PC3 (prostate), 
HepG2 (liver), MG63 (osteosarcoma) and RKO (colon) and two primary human cell 
types, namely, skin fibroblasts (SF)and gingival fibroblasts (GF). On the one hand, the 
right conjugation of the cation and the anion can be relevant on modifying the 
correspondent biopharmaceutic drug classification system (BCS)9,32, as well as their 
drug formulation process. On the other hand it increases the activity of the drug or 
gives the drug a new function.  
This work also pretends to show the applications of the neutralization method using 
exchange resin in pharmaceutical industry. The applications of this method are 
described on the synthesis of Amphotericin B (AmphB) conjugated with different 
cations. AmphB is a polyene antibiotic and one of the most frequently used against 
fungal infections33. Due to the fact that AmphB is insoluble in water there are two ways 
of administering AmphB. One is through the addition of sodium desoxycholate to 
form a mixture, which provides a colloidal dispersion for intravenous infusion, 
following reconstitution (Fungizone)33,34. But this approach has some inconvenient 
side effects such as nephrotoxicity33,35. The other form of administration is by single 
bilayer liposomal drug delivery system (Ambisome®)33,36. This allows large dose 
tolerance and less side effects but needs more repetitive administrations. 
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1.2 Objectives 
The general objectives of the present work were: 
a) the synthesis of ILs based on antibiotics (ampicillin, penicillin G and 
amoxicillin) and Amphotericin B 
b) the study of the physical and chemical properties of the compounds newly 
synthetized; 
c) the study of the biological properties of the new compounds obtained.  
c1) the study of antimicrobial activity on bacteria and yeast cells 
c2) the study of cellular viability and the cytotoxicity of the new 
compounds obtained on human cell lines 
The particular objectives of each chapter are described as follows: 
Chapter 4 – the objectives were to develop a method to synthesize ILs 
based on ampicillin and to analyze the physical and chemical properties of 
these new ILs. 
Chapter 5 – in this chapter the aims were to study the antibacterial 
activity of ILs based on ampicillin against Gram-positive and Gram-negative 
and against resistant strains and to compare the results with sodium ampicillin. 
Chapter 6 – the goal was to study the anti-proliferative activity against 
five different human cancer cell lines, in particular T47D (breast), PC3 
(prostate), HepG2 (liver), MG63 (osteosarcoma) and RKO (colon) of the 
Ampicillin-ILs. Besides that, evaluate the toxicity on two human cell lines. 
Chapter 7 – Here, the intention was to synthetize several ILs based on 
beta-antibiotics (penicillin G and amoxicillin) and the anti-fungal drug 
(amphotericin B) as well as to evaluate their biological behaviour. 
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1.3 General Plan 
The present work is composed of 9 chapters, including the current chapter describing 
the objectives and the general plan of the work developed (Chapter 1). In Chapter 2 the 
state of the art of the work in ILs and the importance that ILs have on the development 
of APIs is described. A mini review in ILs as APIs was included in this chapter (the 
content of this subchapter was published in Chemmedchem, 2011, 6, 975-9859). Chapter 3 
describes all the material and methods used during this work. Chapter 4, Chapter 5, 6, 
and 7 describe the work developed according to specific objectives. These Chapters 
present the results obtained, and are reproductions of the papers that have already 
been published, accepted or submitted. 
In Chapter 4 – Development of Novel Ionic Liquids Based on Ampicillin, which was 
published in Medchemcomm, 2012, 3, 494-497, describes a new methodology of the 
synthesis of ampicillin ILs and the relevant physical properties of these novel ionic 
liquids based on ampicillin. 
In Chapter 5 – Antibacterial Activity of Ionic Liquids Based on Ampicillin Against 
Resistant Bacteria - the antibacterial activity of new ionic liquids (ILs) containing 
ampicillin anion was described in comparison to sodium salt of ampicillin on resistant 
bacteria. This chapter was submitted to RSC Advances and is a reproduction of the 
paper.  
On the other hand, Chapter 6 – Anti-tumoral Activity of Ampicillin Ionic Liquids 
and Their Salts, describes anti-proliferative effects against different tumour cell lines 
using innovative APIs. The content of this chapter is a reproduction of a manuscript 
ready to submit.  
Chapter 8 – Discussion and Conclusion, gives a general discussion of all the work, 
summarizing the main conclusions. In this chapter the future perspectives are also 
presented. 
Chapter 9 – References, this presents the bibliography used. 
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2 
 
General Introduction 
 
 
2.1 Active Pharmaceutical Ingredients 
The World Health Organization (WHO) defines APIs as “a substance used in a finished 
pharmaceutical product (FPP), intended to furnish pharmacological activity or to 
otherwise have direct effect in the diagnosis, cure, mitigation, treatment or prevention 
of a disease, or to have direct effect in restoring, correcting or modifying physiological 
functions in human beings”37. Therefore, the API is the active compound present in a 
drug while the inactive substances are the excipients. For the pharmaceutical industry, 
the differences between APIs and drugs are of extreme importance. Understanding 
these differences is fundamental for manufacturers to specialize in, for regulators to 
focus on resources; and for pharmacists to produce equivalents to brand name 
products. 
2.2 Antimicrobials Agents 
2.2.1 Beta-lactam Antibiotics 
A compound responsible for killing or inhibiting the growth of a microorganism is 
called an antimicrobial agent38. An antibiotic compound indicates that it came from a 
natural source.38 
There are many classes of antibiotics. One of the most important, due to its extensive 
use are the beta-lactamic antibiotics. This class is characterized by the presence of a 
beta-lactam ring, a highly strained and reactive cycle amide38. Attending to the type of 
ring structure, this class of antibiotics is divided into several groups, being the most 
important: penam, penem, carbapenem, cephem and monobactam (Figure 2.1). 
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Figure 2.1 General strutures for the five relevant ring strutures of beta-lactams. 
The largest group of beta-lactam antibiotics are penams. This group includes penicillin, 
ampicillin and amoxicillin. Penams are composed of an enclosed dipeptide formed by 
the condensation of L-Cysteine and D-Valine resulting in the beta-lactam ring and in 
the thiazolidinic ring producing the 6-aminopenicillanic acid38,39. 
Beta-lactamic antibiotics are specific for bacteria. Bacteria are prokaryotic cells, so they 
have many structural and metabolic pathways that are different from eukaryotic cells38. 
2.2.2 Anti-fungal Agents 
Amphotericin B (AmphB) entered in clinics in 1958 (Figure 2.2) and for nearly 30 years 
it was almost the only drug available for controlling some severe fungal infections40,41. 
There are other types of anti-fungals; especially heterocyclic compounds like imidazole 
or triazole40,42. 
 
Figure 2.2 Struture of Amphotericin B. 
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At the present time, the most common antifungal therapies are limited because of 
drug’s toxicity42. Nevertheless, AmphB, such a well-known nephrotoxic drug continues 
to be the drug of choice against life-threatening systemic infections with fungi, such as 
Candida albicans or Aspergillus fumigatus42 and also against visceral and cutaneous 
leishmaniasis. To avoid and decrease the toxicity of AmphB new formulations have 
been made since 199043. 
AmphB is a low-soluble polyene antifungal which is able to self-aggregate43 and is the 
most important member of the mycosamine family, which includes nystatin, candidin 
and rimodicin. AmphB at an industrial scale is extracted from Streptomyces nodosus43,44. 
In 1988 the total synthesis of AmphB was described by Nicolaou et al.45 but the 
biotechnological production was much cheaper and more efficient44. There have been 
some innovations in synthetic procedures, but the focus is in the synthesis of new 
analogues with improved antifungal activity and/or water solubility44. AmphB is a 
yellow product and has a polar and apolar side of the lactone ring giving the molecule 
its amphiphilic behaviour. Besides, AmphB has an ionisable carboxyl and amine group 
(Figure 2.2), which gives amphoteric properties to this drug42-44. These physico-
chemical properties are the reason why AmphB is poorly soluble in all aqueous 
solvents and in many organic solvents43. As shown in Table 2.1, the solubility of 
AmphB in water is less than 1 mgL-1 at physiological pH, at pH below 2 or above 11 is 
soluble but is not stable under these conditions43. 
Table 2.1 Solubility of AmphB in different solvents from Lemke et al.44 
Solvent Solubility (mgL-1) 
Water  <1 (at pH 6–7) 
Methanol  2000 
Ethanol  500 
Chloroform  100 
Petrol ether  10 
Dimethyl formamide  2 
Propylene glycol 1 
Cyclohexane  20 
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Due to AmphB´s toxicity problems (nephrotoxicity) and to its poor oral absorption, it 
was necessary to adapt some formulations of the drug: liposomes or colloidal 
dispersions33,43. AmphB form of Fungizone® is a surfactant-stabilised formulation that 
helps in the oral solubility and is currently and exclusively administered 
parenterally33,34. However, this has been associated to some adverse side effects33,35. 
Liposomal preparations, like Ambisome®, allow the application of higher dose tolerance 
of dissolved AmphB33,43 without inducing the adverse side effects. This formulation 
could be the most popular choice in the future43. 
2.2.3 Mechanisms of Anti-Microbial Action and Resistance 
One of the biggest problems of ampicillin, amoxicillin, penicillin and the other penams 
is the reactivity of the highly strained ring that causes the degradation process of these 
compounds. At room temperature, the nitrogen of the beta-lactam ring is easily 
protonated by acids, and is followed by nucleophilic attack of the remaining lateral 
chain carbonyl38,39. Therefore, the oxazoline formed will produce a new imidazole and 
finally penicillic acid. 
Another problem, besides chemical degradation, is that of a group of enzymes that 
specifically destroy and inactivate beta-lactams. Many bacteria produce these enzymes 
called penicillinases and the beta-lactamase is the most prevalent type of these 
enzymes38,46.  
Normally, antibiotics can be divided in 5 categories, according to the mechanism of 
action38: a) inhibition of cell wall synthesis; b) impairment cytoplasmic membrane; c) 
inhibition of nucleic acid synthesis d) inhibition of protein synthesis; and e) metabolic 
antagonist action. Bacteria, on the other hand, found several ways to resist antibiotics: 
1) enzymatic inactivation of the drug by the presence of beta-lactamases; 2) presence of 
an enhanced efflux pump; 3) porin mutation that obstruct the drug entrance and 4) 
target modification of the drug, such as the mutation of penicillin binding proteins 
(PBPs). Figure 2.3 is an example of resistance mechanisms in Gram-negative bacteria. 
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Figure 2.3 Mechanisms of antimicrobial action and resistance in Gram-negative organisms. This 
picture represents a Gram-negative bacteria cell. Black boxes represent mechanisms 
of drug action and white boxes represent mechanisms of resistance. Below or on the 
side of each box there are several examples of drugs presenting those types of 
mechanisms. The main mechanisms of antimicrobial action can be divided into five 
major classes: (A) those which act in the cell wall synthesis; (B) those which act in the 
protein translation; (C) those which act in metabolic precursor biosynthesis; (D) 
those which act in the molecular genetics processes (replication, transcription); and 
(E) those which disrupt membrane function and permeability. Some of the resistance 
mechanisms are represented here by numbers: (1) enzymatic inactivation of the drug 
by the presence of beta-lactamases (1.1); (2) presence of an enhanced efflux pump, 
whether it is by an active transport system involving ATPases (2.1) or rather if it is 
driven by proton motive force (2.2), (2.3); (3) porin mutation obstructing the drug 
entrance; and (4) target modification of the drug, such as the mutation in the 
penicillin binding proteins (PBPs) (Authorized reproduction). 
Until approximately 1960, scientists produced and developed more than 20 new classes 
of antibiotics. Since then, only two new classes of antibiotics have appeared47. The 
problem of resistance presented by bacteria has been well known for approximately 20 
                                                     
 This figure was kindly offered by the author from “beta-Lactams: chemical structure, mode of 
action and mechanisms of resistance”, Reviews in Medical Microbiology, R. Fernandes, P. Amador 
and C. Prudêncio, 2013, 24, 7-17. 
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years or more but the pharmaceutical industry does not invest in the development of 
new antibiotics47. This may be due to the fact that the period necessary for bacteria to 
develop resistance is becoming shorter48, which consequently increases the challenges 
that pharmaceutical industry faces9. Instead of developing new antimicrobial agents 
that have proved to be more expensive and unsuccessful48 ,the scientific community 
seems now to be opting for another approach – the modification of existing 
antimicrobial agents48,49. 
Nowadays, bacterial resistance to different antibiotics is a major public health 
problem27,30,50,51. Recent outbreaks that evidence this problem27-29,52 are cases such as the 
one found in Germany for E. coli O10453,54 as well as the emergence of multi-drug-
resistant organisms, as in the of Gram-negative Enterobacteriaceae associated to the 
New Delhi metallo β-lactamase55-57. In fact, bacterial resistance, not only has public 
health implications, but is also a global safety threat, specifically at an economic and 
social level58,59. The latest studies have also reported the significant financial burden on 
health care-associated infections (HAIs) in the USA60,61. In the UK, approximately 9% of 
hospitalized patients acquire an infection after post-admission to hospital, which 
increases the costs in the health care system60,62. 
In this context, it is important to know and study the resistance mechanisms, and also 
to study non-antibiotic compounds as antimicrobial agents to find new therapeutic 
strategies to reduce the spread of resistant bacteria and their evolution. 
2.3 Anti-cancer Agents 
Anti-cancer agents are drugs used to inhibit cell cancer growth. Nowadays, cancer is 
one of the most important causes of morbidity and mortality worldwide63. In most 
cases, effective cancer care requires the linkage of early diagnosis to the appropriate 
use of therapy63. The research for new anti-cancer agents is focused on avoiding 
tumour resistance and decreasing the toxicity associated with chemotherapies23. In 
recent years, some of the compounds that have desirable drug like properties have 
suffered of poor solubility in water and physiological fluids31,64 – when a chemical 
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entity has some pharmaceutical relevance, its bioavailability also becomes a 
challenge31,64,65. Because of that, the research for new strategies to solubilize these types 
of substances is essential64,66,67. One way to overcome the solubility and stability 
problems of APIs is salt formation23,31. There are many examples where pharmaceutical 
active cations and anions have been combined together. The resulting salt exhibits 
therapeutic effects of both its components31 and many of these salts have some 
characteristics of ILs. So it is possible to prepare ILs (using their tuneable properties) as 
anti-cancer agents31,68. 
2.4 APIs Issues in the Pharmaceutical Industry 
“The pharmaceutical industries are undoubtedly experiencing a series of challenges”69. 
This industry has always faced difficult challenges in the innovation of drugs, but 
normally, these difficulties can be overcome with an increase of the final product 
prices70. One of the difficulties is the amount of regulation that authorities demand to 
approve a new drug (particularly in the case of the US Food and Drug Administration 
(FDA))70. The complications are due to the solid form of many drugs, like low 
solubility, polymorphism and low bioavailability. Adding to these, there are related 
problems, like low solubility media of the drug molecule or the starting material for 
synthesis of drugs in aqueous systems and in most of the pharmaceutical acceptable 
organic solvents69. 
In the salt formation process of pharmaceuticals, the cation most commonly used is 
sodium ion and chloride ion is the most used anion. The use of solid crystalline forms 
for the delivery of APIs is still the most reliable for the pharmaceutical industry, in 
spite of the fact that many drugs exhibit multiple crystalline forms (polymorphs, 
solvates, etc.), which, as said before, can have a profound effect on the solubility, 
physical and chemical stability, dissolution rate and, in some cases, bioavailability of 
the compound71-74. 
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These issues like polymorphism could be solved using ILs form of the API because ILs 
can be specially made with pre-selected characteristics by varying the cations and 
anions of which they are comprised.71 
As referred before, there is another big problem that the pharmaceutical industry is 
facing, drug resistance. This is a problem of the pharmaceutical industry but it also 
affects public health. In general, antimicrobial resistance is the capacity that any 
microorganism, like bacteria, fungi and parasites has to neutralize or to deteriorate the 
drugs which become ineffective38,75-77. This is of major concern because drug resistance 
is deadly, can spread to other microorganisms, and carry out costs to individuals and 
society75-82. Many of the drug treatment breakthroughs of the last century could be lost 
through the spread of antimicrobial resistance. As a result, many infectious diseases 
may one day become uncontrollable and could rapidly spread throughout the world82. 
In terms of bacteria resistance, this problem is currently and directly responsible for 15 
times as many deaths as AIDS every year in Europe75. 
2.5 Methods of Preparing Ionic Liquids 
ILs are usually prepared from ammonium, phosphonium or sulphonates ions83. There 
are 2 main methods of preparing ILs: metathesis and acid base neutralization (Erro! A 
origem da referência não foi encontrada.). In the case of imidazolium cations we could 
consider another method, that developed by Earl and Seddon: the reaction of 
imidazole carbenes as strong bases84.  
 
Scheme 2.1 General procedure for the metathesis reaction and acid base neutralization. 
Nowadays, there are many alkylammonium halides commercially available and they 
can be used directly in metathesis reactions85. In other cases, a quaternization reaction 
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is necessary, when an organic halide salt is formed through the alkylation of a base by 
a haloalkane85. This method can also be used to prepare pyridinium and imidazolium 
halides (Scheme 2.2). Currently, the use of non-conventional methods like 
microwave24,86 and ultrasound techniques 24,87 is being applied in the quaternization 
reaction with better results24,88.  
 
Scheme 2.2 Examples of the preparation of imidazolium halides using classic methods from 
Lévêque et. al88. 
The metathesis reaction is used to prepare ILs halide free like [EMIM][BF4] from the 
halide salt ([EMIM]I) and from silver or a group 1 metal (Ag[BF4])85. Other ILs have 
been prepared using metathesis reaction like thiocyanate, nonafluorobutanesulfonate, 
bis((trifluoromethyl)sulfonyl)imide, tris(trifluoromethyl)sulfonyl, methide, trifluoro-
acetate, and heptafluorobutanoate. This reaction is quite simple and easy to prepare. 
Nevertheless, this reaction has some inconvenients, like the contamination with a small 
amount of halide ions, which may react with solute materials and the presence of water 
or silver24,85. Recently Srour et al.24 have shown a silver and water free metathesis 
reaction. Another problem considering metathesis reactions is the limited variety of 
commercially available metal salts and also the coordination transition metal with 
bioactive compounds like aminoacids26,89. 
The acid base neutralization method avoids the contamination problem90. This 
procedure is also quite simple and through the use of equimolar mixing, it is possible 
to obtain the salts without the formation of by products90. This method results very 
well with tertiary amines with halide acids or some organic acids. The only problem is 
when we have weaker acids than hydrohalic acids91. In this case the neutralization has 
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to use hydroxide quaternary cations30. Recently ion exchange resin methods have been 
developed by Ohno and co-workers26,91-93. 
The use of imidazole carbenes as a strong base84 (Scheme 2.3) also has the advantage of 
non-contaminated ILs with halide ions or metal ions, but the main advantage is the 
possibility of preparing ILs or salts from alcohols like methanol and propanol, from 
carbonic acid, acetic acid and alkyl sulphonic acid. The disadvantage is that it only 
works to prepare imidazolium ILs. 
 
Scheme 2.3 General procedure for the synthesis of ILs using imidazole carbenes. 
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2.6 Ionic Liquids as Active Pharmaceutical Ingredients* 
2.6.1 Abstract 
Ionic liquids (ILs) are ionic compounds that possess a melting temperature below 100 
oC. Their physical and chemical properties are attractive for various applications. 
Several organic materials that are now classified as ionic liquids were described as far 
back as the mid-19th century. The search for new and different ILs has led to the 
progressive development and application of three generations of ILs: 
1) The focus of the first generation was mainly on their unique intrinsic physical and 
chemical properties, such as density, viscosity, conductivity, solubility, and high 
thermal and chemical stability. 
2) The second generation of ILs offered the potential to tune some of these physical and 
chemical properties, allowing the formation of “task-specific ionic liquids” which can 
be used as lubricants, energetic materials (in the case of selective separation and 
extraction processes), and as more environmentally friendly (greener) reaction 
solvents, among others. 
3) The third and most recent generation of ILs involves active pharmaceutical 
ingredients (API), which are being used to produce ILs with biological activity.  
Herein, we summarize recent developments in the area of the third-generation ionic 
liquids that are being used as APIs, with a particular focus on the efforts to overcome 
current hurdles encountered by APIs. We also offer some innovative solutions in new 
medical treatment and delivery options. 
                                                     
* This subchapter is a reprint of a published review article: Ionic Liquids as Active 
Pharmaceutical Ingredients, Ricardo Ferraz, Luís C. Branco, Cristina Prudêncio, João Paulo 
Noronha, Željko Petrovski, Chemmedchem, 2011, 6, 975-985 (authorized reproduction). 
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2.6.2 Introduction 
Ionic liquids (ILs) have been a topic of great interest since the mid-1990s1.They have 
attracted particularly high attention in recent years; approximately 1800 papers were 
published in the area of ILs in 2008 alone,94 documenting a variety of new IL 
applications. The range of IL uses has broadened, and there has been a significant 
increase in the scope of both physical and chemical IL properties over the years2,95. 
ILs are generally defined as organic salts with melting points below 100 oC (some of 
them are liquid at room temperature) and composed entirely of ions94-97. Despite the 
fact that ILs were first reported in the mid-1800s, widespread interest in this compound 
class has occurred only recently. ILs have come under worldwide scrutiny mainly 
through their use as solvents2-4,94. In particular, the room temperature ionic liquids 
(RTILs), also known as “designer solvents” (because it is possible to create an IL with a 
given required property), have served as greener alternatives to conventional toxic 
organic solvents3,94,98. RTILs have been used for several other applications, and their 
development continues at a considerable rate owing to their peculiar physical and 
chemical properties such as high thermal and chemical stability, lack of inflammability, 
low volatility, and tunable solubility with several organic compounds. By taking 
advantage of their unique properties,94,99 several IL applications have been described, 
including reaction media for many organic transformations,94,100 in separations and 
extractions,94,101,102 as electrolytes for electrochemistry,94,103,104 in nanotechnology,94,105,106 
in biotechnology,94,107 and in engineering processes,94,108,109 among others. 
ILs can be grouped into three generations according to their properties and 
characteristics8. The first generation includes ILs for which the accessible physical 
properties such as decreased vapor pressure and high thermal stability110 are often 
unique (Figure 2.4, 1st Generation). The second-generation ILs have potential use as 
functional materials, such as energetic materials, lubricants, and metal ion complexing 
agents, (Figure 2.4, 2nd Generation). By taking advantage of their tunable physical and 
chemical properties, ILs can produce a remarkable platform on which—at least 
potentially—the properties of both cation and anion can be independently modified 
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and designed to enable the production of new useful materials while maintaining the 
main properties of an IL. Some RTILs have been used as reaction media to produce or 
improve the preparation of various pharmaceuticals3,111,112. Recently, the third 
generation of ILs8 (Figure 2.4, 3rd Generation) has been described using active 
pharmaceutical ingredients (APIs) to produce ILs with biological activity. 
 
Figure 2.4 The scientific evolution of ILs, from unique physical properties (Generation 1) 
through the combination of chemical and physical properties (Generation 2), to the 
more recent studies of their biological and pharmaceutical activities (Generation 3) 
[adapted from Hough et al.]8 . 
While a tremendous amount of research has focused on the physical and chemical 
properties of ILs, more recently, the toxicity and biological behavior of ILs have been 
included as two of the most highly debated topics in this field. Biologically, active ions 
have been used to develop novel ILs; however, the primary drive behind the research 
into these materials has been focused on the use of well-known low-toxicity ions to 
obtain ILs with the desired set of properties5,8,113. 
2.6.2.1 Historical Perspective 
The first ionic liquid was described as “red oil” and was produced in the course of 
Friedel-Crafts reactions carried out in the mid-19th century. However, the composition 
of this red oil was only lately identified as a salt. For AlCl3-catalyzed reactions, the 
structure proposed for this liquid was the heptachlorodialuminate salt shown in Figure 
2.5. This IL as red oil, along with more complicated structures, were patented as useful 
materials, but no industrial application has been reported3,114. 
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Figure 2.5 The structure proposed for the heptachlorodialuminate salt (1), intermediate in the 
Friedel-Crafts reactions. An example of alkylammonium nitrates: ethylammonium 
nitrate (2). 
Modern ILs are quite different from those of the beginning of the 20th century, such as 
the alkylammonium nitrates 2, shown in Figure 2.5114. The most common ILs 
containing quaternary heterocyclic cations (such as alkylpyridinium or 
dialkylimidazolium) and inorganic anions have an ancestry traceable to traditional 
high-temperature molten salts114. The inorganic chloroaluminates are considered 
examples of salts between the truly high-temperature molten salts (such as cryolite or 
LiCl–KCl) and the current ionic liquids. 
The history behind the alkali chloroaluminate molten salts is a good example of 
fundamental research emerging rather quickly into practical application. In an example 
case, researchers at the United States Air Force Academy (Colorado Springs, CO, USA) 
picked up on the work carried out by Frank Hurley and Thomas Wier115,116 about 
electrodeposition of aluminum using AlCl3 – based molten salts. This led to the 
development of electrolytes for thermal batteries based on mixtures of AlCl3 and 1-
ethylpyridinium halides, mainly bromide (Figure 2.6). 
 
Figure 2.6 Mixture of AlCl3 and 1-ethylpyridinium bromide (5). 
One of most important breakthroughs in the history of ILs is related to the discovery of 
the 1-butylpyridinium chloride–aluminum chloride mixture (BPC–AlCl3, Figure 2.7)117. 
This all chloride system represented a substantial improvement over the mixed 
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bromide–chloride ionic liquids117, but had some disadvantages, which lead to new 
research and developments that brought forth the water-stable ionic liquids114,118,119. 
 
Figure 2.7 1-Butylpyridinium chloride (6) and aluminum chloride mixture (BPC–AlCl3). 
The research for novel water-soluble ILs was described by Fuller et al.120,121 using a 
series of ILs from the traditional dialkylimidazolium cations combined with different 
anions (tetrafluoroborate, hexafluorophosphate, nitrate, acetate, and sulfate) along 
with the additional series of mostly larger anions (Figure 2.8). Over the years, new 
classes of cations and anions have been reported94. Because ILs are intrinsically safer 
than highly volatile and flammable organic solvents, their use as solvents improves the 
safety margins and the environmental performance in solution chemistry95. Nowadays, 
the interest from disciplines outside chemistry and engineering is growing. Recent IL 
applications include the use in sensors, solar cells, solid-state photocells and batteries, 
as well as thermal fluids, lubricants, hydraulic fluids, and ionogels. ILs are indeed 
tunable, multipurpose materials for a variety of applications12. 
 
Figure 2.8 Tetrafluoroborate (7), hexafluorophosphate (8), nitrate (9), acetate salts (10), and 
sulfate (11) as anions combined with 1-ethyl-2-methylimidazolium cation ILs. 
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Finally, the particular interest in ILs from biological and pharmaceutical sciences is not 
only for use as reaction media, but as pharmaceutical solvents or co-solvents for the 
delivery of drugs with poor water solubility6. They are also applied in micro-emulsion 
systems, which can facilitate the dissolution of drugs that are insoluble or poorly 
soluble in water. Some IL micro-emulsions can be used as modern colloidal carriers for 
topical and transdermal delivery, while other IL systems have been used as 
entrapped/solubilized drug reservoirs for controlled release122. 
2.6.3 ILs as Active Pharmaceutical Ingredients (APIs) 
2.6.3.1 Ionic Pharmaceuticals and the Polymorphism Problem 
The pharmaceutical industry is unquestionably facing a series of challenges. While 
many of these challenges are related to the features of this industry and present 
business models, there is also an urgent need for new scientific advances that yield 
innovative and effective drugs and therapies. The classical strategies currently being 
followed are reaching the point at which it is difficult to come up with effective and 
acceptable new chemical entities. Very few drugs (<10%) that are evaluated in clinical 
tests make it to the market, decreasing the accessibility of efficient therapies for the 
people who need them123. 
Roughly 50% of available drugs are administrated as salts. The physicochemical and 
biopharmaceutical properties of a given drug can be finely tuned by pairing with 
various counterions. From a pharmaceutical point of view, melting temperature and 
solubility are relevant parameters because of their routine measurement and due to 
their potential influence on drug processing and bioavailability124. This is an easy way 
to adjust the properties of a drug with ionizable functional groups to overcome 
undesirable features present in the parent drug74,125. The quality, safety, and 
performance of a drug are related to the salt structure. The selected ion pair can 
significantly influence the pharmacokinetics of a drug candidate. This is one of the 
reasons why regulatory authorities have begun to classify novel salts of a registered 
drug as a new chemical entity. 
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The development of salts of the targeted active compounds is a suitable and well-
known approach to overcome the limitations faced by the pharmaceutical industry. In 
spite of this, cocrystals, amorphous forms, and polymer-embedded pharmaceuticals 
have been tested in order to solve such classical problems as spontaneous polymorphic 
transformation of crystalline drug forms; this can pose significant problems for drug 
designers and can convert an effective dose into a lethal dose by altering the solubility 
of the active ingredient123. Pure compounds, salts, all kinds of pharmaceuticals and 
drug candidates can suffer polymorphism (Figure 2.9), and there are no means to 
predict the emergence of polymorphism in any given compound despite recent efforts 
toward a better understanding of crystal polymorphism in pharmaceutical 
compounds126-128. 
The cost of a pharmaceutical product depends directly on crystal polymorphism and 
solvation state. This situation has been illustrated by costly product failures and 
protracted patent litigation. For example, the case of the Norvir capsule product failure 
in 1998 was recounted and rationalized by solving the crystal structures of the 
Ritonavir polymorphs129. In theory, all solid drugs are susceptible to unpredictable 
polymorph formation. An unexpected metastable form of 5-fluorouracil (a well-known 
drug) was described as a new polymorphic structure71,126. The use of initial generic 
versions of some relevant drugs has been permitted based on patently different yet 
pharmaceutically equivalent polymo130rphs (or hydrates), which in some cases have led 
to legal disputes126. Academic researchers are currently working with both 
experimental (engineering) and theoretical (prediction) insight into crystal forms128. 
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Figure 2.9 Examples of the types of crystal forms of pharmaceutical compounds that can have 
problems with polymorphism. 
The pharmaceutical industry should be open to the potential benefits that crystal 
engineering can offer, but it also has to be aware of other non-crystalline forms. Drug 
companies mainly rely on solid, primarily crystalline forms for the delivery of APIs for 
reasons of purity, thermal stability, manufacturability, and ease of handling. In 
contrast, liquid drug formulations are much less common, and are usually based on 
eutectic mixtures130,131. However, problems associated with the solid form of many 
drugs have been consistently reported; issues include polymorphic conversion, low 
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solubility, low bioavailability for crystalline solids, and the tendency of amorphous 
forms to spontaneously crystallize. For these reasons, and also due to considerable 
financial interests brought about by legal ramifications, screening for new drug forms, 
including salts, solvates, and cocrystals is a continuous pursuit126,130. Therefore, the use 
of an active drug in liquid form can avoid some of polymorphism problems associated 
with solids. Other similar approaches have been developed with liquid drug 
formulations prepared as eutectic mixtures130,132, but these can dilute the APIs owing to 
large quantities of inactive ballast in the formulation. In this light, pure liquid-phase 
APIs would provide new perspectives for drug delivery and treatment approaches. 
From the point of view of the pharmaceutical industry, the use of liquid salts is 
relevant, preferably those with melting points below room temperature. Some 
synthetic strategies that have been employed to decrease the melting point of the salts 
include a selection of cations with a low tendency to crystallize, or ions with a more 
diffuse charge. For example, 3-ethyl-1-methylimidazolium chloride is an organic salt 
with a melting point of 77–79 oC, which can be lowered to -21 oC by simple replacement 
of the chloride with a dicyanamide anion130,133. 
2.6.3.2 Pharmaceutical Activity 
The question of IL toxicity has delayed the entry of ILs into the biosciences. The 
toxicities observed toward microorganisms and cell cultures cover a wide range of 
biocidal potencies: from those of rather inactive molecular solvents, such as ethanol or 
dimethyl sulfoxide, which are biocompatible to very high aqueous concentrations, to 
highly active biocides. The latter have even led to the proposal for the use of some ionic 
liquids as wood preservatives and in a variety of other pharmaceutical 
applications130,134(Figure 2.10). 
The number of publications reporting antimicrobial activity for ILs is growing, and this 
could be very interesting for the development of new bioactive materials as 
antiseptics31,130,135,136, for example (Figure 2.11).  
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Figure 2.10 Some examples of ILs and their application. 
Table 2.2 and Table 2.3 list some examples of antimicrobial activity (minimum 
inhibitory concentration and minimum bactericidal or fungicidal concentration, 
respectively) observed for ILs based on ammonium and benzalkonium cations 
combined with saccharinate and acesulfamate anions. These results demonstrate the 
potential use of ILs, in particular, against Streptococcus mutans.  
 
Figure 2.11 Examples of antibacterial agents. 
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Table 2.2 Minimum inhibitory concentrations (MIC) for various ILs and starting salts 
Strain 
MIC [ppm][a] 
[BA][Sac][b] 
(23) 
[DDA][Sac][c] 
(19) 
[Ba][Ace][d] 
(24) 
[DDA][Ace][e] 
(25) 
[BA][Cl][f] [DDA][Cl][f] 
Staphylococcus aureus 4 4 4 8 2 2 
Staphylococcus aureus (MRSA) 4 4 4 4 2 2 
Enterococcus faecium 8 8 8 8 4 4 
Escherichia coli 16 16 31 16 8 8 
Micrococcus luteus 8 4 8 8 4 2 
Staphylococcus epidermidis 4 4 4 4 2 2 
Klebsiella pneumoniae 4 4 8 4 4 4 
Candida albicans 16 16 16 16 8 8 
Rhodotorula rubra 16 16 16 16 8 4 
Streptococcus mutans 0.1 31 1 16 2 2 
[a] Lowest compound concentration that inhibits visible growth of a microorganism after overnight incubation 
[b] Benzalkonium saccharinate. [c] Didecyldimethylammonium saccharinate. [d] Benzalkonium acesulfamate.  
[e] Didecyldimethylammonium acesulfamate. [f] Starting salts: benzalkonium chloride ([BA][Cl]) and 
didecyldimethylammonium chloride ([DDA][Cl]); data from Hough-Troutman et al.,133 listed for comparison. 
 
Table 2.3 The minimum bactericidal or fungicidal (MBC) concentrations for various ILs and starting salts. 
Strain 
MBC [ppm][a] 
[BA][Sac][b] 
(23) 
[DDA][Sac][c] 
(19) 
[Ba][Ace][d] 
(24) 
[DDA][Ace][e] 
(25) 
[BA][Cl][f] [DDA][Cl][f] 
Staphylococcus aureus 31.2 62.5 31.2 16 62.5 31.2 
Staphylococcus aureus 
(MRSA) 
31.2 31.2 31.2 31.2 31.2 31.2 
Enterococcus faecium 16 16 31.2 31.2 31.2 31.2 
Escherichia coli 62.5 16 125 62.5 62.5 31.2 
Micrococcus luteus 62.5 31.2 62.5 62.5 31.2 31.2 
Staphylococcus epidermidis 31.2 16 62.5 31.2 16 31.2 
Klebsiella pneumoniae 62.5 16 31.2 31.2 31.2 16 
Candida albicans 31.2 16 31.2 31.2 16 16 
Rhodotorula rubra 62.5 31.2 62.5 62.5 31.2 31.2 
Streptococcus mutans 0.5 62.5 16 125 16 16 
[a] Lowest compound concentration required to kill a microorganism. [b] Benzalkonium saccharinate.  
[c] Didecyldimethylammonium saccharinate. [d] Benzalkonium acesulfamate. [e] Didecyldimethylammonium 
acesulfamate. [f] Starting salts: benzalkonium chloride ([BA][Cl]) and didecyldimethylammonium chloride ([DDA][Cl]); 
data from Hough-Troutman et al.,133 listed for comparison. 
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ILs could even be used as potential anticancer agents113,130,137,138 (Figure 2.12 and Table 
2.4). Recently the anti-biofilm activity of some ILs and their reported potent, broad-
spectrum activity against a variety of clinically significant microbial pathogens, 
including methicillin-resistant Staphylococcus aureus (MRSA)71, have been 
investigated139 (Figure 2.4 and Table 2.5).  
 
Figure 2.12 Examples of potential anticancer agents31. 
Microbial biofilms are everywhere in nature and represent the dominant mode of 
microorganism growth. Various types of bacteria, such as MRSA, are observed in 
colonies adherent to material surfaces. These colonies often form coatings, known as 
biofilms. A common feature of biofilm communities is their tendency to exhibit 
significant tolerance and resistance to antibiotics and antimicrobial or biocidal 
challenge, relative to planktonic bacteria of the same species135. One of the attractions of 
ionic liquids in this regard is the possibility to tailor their physical, chemical, and 
biological properties by building specific features into the chemical structures of the 
cation and/or anion components that could facilitate antibiotic entry into the biofilm. 
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Table 2.4 Antitumor activity (GI50 [mm][a] and LC50 [mm][b] data) of compounds 26–30 (Figure 
2.12) from five dose studies with the NCI 60-cell-line[c] screen from Kumar and 
Malhotra31. 
 26 27 28 29 30 
GI50 LC50 GI50 LC50 GI50 LC50 GI50 LC50 GI50 LC50 
Leukaemia           
CCRF-CEM 0.026 8.458 0.038 2.140 0.034 nd 4.410 >100 0.190 2.440 
HL-60(TB) 0.046 0.711 0.025 0.642 0.039 nd 2.420 >100 0.173 1.230 
K-562 0.041 >100 0.087 >100 0.038 >100 1.680 >100 0.186 4.859 
MOLT-4 0.069 >100 0.046 1.750 0.090 >100 10.70 >100 0.324 4.890 
RPMI-8226 0.016 0.098 0.042 49.10 0.016 nd 1.640 >100 0.046 0.951 
SR 0.072 8.085 0.047 3.580 0.107 >100 34.60 >100 0.162 5.134 
Non-small cell lung cancer         
A549/ATCC 0.292 >100 0.377 9.840 0.391 >100 3.340 >100 1.900 8.580 
EKVX 0.123 >100 0.069 4.600 0.206 nd 2.470 >100 0.215 4.310 
HOP-62 0.435 >100 0.245 5.010 0.399 >100 5.170 >100 0.787 7.770 
HOP-92 0.030 >100 0.025 3.350 0.038 nd 4.790 >100 0.206 4.470 
NCI-H226 0.105 >100 0.088 4.230 0.189 nd 3.910 >100 0.478 4.410 
NCI-H23 0.192 >100 0.143 9.260 0.236 >100 1.950 >100 0.308 6.330 
NCI-H322M 0.321 >100 0.359 4.230 0.401 nd 6.120 >100 1.810 6.120 
NCI-H460 0.315 >100 0.285 3.560 0.346 >100 2.840 >100 0.362 4.100 
NCI-H522 0.105 >100 0.069 4.260 0.158 >100 3.420 >100 0.287 5.400 
Colon cancer        
COLO 205 0.182 >100 1.730 >100 0.243 >100 1.700 9.160 0.292 >100 
HCC-2998 0.240 >100 1.230 7.440 0.297 >100 2.410 >100 0.425 6.960 
HCT-116 0.061 >100 0.050 6.960 0.084 >100 2.630 >100 0.319 9.900 
HCT-15 0.291 >100 0.246 3.710 0.339 nd 2.880 >100 0.993 5.230 
HT29 0.053 >100 0.057 6.490 0.061 >100 3.800 >100 0.305 5.170 
KM12 0.049 >100 0.045 0.080 0.059 >100 2.890 >100 0.310 5.310 
SW-620 0.049 >100 0.047 6.580 0.072 >100 2.870 >100 0.378 10.00 
CNS cancer         
SF-268 0.072 >100 0.066 6.270 0.088 >100 7.440 >100 0.493 5.500 
SF-295 0.205 >100 0.147 6.690 0.251 >100 4.070 >100 0.333 4.570 
SF-539 0.174 >100 0.100 3.450 0.234 nd 5.290 >100 0.514 4.190 
SNB-19 0.069 >100 0.068 7.830 0.097 >100 3.180 >100 0.587 8.250 
SNB-75 0.076 >100 0.255 5.780 0.223 >100 4.510 >100 0.336 3.770 
U251 0.041 5.620 0.037 3.610 0.037 nd 2.630 >100 0.334 4.320 
Melanoma           
LOX IMVI 0.058 0.592 0.037 0.418 0.050  4.240 >100 0.192 1.080 
MALME-3M 0.029 5.380 0.041 4.110 0.034 >100 2.000 >100 0.290 4.110 
M14 0.052 >100 0.044 5.490 0.087 >100 3.050 >100 0.453 9.190 
SK-MEL-2 0.027 >100 nd nd 0.081 >100 8.250 >100 0.356 >100 
SK-MEL-28 0.207 6.590 0.178 6.060 0.376 >100 1.800 >100 0.710 7.180 
SK-MEL-5 0.079 0.829 0.052 0.663 0.074 nd 2.470 >100 0.177 0.677 
UACC-257 0.103 >100 0.112 4.810 0.272 nd 2.380 >100 0.411 6.160 
UACC-62 0.045 >100 0.043 4.180 0.061 nd 3.440 >100 0.335 4.100 
Ovarian cancer           
IGROV1 0.071 >100 nd nd 0.316 >100 7.460 >100 0.388 >100 
OVCAR-3 0.051 6.760 0.036 3.100 0.118 >100 2.620 >100 0.315 4.180 
OVCAR-4 0.073 >100 0.096 8.690 0.125 >100 4.340 >100 0.309 5.800 
OVCAR-5 0.318 >100 0.279 7.590 0.337 nd 3.300 >100 1.240 8.170 
OVCAR-8 0.086 >100 0.079 6.460 0.229 >100 5.120 >100 0.468 5.880 
SK-OV-3 2.610 >100 0.254 5.000 0.331 >100 2.70 >100 0.565 5.120 
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Table 2.4 Antitumor activity (GI50 [mm][a] and LC50 [mm][b] data) of compounds 26–30 (Figure 
2.12) from five dose studies with the NCI 60-cell-line[c] screen from Kumar and Malhotra31 
(continued). 
 26 27 28 29 30 
 GI50 LC50 GI50 LC50 GI50 LC50 GI50 LC50 GI50 LC50 
Renal cancer        
786-0 0.253 >100 0.086 5.890 0.211 >100 5.290 >100 0.415 5.020 
A498 0.310 >100 0.451 6.080 0.472 nd 2.360 >100 1.820 6.360 
ACHN 0.260 >100 0.212 3.390 0.244 nd 2.920 >100 0.630 4.520 
CAK-1 0.236 >100 0.207 4.480 0.350 >100 3.130 >100 0.084 3.280 
RXF 393 0.141 >100 0.179 >100 0.352 >100 7.660 >100 0.464 5.750 
SN12C 0.042 4.440 0.043 3.560 0.062 nd 3.310 >100 0.367 4.060 
TK-10 0.341 >100 0.145 4.490 0.234 nd 2.570 >100 0.503 4.860 
UO-31 0.350 >100 0.298 5.410 0.398 >100 4.330 >100 0.686 5.950 
Prostate cancer         
PC-3 0.045 5.900 0.035 0.779 0.044 >100 3.780 >100 0.282 3.990 
DU-145 0.156 >100 0.117 5.290 0.357 >100 6.020 >100 0.407 4.440 
Breast cancer         
MCF7 0.144 >100 0.082 3.910 0.253 >100 3.050 >100 0.317 4.020 
NCI/ADR-RES 0.730 >100 0.765 8.400 0.947 nd 3.080 >100 1.680 8.130 
MDA-MB-231ATCC 0.056 >100 0.047 3.220 0.107 nd 6.980 >100 0.345 3.630 
HS 578T 0.053 >100 0.077 9.390 0.084 >100 1.760 >100 0.417 >100 
MDA-MB-435 0.045 19.80 0.038 8.460 0.050 >100 3.560 >100 0.335 5.700 
BT-549 0.066 >100 0.061 4.370 0.094 >100 3.100 >100 0.421 4.420 
T-47D 0.073 >100 0.068 20.40 0.089 >100 1.150 >100 0.428 >100 
MDA-MB-468 0.036 2.560 0.044 4.240 0.053 >100 2.220 >100 0.119 2.110 
[a] Drug concentration that results in a 50% decrease in net protein increase relative to control cells and toxicity. 
[b] Drug concentration lethal to 50% of cells; nd: not determined. [c] A 60-cell-line panel used as an in vitro 
substitute for the use of transplantable animal tumours in anticancer drug screening140. 
 
 
Figure 2.13 Examples of anti-biofilm agents135. 
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The pharmaceutical industry is currently paying more attention to ILs because they are 
customizable materials that can be specially tailored with selected characteristics by 
varying the combination of their cations and anions. This combination results in 
various ILs that can offer a wide range of hydrophobicity/hydrophilicity, 
acidity/basicity, viscosities, among other attributes130,137.  
Table 2.5 MIC and minimum biofilm eradication concentration (MBEC)[a] in mM of 1-alkyl-3-
methylimidazolium chlorides ([Cnmim]Cl) (33) from Carson et al135. 
Organism 
 n 
 8 10 12 14 
S. aureus ATCC 29213 
MIC 722 40 18 16 
MBEC 2708 2415 272 124 
E-MRSA 15 
MIC 722 40 18 16 
MBEC 2708 1207 272 248 
MRSA 
MIC 1444 160 36 16 
MBEC 21666 4829 545 124 
S. epidermidis ATCC 35984 
MIC 722 40 36 7.75 
MBEC 10833 4829 272 124 
E. coli NCTC 8196 
MIC 722 321 73 33 
MBEC 21666 9659 1089 124 
P. aeruginosa PA01 
MIC 5416[b] 2415[b] 580 264 
MBEC 21666 2415 1089 496 
K. aerogenes NCTC 7427 
MIC 1444 643 73 33 
MBEC 43331 19318 2179 248 
B. cenocepacia J2315 
MIC >1444 1287 290 132 
MBEC 43331 19318 2179 496 
P. mirabilis NCTC 12442 
MIC 1444 1287 580 264 
MBEC 43331 9659 4357 1984 
C. tropicalis NCTC 7393 
MIC 1444 321 73 66 
MBEC >43331 19318 8714 248 
[a] MBEC is the concentration of an antimicrobial agent required to kill a microbial biofilm141. [b] MIC values 
determined by the chemical bath deposition (CBD) method as per manufacturer’s protocol, and defined as 
the lowest concentration of antibiotic at which a planktonic population could not be established by 
shedding of bacteria from a biofilm 141; data are included for clarification and comparison only. 
 
The arrangement of cations and anions with few possibilities for strong attractive 
intermolecular hydrogen bonding interactions decreases the potential for 
crystallization and provides facile access to pharmaceutically active ILs71,138. This will 
naturally lead to ILs or salts that otherwise would not be explored if crystallization is 
the primary goal. One such example is the combination of a didecyldimethyl-
Chapter 2 General Introduction 
36 
ammonium cation and saccharinate: the former is a cation with antimicrobial activity, 
and the latter is an anion with a sweet taste (compound 19, Figure 2.10). Indeed, the 
frequent designation of “designer solvents” for ILs might be easily adapted for IL 
“designer drugs,” as physical, chemical, and biological properties of a drug can be 
tuned by choice of counterion rather than by covalent modification. 
Some compounds have difficulty in penetrating biological membranes because they are 
very hydrophilic. The correct arrangement between an active ion with another more 
lipophilic character could offer a solution for this problem. An elucidative example is 
the case of lidocaine docusate, which combines the local surface anesthetic lidocaine 
cation with the hydrophobic anion, docusate (an emollient) to create a novel 
hydrophobic IL salt. This IL demonstrates decreased or controlled water solubility, and 
thus should exhibit extended residence time on the skin8,71,130 (Figure 2.14). The 
counterions are chosen by their inactive nature in order to give the desired 
physicochemical properties of a neutral drug. Recently, a small number of so-called 
“combination salts” have been prepared, including two active units (APIs) (compound 
36, Figure 2.14) in the same singular compound coupled as a cation and an anion71,142. 
In general, this approach tends to be influenced by the need to obtain a crystalline 
material, or the fixed stoichiometry of active units found in such a crystalline salt. The 
so called “dual functionality” has been explored as an important aspect of the IL field 
(for example, in dual acidic or double chiral ILs)130,143. In the context of APIs, these 
kinds of studies open new avenues for further exploration in the pharmaceutical field.  
Some examples of ILs composed of two biologically active ions were recently described 
in which both the cation and anion were selected based on the desired physical, 
chemical, and biological properties133. Such ILs are frequently found as antimicrobials 
and disinfectants144, for which the introduction of sweetness as a second functionality 
in the same formulation can be a desired factor for oral applications, such as 
mouthwashes.  
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Figure 2.14 Examples of ILs with targeted biological properties combined with adequate 
selected physical and chemical properties8. 
In the context of APIs, a variety of approaches can be contemplated and for which the 
two actives can be chosen. The counterions can be selected to synergistically enhance 
the desired effects or to neutralize unwanted side effects of the active entity. The 
counterion can also be chosen to pharmacologically act in an independent way71,130,142. 
In 2007, Rogers and co-workers patented a method for the preparation of ILs 
containing active pharmaceutical, biological, nutritional and energetic ingredients. 
When a pharmaceutical activity is a desired property of the IL, one or more of the ions 
in the disclosed IL composition can be a pharmaceutical ingredient10,145 (Figure 2.15). 
 
Figure 2.15 Examples of an antibiotic (37), nonsteroidal anti-inflammatory agent/analgesic (38), 
and an antiepileptic agent (39) as ILs8,10,145. 
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Importantly, a co-formation of two separate solid actives in a solid dosage form is 
significantly different from IL formulation. The ions from an IL will dissolve in bodily 
fluids in exactly the same way, as one ion cannot dissolve without the other. This is not 
true of separate solid forms administered at the same time, as each may dissolve at 
quite different rates71. 
2.6.3.3 Biopharmaceutics Drug Classification System (BCS) 
The development of drugs is always associated with standards and directives that also 
aid in drug classification. Biopharmaceutics is defined by the physical and chemical 
properties of a biologically active compound as well as the formulation and physiology 
of the route of administration. Nowadays, numerous molecules are classified through 
screening processes, and promising candidates are selected for additional in vitro and 
in vivo tests. At the end of the process, regulatory agencies make the ultimate 
authorization146. 
The introduction of the biopharmaceutics drug classification system (BCS)32 (Table 2.6) 
into the guidelines of the US Food and Drug Administration (FDA) is a major step 
forward in classifying the biopharmaceutical properties of drugs and drug products. 
Based on mechanistic approaches to the drug absorption and dissolution processes, as 
well as intestinal permeability, the BCS enables regulatory bodies to simplify and 
improve the drug approval process. The knowledge of the characteristics of a drug in a 
formulation, according to BCS, can also be used by formulation scientists to develop a 
more optimized dosage form based on fundamental mechanistic, rather than empirical, 
information. In this context, the combination of the appropriate anion or cation with a 
drug could be a simple method to change a pharmaceutical ingredient in the BCS. 
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Table 2.6 BCS[a] classification of drugs and in vitro/in vivo correlation (IV/IVC) expectations for 
immediate release products based on the biopharmaceutics class, from Löbenberg et 
al146. 
Class Solubility Permeability IV/IVC expectation 
I High High 
IV/IVC if the dissolution rate is slower than the gastric emptying 
rate, otherwise limited or no correlation 
II Low High 
IV/IVC expected if the in vitro dissolution rate is similar to the in 
vivo dissolution rate, unless the dose is very high 
III High Low 
Absorption (permeability) is rate determining and limited or no 
IV/IVC with dissolution rate 
IV Low Low Limited or no IV/IVC expected 
[a] BCS biopharmaceutics drug classification systems. 
 
2.6.3.4 Some Examples of Ionic APIs 
There are numerous published examples in which pharmaceutically active compounds 
are salts of an active ion in combination with a relatively simple and inert counterion, 
or that can be easily transformed into cationic or anionic species. Table 2.7 illustrates 
some examples of drugs (or their APIs) that could be used for preparation of novel and 
pharmaceutically active ILs. The examples selected herein were listed in the 2009 Top-
200 generic drug list by retail dollars147. From the IL point of view, it is possible to use 
some examples from Table 2.7 as the cation unit, such as Omeprazole (rank 2), a drug 
used to treat gastroesophageal reflux disease, or the anion unit, such as the amoxicillin 
antibiotic (rank 9 and 28). Some of these possess dual functionalities, so they can be 
used as cation or anion, such as the antiepileptic Gabapentin (rank 8), or the 
angiotensin-converting enzyme inhibitor Lisinopril (rank 13), which is used for 
hypertension. 
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Table 2.7 Examples of drugs (or their APIs) that could be used in ILs as listed in the 2009 Top-
200 generic drugs by retail dollars147. 
Rank Drug[a] Rank Drug[a] 
2 Omeprazole 
 
 
Treat symptoms of gastroesophageal reflux 
disease 
3 Metoprolol succinate 
 
For hypertension treatment 
7 Amlodipine besylate benazepril 
 
For hypertension treatment 
8 Gabapentin 
 
 
 
Treatment of epilepsy, and major depressive 
disorder 
9 Amoxicillin/potassium clavunate 
 
 
Antibiotic with β-lactamase inhibitor 
10 Fexofenadine 
 
Anti-histamine drug 
13 Lisinopril 
 
For hypertension treatment 
14 Sumatriptan oral 
 
 
For migraine headaches  
15 Lamotrigine 
 
Treatment of epilepsy 
16 Levothyroxine 
 
Hormone replacement for patients with 
thyroid problems 
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Table 2.7 Examples of drugs (or their APIs) that could be used in ILs as listed in the 2009 Top-
200 generic drugs by retail dollars147 (continued). 
Rank Drug[a] Rank Drug[a] 
17 Amlodipine besylate 
 
For hypertension treatment 
18 Amphetmn. salt cmb. SR 
 
 
 
Increased wakefulness and focus 
21 Pantoprazole 
 
 
 
Treat symptoms of gastroesophageal reflux 
disease 
22 Cefdinir  
 
Antibiotic 
24 Metformin 
 
Anti-diabetic  
25 Divalproex sodium 
 
Treatment of epilepsy 
26 Sertaline 
 
 
Antidepressant 
 
27 Budeprion XL 
 
 
Antidepressant and smoking cessation 
28 Amoxicillin 
 
Antibiotic 
32 Bupropion XL 
 
 
Antidepressant and smoking cessation 
34 Fluoxetine 
 
 
Antidepressant 
35 Pravastatin 
 
Lowering cholesterol and preventing 
cardiovascular disease 
[a] The chemical formula of some compounds from the table is a rather simplified presentation of all 
functional groups present without analysis of acid-base reaction. 
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There are also numerous published examples of APIs in which both cation and anion 
are active pharmaceutical ingredients (Table 2.8)142. Following dissociation in solution, 
the cation and anion will each follow their independent kinetic and metabolic 
pathways. 
Table 2.8 Some examples of ionic liquid salt pairs having both cation and anion as active 
component from Kumar et al.142 
Cationic drug component Anionic drug component Salt pair 
Phenazone 
 
m.p. = 113 oC 
analgesic, anti-inflammatory, 
antipyretic 
Gentisic acid 
 
m.p. = 200-205 oC 
analgesic, anti-inflammatory, 
antipyretic 
Phenazone gentisate 
 
m.p.= 87-88 oC 
analgesic, anti-inflammatory, 
antipyretic148 
Benzalkonium 
 
Antibacterial  
 
Ibuprofenate 
 
Anti-inflammatory 
Benzalkonium ibuprofenate 
m.p.= -41 oC7 
Didecyldimethylammonium 
 
 
Antibacterial 
 
Ibuprofenate 
 
Anti-inflammatory 
Didecyldimethylammonium 
ibuprofenate 
 
m.p.:  liquid at room temperature 
(RT)8 
Benzalkonium 
 
Anti-bacterial 
Colawet MA-80 
 
Wetting agent 
 
Benzalkonium colawet MA-80 
 
m.p.:  liquid at RT7 
 
Benzalkonium 
 
 
Anti-bacterial 
 
Sulfacetamide 
 
 
Anti-acne 
Benzalkonium sulfacetamide 
 
m.p.: liquid at RT7 
 
Ranitidine 
 
Histamine H2-receptor 
antagonist 
Docusate 
 
Emollient 
Ranitidine docusate8 
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2.6.4 Conclusions and Future Perspectives 
The development of new synthetic strategies in organic chemistry using “eco-friendly” 
conditions is an issue of increasing interest. This leads to ILs, and has attracted the 
attention of the pharmaceutical industry. Naturally, further studies must be carried out 
in order to discover the full potential of their biomedical applications. The 
incorporation of the IL approach into pharmaceuticals will continue to open new 
perspectives in industry and modern society. It is particularly important to emphasize 
that even slight modifications of an API can significantly change a drug’s physical 
properties as well as its classification in the BCS. This approach can provide a platform 
to improve the pharmaceutical activity for new treatment options or even personalized 
medicine. In summary, this Mini Review highlights the very recent progress in the 
API–IL field, and demonstrates that ILs have the potential to impart an incredible 
degree of flexibility in the fine tuning of physical, chemical, and biological properties 
without covalent manipulation of the active units. Certainly, there are associated 
challenges to bear in mind, including manufacture, scale-up, purification, stability, 
toxicity, and delivery, among others. However, the rush to obtain new drugs by 
molecular manipulation and discovery may have obscured the fact that many known 
drugs could be manipulated into more effective species by simple salt chemistry — 
albeit a salt chemistry unlike any other yet attempted by the industry. For that reason, 
the liquid state by itself should not be overlooked, but should be considered as an 
alternative to common solid-state techniques. In this context, new possibilities, 
challenges, and thrilling opportunities might be the reward. 
  
Chapter 2 General Introduction 
44 
2.7 Recent applications of ILs-APIs 
From 2011 until now there have been more dissemination of novel work related to  
ILs-API. In the case of the synthesis of ILs with APIs, there has only been reported the 
synthesis of ampicillin19,30,149 and the synthesis of IL forms of aspirin and salicylic acid 
in combination with different pharmaceutically active cations149,150. ILs-APIs are 
characterized by the presence of the cation or anion with pharmaceutical activities 
(pharmacokinetic and pharmacological).  
Other approaches are being made between ILs and APIs. Rogers’s group have been 
working in this field. Recently, his group has described the use of ILs as prodrugs 
(acetaminophen prodrugs paired with the docusate anion)151, the use of ILs to improve 
the water solubility of APIs like amphotericin B and itraconazole152. This demonstrate  
that ionic liquids can be used as both drug delivery systems and solubilisation agents 
in order to improve the aqueous solubility of many drugs152. Another approach, ILs 
with herbicide, is being made not only by Rogers153, but also by Pernak153,154.  
In the case of biological properties and toxicity of ILs, many studies have been made 
between 2011 and now. There are some studies of Ventura et al.155,156 that describes the 
relation between the chemical structure and the toxicity. Pham et al. describes the 
environmental risk assessment of ILs157.  
In a recent publication, Frizzo et al.149 summarize the ILs applications where it is 
concluded that ILs-APIs are a research area developed by few groups and that it is 
necessary to produce important results in this area with a complete and elaborate 
work, which include synthesis, physical and chemical property studies as well as 
pharmacological activity estimation149. 
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3 
 
Material and Methods 
 
 
This chapter presents a detailed description of the methods and the materials used to 
synthesize the new ILs as well as the methodology followed to characterize the 
biological, chemical and physical properties of these compounds. These procedures are 
partially described in the next chapters, which are presented as reproduction of 
accepted or submitted papers. 
3.1 Synthesis 
Commercially available reagents were purchased from Aldrich, BDH – laboratory 
reagents, Frilabo and Solchemar and were used as received. The solvents were from 
Valente & Ribeiro and distilled before used. Whenever necessary, the solvents were 
dried by standard procedures, distilled under nitrogen and stored over molecular 
sieves. 
The basic anion-exchange resin Amberlite IRA-400-OH (ion-exchange capacity 1.4 
eq.mL-1) was purchased from Supelco. 1H and 13C-NMR spectra in (CD3)2SO or CD3OD 
(from Euriso-Top) were recorded on a Bruker AMX400 spectrometer at room 
temperature unless specified otherwise. Chemical shifts are reported downfield in 
parts per million (ppm). Mass spectra for Ampicillin ILs were obtained in Espectro ESI-
FIA-TOF-Medida de Masas Exactas from Unidade de Espectrometria de Masas e 
Proteómica at Universidade de Santiago de Compostela. Mass spectra for Amoxicillin 
and Penicillin G ILs were obtained in API-ION TRAP(PO03MS) from Mass 
Spectrometry Laboratory at Instituto de Tecnologia Química e Biológica. The mass 
spectra of Amphotericin B ILs were made by Matrix Assisted Laser Desorption 
Ionization – Time Of Flight (MALDI-TOF) in voyager DE PRO ™ Biospectrometry 
Workstation IR at Faculdade de Ciências e Tecnologia da Universidade Nova de 
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Lisboa. IR spectra were measured on a Perkin Elmer 683. Optical rotations were 
recorded on a Perkin Elmer 241MC. The water content of the liquid [was determined 
by Karl Fischer titration in an 831 KF coulometer Metrohom. The Melting temperature 
(mT) was determined by melting point apparatus (Stuart Scientific). DSC analysis was 
carried out using a TA Instruments Q-seriesTM Q200 DSC with a refrigerated cooling 
system. The sample was continuously purged with 50 mLmin-1 nitrogen. About 5 to 10 
mg of the synthesized IL was crimped in an aluminium standard sample pan with lid. 
3.1.1 Synthesis of Ampicillin ILs 
3.1.1.1 Preparation of Tetraethylammonium (2S,5R,6R)-6-((R)-2-amino-2-
phenylacetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-
carboxylate [TEA][Amp]  
 
Figure 3.1 Struture of [TEA][Amp]. 
Tetraethylammonium bromide (0.321 g; 1.53 mmol) was dissolved in methanol and 
passed through an ion-exchange column Amberlite IRA-400-OH26,30 (5 eq., flux rate 
0.133 mLmL-1min-1 = 8 BVh-1). Then, tetraethylammonium hydroxide solution was 
slowly added to ampicillin (0.549 g; 1.57 mmol) dissolved in 1.0 M ammonium solution 
(50 mgmL-1). The reaction mixture was stirred at room temperature for 1 h. After 
solvent evaporation, the residue was dissolved in 20 mL of (methanol/acetonitrile 
1:9)26,30 and left refrigerated overnight (4 oC)30 to induce crystallization of excess of the 
ampicillin. Then ampicillin crystals were filtered from the solution, the solution was 
evaporated and dried in vacuum for 24 h. The desired product was obtained as a yellow 
solid (0.556 g; 76.0 %). m.p. 79 oC; [α]D27= 48.7  2.5 (c = 2 mgmL-1 in methanol); 1H-NMR 
(400.13 MHz, CD3OD)  = 7.48 (d, 2H, J = 7.4Hz), 7.36 (t, 1H, J = 7.3Hz), 7.30 (d, 2H, J = 
6.1Hz), 5.00 (d, 1H, J = 6.0Hz), 4.64 (s, 1H), 4.33 (d, 1H, J = 6.0Hz), 3.42, (s, 1H) 3.28 (q, 
8H, J = 7.3 Hz), 1.45 (s, 3H), 1.28 (tt, 12H, J = 1.9 Hz, J = 7.3 Hz), 1.22 (s, 3H) ppm; 13C-
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NMR (100.62 MHz, CD3OD)  = 175.58, 174.83, 140.88, 130.06, 129.88, 129.22, 128.58, 
77.13, 66.66, 60.19, 60.00, 59.54, 53.27, 53.24, 53.21, 27.79, 27.44, 7.63 ppm; IR (KBr):  = 
3390, 2978, 2929, 1674, 1598, 1488, 1456, 1394, 1304, 1253, 1185, 1174, 1130, 1069, 1029, 
1002, 968, 920, 871, 787, 701, 636 cm–1; (EI+) m/z calcd for C8H20N+: 130.1590, found 
130.1590; (EI-) m/z calcd for C16H18N3O4S-: 348.1024, found 348.1013. 
 
Figure 3.2. [TEA][Amp] 1H-NMR spectrum in CD3OD. 
 
Figure 3.3. [TEA][Amp] 13C-NMR spectrum in (CD3)2SO. 
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Figure 3.4. [TEA][Amp] IR spectrum in KBr. 
3.1.1.2 Preparation of Trihexyltetradecylphosphonium (2S,5R,6R)-6-((R)-2-
amino-2-phenylacetamido)-3,3-dimethyl-7-oxo-4-thia-1-
azabicyclo[3.2.0]heptane-2-carboxylate [P6,6,6,14][Amp] 
 
Figure 3.5 Struture of [P6,6,6,14][Amp]. 
Trihexyltetradecyl phosphonium chloride (1.006 g; 1.94 mmol) was dissolved in 
methanol and passed through an ion-exchange column Amberlite IRA-400-OH26,30 (5 
eq., flux rate 0.133 mLmL-1min-1 = 8 BVh-1). Then, trihexyltetradecylphosphonium 
hydroxide solution was slowly added to ampicillin (0.761 g; 2.18 mmol) dissolved in 
1.0 M ammonium solution (50 mgmL-1). The mixture was stirred at room temperature 
for 1 h. After solvent evaporation, the residue was dissolved in 20 mL of 
(methanol/acetonitrile 1:9)26,30 and left refrigerated overnight (4 oC)30 to induce 
crystallization of ampicillin excess. Then, ampicillin crystals were filtered from the 
solution which was evaporated and dried in vacuum for 24 h. The desired product was 
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obtained as a yellow viscous liquid (1.331 g; 80.0 %). [α]D27= 22.3 ± 1.5 (c = 2 mgmL-1 in 
methanol; Water content = 14.7 ppm (determined by Karl Fisher titration); 1H-NMR 
(400.13 MHz, CD3OD)  = 7.48-7.27 (m, 5H), 5.01 (d, 1H, J  = 6.0 Hz), 4.59 (s, 1H), 4.31 (d, 
1H, J  = 6.0 Hz), 3.44 (s, 1H), 2.19 (m, 8H), 1.65-1.22 (m, 54H) 0.94 (m, 12H) ppm; 13C-
NMR (100.62 MHz, CD3OD)  = 175.60, 174.90, 141.97, 129.76, 128.91, 128.35, 77.15, 
66.59, 60.34, 60.16, 59.52, 33.12, 32.20, 31.85, 31.70, 31.63, 31.48, 30.85, 30.83, 30.81, 30.71, 
30.53, 30.46, 29.92, 27.80, 27.46, 23.79, 23.51, 22.39, 22.35 22.30, 19.50, 19.44, 19.03, 18.97, 
14.51, 14.38 ppm; IR (KBr): ν = 3301, 3186, 3060, 2956, 2952, 2855, 1671, 1601, 1485, 1317, 
1299, 1268, 1215, 1130, 1111, 1028 cm-1; (EI+) m/z calcd for C32H68P+: 483.5053, found 
483.5056; (EI-) m/z calcd for C16H18N3O4S-: 348.1024, found 348.1013.  
 
Figure 3.6. [P6,6,6,14][Amp] 1H-NMR spectrum in CD3OD. 
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Figure 3.7. [P6,6,6,14][Amp] 13C-NMR spectrum in CD3OD. 
 
Figure 3.8. [P6,6,6,14][Amp] IR spectrum in KBr. 
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3.1.1.3 Preparation of 1-Hexadecylpyridin-1-ium (2S,5R,6R)-6-((R)-2-amino-2-
phenylacetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-
carboxylate [C16Pyr][Amp]  
 
Figure 3.9 Struture of [C16Pyr][Amp]. 
Cetylpyridinium chloride (0.694 g; 2.04 mmol), was dissolved in methanol and passed 
through an ion-exchange column Amberlite IRA-400-OH26,30 (5 eq., flux rate  
0.133 mLmL-1min-1 = 8 BVh-1). Then, cetylpyridinium hydroxide solution was slowly 
added to ampicillin (0.714 g; 2.12 mmol) dissolved in 1.0 M ammonium solution (50 
mgmL-1). The mixture was stirred at room temperature for 1 h. After solvent 
evaporation the residue was dissolved in 20 mL of (methanol/acetonitrile 1:9)26,30 and 
left refrigerated overnight (4 oC)30 to induce crystallization of ampicillin excess. Then, 
ampicillin crystals were filtered from the solution which was evaporated and dried in 
vacuum for 24h. The desired product was obtained as a yellow solid (1.018 g; 76.4 %). 
m.p. 86oC; [α]D27= 51.7  0.9 (c = 2 mgmL-1 in methanol); 1H-NMR (400.13 MHz, CD3OD) 
 = 8.98 (2H, d, J = 5.5Hz), 8.58 (1H, t, J = 7.8Hz), 8.10 (2H, t, J = 6.70Hz) 7.47 (2H, d, J = 
7.3Hz), 7.35 (2H, t, J = 7.4Hz), 7.28 (1H, d, J = 7.3Hz), 5.0 (1H, d, J = 6.0 Hz), 4.62 (3H,m), 
4.33 (1H, d, J = 6.0), 3.43 (1H, s), 2.01 (2H, m), 1.65-1.11 (32H), 0.90 (3H, t, J = 6.7 Hz) 
ppm; 13C-NMR (100.62MHz, CD3OD)  = 175.52, 174.80 , 170.23, 146.87, 145.93, 129.88, 
129.78, 129.76, 129.72, 129.56, 129.02, 128.59, 77.15, 66.65, 63.15, 62.40, 61.41, 60,18, 59.55, 
33.09, 32.52, 30.80, 30.78, 30.74, 30.65, 30.53, 30.49, 30.15, 27.78, 27.45, 27.73, 23.76, 14.48 
ppm; IR (KBr):  = 3419, 3061, 2923, 2852, 1688, 1593, 1483, 1456, 1385, 1176, 1130, 1029, 
964, 778, 686 cm–1; (EI+) m/z calcd for C21H38N+: 304.2999, found 304.2999; (EI-) m/z calcd 
for C16H18N3O4S-: 348.1024, found 348.1013.  
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Figure 3.10. [C16Pyr][Amp] 1H-NMR spectrum in CD3OD. 
 
Figure 3.11. [C16Pyr][Amp] 13C-NMR spectrum in CD3OD. 
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Figure 3.12. [C16Pyr][Amp] IR spectrum in KBr. 
3.1.1.4 Preparation of (2-Hydroxyethyl)trimethylammonium (2S,5R,6R)-6-((R)-
2-amino-2-phenylacetamido)-3,3-dimethyl-7-oxo-4-thia-1-
azabicyclo[3.2.0]heptane-2-carboxylate [Cholin][Amp] 
 
Figure 3.13 Struture of [Cholin][Amp]. 
(2-Hydroxyethyl)-trimethylammonium chloride (0.546 g; 3.91 mmol) was dissolved in 
methanol and passed through an ion-exchange column Amberlite IRA-400-OH26,30 (5 
eq., flux rate 0.133 mLmL-1min-1 = 8 BVh-1).  Then, choline hydroxide solution was 
slowly added to ampicillin (1.606 g; 4.60 mmol) dissolved in 1.0 M ammonium solution 
(50 mgmL-1). The mixture was stirred at room temperature for 1 h. After solvent 
evaporation, the residue was dissolved in 20 mL of (methanol/acetonitrile 1:9)26,30 and 
left refrigerated overnight (4 oC)30 to induce crystallization of ampicillin excess. Then, 
ampicillin crystals were filtered from the solution which was evaporated and dried in 
vacuum for 24 h. The desired product was obtained as a yellow solid (1.252 g; 70.7 %). 
m.p. 58 oC; [α]D27= 52.3 ± 0.8 (c = 2 mgmL-1 in methanol); 1H-NMR (400.13 MHz, 
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(CD3OD)  = 7.49-7.27 (5H, m, Ar), 5.00 (1H, d, J = 6.0 Hz), 4.65 (1H, s), 4.34 (1H, d, J = 
6.0Hz), 3.98 (2H, m), 3.46 (2H, m), 3.42 (1H, s), 3.19 (9H, s), 1.45 (3H, s), 1.22 (3H, s) 
ppm; 13C-NMR (100.62 MHz, CD3OD)  = 175.59, 174.91, 174.82, 140.95, 129.88, 129.22, 
128.56, 77.11, 69.06, 66.67, 60,20, 60.04, 59.53, 57.10, 54.73, 27.78, 27.47 ppm; IR (KBr):  = 
3042, 2826, 1668, 1595, 1490, 1456, 1385, 1285, 1194, 1132, 1086, 1005, 922, 866, 784, 740, 
702 cm-1; (EI+) m/z calcd for C5H14NO+: 104,1070, found 104.1070; (EI-) m/z calcd for 
C16H18N3O4S-: 348,1024, found 348.1013. 
 
Figure 3.14. [Choline][Amp] 1H-NMR spectrum in CD3OD. 
 
Figure 3.15. [choline][Amp] 13C-NMR spectrum in CD3OD. 
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Figure 3.16. [choline][Amp] IR spectrum in KBr. 
3.1.1.5 Preparation of 1-Ethyl-3-methyl-1H-imidazol-3-ium (2S,5R,6R)-6-((R)-
2-amino-2-phenylacetamido)-3,3-dimethyl-7-oxo-4-thia-1-
azabicyclo[3.2.0]heptane-2-carboxylate [EMIM][Amp]  
 
Figure 3.17 Struture of [EMIM][Amp]. 
1-Ethyl-3-methyl-1H-imidazol-3-ium chloride (0.576 g; 3.93 mmol) was dissolved in 
methanol and passed through an ion-exchange column Amberlite IRA-400-OH26,30 (5 
eq., flux rate 0.133 mLmL-1min-1 = 8 BVh-1). Then the 1-ethyl-3-methylimidazolium 
hydroxide solution was slowly added to Ampicillin (1.606 g; 4.60 mmol) dissolved in 
1M ammonium solution (50 mgmL-1). The mixture was stirred at room temperature for 
1 h. After solvent evaporation, the residue was dissolved in 20 mL solution 
(methanol/acetonitrile 1:9)26,30 and left refrigerated overnight (4 oC)30 to induce 
crystallization of excess of ampicillin. Then, ampicillin crystals were filtered from the 
solution which was evaporated and dried in vacuum for 24 h. The desired product was 
obtained as a yellow solid (1.709 g; 94.6 %). m.p.  70-72 oC); [α]D27 = 89.3  5.5 (c = 2 
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mgmL-1 in methanol); 1H-NMR (400.13 MHz, CD3OD)  = 7.63 (1H, d, J = 1.9Hz), 7.55 
(1H, d, J = 1.9Hz), 7.48-7.46 (2H, m), 7.36-7.32 (2H, m), 7.27-7.25 (1H, m), 5.01 (1H, d, J = 
6.0 Hz), 4.59 (1H, s), 4.32 (1H, d, J = 6.0 Hz), 4.24 (2H, q, J = 7.4Hz), 3.90 (3H, s), 3.43 
(1H, s), 1.52 (3H, t, J = 7.4Hz), 1.46 (3H, s), 1.22 (s, 3H) ppm; 13C-NMR (100.62, MHz, 
CD3OD)  = 175.57, 175.15, 174.84, 141.24, 129.83, 129.12, 128.50, 124.96, 123.31, 77.12, 
66.67, 60,18, 60.11, 59.54, 46.03, 36.46, 27.78, 27.47, 15.63 ppm; IR (KBr):  = 3381, 2974, 
2925, 2828, 1668, 1591, 1516, 1456, 1393, 1255, 1169, 1130, 1029, 962, 877, 824, 788, 746, 
702, 648 cm-1; (EI+) m/z calcd for C6H11N2+: 111,0917, found 111.0917; (EI-) m/z calcd for 
C16H18N3O4S-: 348,1024, found 348.1013. 
 
Figure 3.18. [EMIM][Amp] 1H-NMR spectrum in CD3OD. 
Chapter 3 Material and Methods 
59 
 
 
Figure 3.19. [EMIM][Amp] 13C-NMR spectrum in CD3OD. 
 
Figure 3.20. [EMIM][Amp] IR spectrum in KBr. 
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3.1.1.6 Preparation of 3-(2-Hydroxyethyl)-1-methyl-1H-imidazol-3-ium 
(2S,5R,6R)-6-((R)-2-amino-2-phenylacetamido)-3,3-dimethyl-7-oxo-4-thia-1-
azabicyclo[3.2.0]heptane-2-carboxylate [C2OHMIM][Amp] 
 
Figure 3.21 Struture of [C2OHMIM][Amp]. 
3-(2-Hydroxyethyl)-1-methyl-1H-imidazol-3-ium chloride (0.625 g; 3.86 mmol) was 
dissolved in methanol and passed through an ion-exchange column Amberlite IRA-
400-OH26,30 (5 eq., flux rate 0.133 mLmL-1min-1 = 8 BVh-1).  Then the hydroxide solution 
formed was slowly added to Ampicillin (1.624 g; 4.65 mmol; 1.2 eq) dissolved in 1.0 M 
ammonium solution (50 mgmL-1). The mixture was stirred at room temperature for 1 h. 
After solvent evaporation, the residue was dissolved in 20 mL of (methanol/acetonitrile 
1:9)26,30 and left refrigerated overnight (4 oC)30 to induce crystallization of excess of 
ampicillin. Then, ampicillin crystals were filtered from the solution which was 
evaporated and dried in vacuum for 24 h. The desired product was obtained as a yellow 
solid (1.593 g; 86.8 %). m.p. 115-117 oC; [α]D26= 86.3  4.5 (c = 2 mgmL-1 in methanol); 1H-
NMR (400.13 MHz, CD3OD)  = 7.61 (1H, d, J= 1.8Hz, k), 7.55 (1H, d, J = 1.8Hz, j), 7.47 
(2H, d, J = 7.2Hz, m), 7.35 (2H, t, J = 7.3Hz,l), 7.29 (1H, d, J = 7.2Hz, n), 5.00 (1H, d, J =6.0 
Hz, c), 4.63 (1H, s, b), 4.33 (1H, d, J =6.0 Hz, d), 4.28 (2H, t, J =3.8 Hz, g), 3.92 (3H, s, f), 
3.87 (2H, t, J=3.8 Hz), 3.42 (1H, s), 1.45 (3H, s), 1.22 (3H, s) ppm; 13C-NMR (100.62 MHz, 
CD3OD)  = 175.60, 175.17, 174.85, 141.22, 129.85, 129.14, 128.51, 124.74, 124.03, 77.11, 
66.67, 61.06, 60.19, 60.12, 59.53, 53.29, 36.46, 27.78, 27.48 ppm; IR (KBr):  = 3394, 2969, 
2888, 2836, 1674, 1545, 1456, 1394, 1299, 1253, 1167, 1131, 1073, 1027, 1071, 871, 784, 752, 
702, 652, 622 cm–1; (EI+) m/z calcd for C6H11N2O+: 127.0866, found 127.0866; (EI-) m/z 
calcd for C16H18N3O4S-: 348.1024, found 348.1013. 
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Figure 3.22. [C2OHMIM][Amp] 1H-NMR spectrum in CD3OD. 
 
Figure 3.23. [C2OHMIM][Amp] 13C-NMR spectrum in CD3OD. 
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Figure 3.24. [C2OHMIM][Amp] IR spectrum in KBr. 
 
3.1.2 Synthesis of Penicillin ILs 
3.1.2.1 Preparation of Ammonium (2S,5R,6R)-3,3-dimethyl-7-oxo-6-(2-
phenylacetamido)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate [NH4][Pen] 
 
Figure 3.25 Struture of [NH4][Pen]. 
The potassium penicillin was transformed in ammonium penicillin before the reaction 
with hydroxide reactants. The ammonium penicillin was obtained by the dissolution of 
potassium penicillin (5.141 g, 13.80 mmol) in 6.5 mL of ammonium sulphate saturate 
solution at a pH = 6.5. The solution was stirred at room temperature for 24 h. After that 
period the solution was filtered and washed with ammonium sulphate solution  
(50 %).The ammonium penicillin was obtained as a white cristaline solid (4.774 g, 98 %) 
and dried in vacuum for 24 h. 1H-NMR (400.13 MHz, D2O)  = 7.28-7.23 (m, 5H), 5.41 (s, 
1H), 5.33 (s, 1H), 4.12 (s, 1H), 3.57 (m, 2H), 1.47 (s, 3H), 1.38 (s, 3H) ppm. 
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Figure 3.26. [NH4+][Pen] 1H-NMR spectrum in D2O. 
3.1.2.2 Preparation of Tetraethylammonium (2S,5R,6R)-3,3-dimethyl-7-oxo-6-
(2-phenylacetamido)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate 
[TEA][Pen]  
 
Figure 3.27 Struture of [TEA][Pen]. 
Tetraethylammonium bromide (0.420 g; 2.00 mmol) was dissolved in methanol and 
passed through an ion-exchange column Amberlite IRA-400-OH26,30 (5 eq., flux rate 
0.133 mLmL-1min-1 = 8 BVh-1). Then the tetraethylammonium hydroxide solution 
formed was slowly added to the ammonium penicillin (0.751 g; 2.14 mmol) dissolved 
in 1.0 M ammonium solution (50 mgmL-1). The reaction mixture was stirred at room 
temperature for 1 h. After solvent evaporation, the residue was dissolved in 20 mL 
solution (methanol/acetonitrile 1:9)26,30 and left refrigerated overnight (4 oC)30 to induce 
crystallization of excess of ammonium penicillin. Then ammonium penicillin crystals 
were filtered from the solution, the solution was evaporated and the rest dried in 
vacuum for 24 h to provide desired the product as a yellow viscous liquid (0.856 g; 
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92%). [α]D25 = 104.0  6.1 (c = 2 mgmL-1 in methanol), 1H-NMR (400.13 MHz, CD3OD)  = 
7.31-7.22 (m, 5H), 5.46 (s, 1H), 4.17 (s, 1H) 3.70 (s, 1H) , 3.63-3.58 (m, 2H), 3.51 (bs, 1H), 
3.27-3.26 (m, 8H), 1.63 (s, 3H), 1.55 (s, 3H), 1.30-1.24 (m, 12H); 13C-NMR (100.62 MHz, 
CD3OD)  = 174.72, 174.37, 174.15, 140.88, 136.73, 130.31, 130.25, 129.63, 127.96, 75.73, 
66.68, 60.19, 59.27, 53.29, 46.65, 43.83, 29.41, 28.67, 28.38, 27.66, 7.64 ppm; IR (KBr):  = 
3420, 2981, 2924, 2862, 1840, 1736, 1721, 1648, 1560, 1543, 1490, 1459, 1432, 1396, 1367, 
1173, 1130, 1053, 1027, 1001, 785, 734, 696, 619, 539 cm-1; (ESI+) m/z calcd for C8H20N+: 
130.1 found 130.0; (ESI-) m/z calcd for C16H17N2O4S- 333.4 found [M+OH]- 349.8. 
 
Figure 3.28. [TEA][Pen] 1H-NMR spectrum in CD3OD. 
 
Figure 3.29. [TEA][Pen] 13C-NMR spectrum in CD3OD. 
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Figure 3.30. [TEA][Pen] IR spectrum in KBr. 
3.1.2.3 Preparation of Trihexyl(tetradecyl)phosphonium 3 (2S,5R,6R)-3,3-
dimethyl-7-oxo-6-(2-phenylacetamido)-4-thia-1-azabicyclo[3.2.0]heptane-2-
carboxylate [P6,6,6,14][Pen] 
 
Figure 3.31 Struture of [P6,6,6,14][Pen]. 
Trihexyl(tetradecyl) chloride (1.000 g; 1.92 mmol) was dissolved in methanol and 
passed through an ion-exchange column Amberlite IRA-400-OH26,30 (5 eq., flux rate 
0.133 mLmL-1min-1 = 8 BVh-1). Then the trihexyl(tetradecyl)phosphonium hydroxide 
solution formed was slowly added to ammonium penicillin (0.853 g; 2.43 mmol) 
dissolved in 1.0 M ammonium solution (50 mgmL-1). The mixture was stirred at room 
temperature for 1 h. After solvent evaporation, the residue was dissolved in 20 mL 
solution (methanol/acetonitrile 1:9)26,30 and left refrigerated overnight (4 oC)28 to induce 
crystallization of excess of ammonium penicillin. Then ammonium penicillin crystals 
were filtered from the solution, the solution was evaporated and the rest dried in 
vacuum for 24 h to provide the desired product as a yellow viscous liquid (1.560 g; 
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99%). [α]D25 = 67.7  3.0 (c = 2 mgmL-1 in methanol); 1H-NMR (400.13 MHz, CD3OD)  = 
7.34-7.22 (m, 5H), 4.97 (1H, d, J = 6.7 Hz), 4.34 (dd, 1H, J = 6.7 Hz), 3.60 (d, 2H, J = 8.2 
Hz), 3.50 (s, 1H), 2.20 (m, 8H), 1.56-1.25 (m, 54H), 0.96-0.88 (m, 12H) ppm ; 13C-NMR 
(100.62 MHz, CD3OD)  = 175.30, 174.83, 173.92, 136.76, 130.37, 129.59, 127.87, 76.81, 
66.78, 60.14, 54.86, 43.68, 33.11, 32.19, 31.92, 31.84, 30.80, 30.51, 30.45, 29.91, 27.88, 23.77, 
23.49, 22.36, 19.53, 19.05, 14.51, 14.38 ppm; IR (KBr): ν = 3308, 3028, 2951, 2923, 2853, 
1737, 1669, 1607, 1536, 1496, 1456, 1418, 1379, 1262, 1201, 1113, 1031, 986, 860, 810, 761, 
722, 694, 617, 454, 439, 424 cm-1; (ESI+) m/z calcd for C32H68P+: 483.4 found 483.8; (ESI-) 
m/z calcd for C16H17N2O4S- 333.4, found [M+OH]- 349.9. 
 
 
Figure 3.32. [P6,6,6,14][Pen] 1H-NMR spectrum in CD3OD. 
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Figure 3.33. [P6,6,6,14][Pen] 13C-NMR spectrum in CD3OD. 
 
Figure 3.34. [P6,6,6,14][Pen] IR spectrum in KBr. 
Chapter 3 Material and Methods 
68 
3.1.2.4 Preparation of 1-Hexadecylpyridin-1-ium (2S,5R,6R)-3,3-dimethyl-7-
oxo-6-(2-phenylacetamido)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate 
[C16Pyr][Pen]  
 
Figure 3.35 Struture of [C16Pyr][Pen]. 
Cetylpyridinium chloride (0.822 g; 2.30 mmol) was dissolved in methanol and passed 
through an ion-exchange column Amberlite IRA-400-OH26,30 (5 eq., flux rate  
0.133 mLmL-1min-1). Then the cetylpyridinium hydroxide solution formed was slowly 
added to ammonium penicillin (0.973 g; 2.77 mmol) dissolved in 1.0 M ammonium 
solution (50 mgmL-1). The mixture was stirred at room temperature for 1 h. After 
solvent evaporation, the residue was dissolved in a 20 mL solution 
(methanol/acetonitrile 1:9)26,30 and left refrigerated overnight (4 oC)30 to induce 
crystallization  of excess of ammonium penicillin. Then ammonium penicillin crystals 
were filtered from the solution, the solution was evaporated and the rest dried in 
vacuum for 24 h to provide the desired product as a yellow solid (1.332 g; 91%). m.p. 76-
78 oC; [α]D25 = 47.3  3.6 (c = 2 mgmL-1 in methanol); 1H-NMR (400.13 MHz, CD3OD)  = 
9.01 (d, 2H, J = 5.7 Hz), 8.59 (t, 1H, J  = 7.8 Hz), 8.12 (t, 2H, J = 6.8 Hz ), 7.33-7.21 (m, 5H), 
4.95 (d, 1H, J = 7.1 Hz), 4.63 (t, 2H, J  = 7.5Hz,), 4.35 (d, 1H, J = 7.0 Hz), 3.60 (2H, d, J = 7.5 
Hz), 3.50 (s, 1H), 1.56 (m, 3H), 1.42-1.09 (m, 31H), 0.90 (t, 3H, J = 6.6 Hz) ppm; 13C-NMR 
(100.62 MHz, CD3OD)  =175.16, 174.78, 173.98, 146.87, 146.00, 136.73, 130.40, 129.80, 
129.60, 127.93, 76.34, 66.64, 63,15, 60.14, 43.67, 33.12, 32.55, 30.81, 30.67, 30.17, 27.86, 
27.24, 23.78, 14.49 ppm; IR (KBr):  = 3041, 3059, 2914, 2848, 1739, 1658, 167, 1601, 1542, 
1528, 1508, 1487, 1472, 1397, 1368, 1322, 1270, 1209, 1177, 1128, 1078, 1032, 987, 960, 926, 
818, 777, 716, 686, 619, 574, 475 cm-1; (ESI+) m/z calcd for C21H38N+: 304.3 found 304.2; 
(ESI-) m/z calcd for C16H17N2O4S- 333.4, found [M+OH]- 349.9.  
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Figure 3.36. [C16Pyr][Pen] 1H-NMR spectrum in CD3OD. 
 
Figure 3.37. [C16Pyr][Pen] 13C-NMR spectrum in CD3OD. 
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Figure 3.38. [C16Pyr][Pen] IR spectrum in KBr. 
3.1.2.5 Preparation of (2-Hydroxyethyl)-Trimethylammonium (2S,5R,6R)-3,3-
dimethyl-7-oxo-6-(2-phenylacetamido)-4-thia-1-azabicyclo[3.2.0]heptane-2-
carboxylate [Cholin][Pen] 
 
Figure 3.39 Struture of [Cholin][Pen]. 
(2-Hydroxyethyl)-trimethylammonium chloride (0.277 g; 1.99 mmol) was dissolved in 
methanol and passed through an ion-exchange column Amberlite IRA-400-OH26,30 (5 
eq., flux rate 0.133 mLmL-1min-1 = 8 BVh-1). Then the hydroxide solution formed was 
slowly added to ammonium penicillin (0.848 g; 2.41 mmol) dissolved in 1.0 M 
ammonium solution (50 mgmL-1). The mixture was stirred at room temperature for 1 h. 
After solvent evaporation, the residue was dissolved in a 20 mL solution 
(methanol/acetonitrile 1:9)26,30 and left refrigerated overnight (4 oC)30 to induce 
crystallization of excess of ammonium penicillin. Then ammonium penicillin crystals 
were filtered from the solution, the solution was evaporated and the rest dried in 
vacuum for 24 h to provide the desired product as a yellow solid (0.856 g; 98 %). m.p. 
69-71 oC; [α]D25 = 47.3  3.6 (c = 2 mgmL-1 in methanol); 1H-NMR (400.13 MHz, CD3OD) 
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 = 7.33-7.29 (m, 5H), 4.95 (d, 1H, J1 = 7.0 Hz), 4.35 (d, 1H, J1 = 7.0 Hz), 4.02-3.98 (m, 2H), 
3.66-3.56 (m, 2H), 3.50-3.47 (m, 3H), 3.20 (s, 9H) 1.56 (s, 3H), 1.25 (s, 3H) ppm; 13C-NMR 
(100.62 MHz, CD3OD)  = 174.72, 174.37, 174.15, 140.88, 136.73, 130.31, 130.25, 129.63, 
127.96, 75.73, 69.06, 66.67, 60.20, 60.04, 59.53, 57.10, 46.65, 27.78, 27.47 ppm; IR (KBr):  = 
3468, 3074, 2966, 1652, 1496, 1479, 1461, 1396, 1356, 1279, 1204, 1131, 1083, 1054, 1010, 
955, 887, 867, 796, 734, 702, 670, 620, 540, 476 cm-1; (ESI+) m/z calcd for C5H14NO+: 104.1, 
found 104.1; (ESI-) m/z calcd for C16H18N3O4S-: 333.4, [M+OH]- 349.9.  
 
Figure 3.40. [Choline][Pen] 1H-NMR spectrum in CD3OD. 
 
Figure 3.41. [Choline][Pen] 13C-NMR spectrum in CD3OD. 
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Figure 3.42. [Choline][Pen] IR spectrum in KBr 
3.1.2.6 Preparation of 1-Ethyl-3-methyl-1H-imidazol-3-ium (2S,5R,6R)-3,3-
dimethyl-7-oxo-6-(2-phenylacetamido)-4-thia-1-azabicyclo[3.2.0]heptane-2-
carboxylate [EMIM][Pen] 
 
Figure 3.43 Struture of [EMIM][Pen]. 
1-Ethyl-3-methyl-1H-imidazol-3-ium bromide (0.578 g; 3.03 mmol) was dissolved in 
methanol and passed through an ion-exchange column Amberlite IRA-400-OH26,30 (5 
eq., flux rate 0.133 mLmL-1min-1 = 8 BVh-1). Then the hydroxide solution formed was 
slowly added to ammonium penicillin (1.11 g; 3.16 mmol) dissolved in 1.0 M 
ammonium solution (50 mgmL-1). The mixture was stirred at room temperature for 1 h. 
After solvent evaporation, the residue was dissolved in a 20 mL solution 
(methanol/acetonitrile 1:9)26,30 and left refrigerated overnight (4 oC)30 to induce 
crystallization  of excess of ammonium penicillin. Then ammonium penicillin crystals 
were filtered from the solution, the solution was evaporated and the rest dried in 
vacuum for 24 h to provide the desired product as a viscous liquid (1.136 g; 84.4%). 
[α]D25 = 89.0  7.0 (c = 2 mgmL-1 in methanol); 1H-NMR (400.13 MHz, CD3OD)  = 8.99 
(bs, 1H), 7.63 (s, 1H) 7.53 (s, 1H), 7.34-7.20 (m, 5H), 4.95 (d, 1H, J = 7.0 Hz), 4.35 (d, 1H, J 
= 7.0 Hz), 4.24 (q, 2H, J = 7.3 Hz), 3.92 (s, 3H), 3.60 (d, 2H, J = 7.2 Hz), 3.50 (s, 1H), 1,60-
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1.50 (m, 6H), 1.25 (s, 3H) ppm; 13C-NMR (100.62 MHz, CD3OD)  = 175.06, 174.83, 
173.99, 136.80, 130.65, 130.39, 129.60, 127.90, 124.94, 123.25, 76.51, 60.13, 60.18, 60.11, 
59.54, 46.02, 43.66, 36.51, 27.81, 27.65, 15.61 pm; IR (KBr):  = 3468, 3368, 2970, 1660, 
1540, 1501, 1456, 1395, 1456, 1395, 1354, 1300, 1258, 1169, 1131, 1301, 965, 918, 862, 828, 
729, 700, 651, 620, 545 cm-1; (ESI+) m/z calcd for C6H11N2+: 111.1, found 111.0; (ESI-) m/z 
calcd for C16H18N3O4S-: 333.4, found [M+OH]- 349.9. 
 
Figure 3.44. [EMIM][Pen] 1H-NMR spectrum in CD3OD. 
 
Figure 3.45. [EMIM][Pen] 13C-NMR spectrum in CD3OD. 
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Figure 3.46. [EMIM][Pen] IR spectrum in KBr. 
3.1.2.7 Preparation of 3-(2-Hydroxyethyl)-1-methyl-1H-imidazol-3-ium  
(2S,5R,6R)-3,3-dimethyl-7-oxo-6-(2-phenylacetamido)-4-thia-1-
azabicyclo[3.2.0]heptane-2-carboxylate [C2OHMIM][Pen] 
 
Figure 3.47 Struture of [C2OHMIM][Pen]. 
3-(2-Hydroxyethyl)-1-methyl-1H-imidazol-3-ium chloride (0.328 g; 2.03 mmol) was 
dissolved in methanol and passed through an ion-exchange column Amberlite IRA-
400(OH)26,30 (5 eq., flux rate 0.133 mLmL-1min-1 = 8 BVh-1). Then the hydroxide solution 
formed was slowly added to ammonium penicillin (0.754 g; 2.14 mmol) dissolved in 1.0 
M ammonium solution (50 mgmL-1). The mixture was stirred at room temperature for 1 
h. After solvent evaporation, the residue was dissolved in 20 mL solution 
(methanol/acetonitrile 1:9)26,30 and left refrigerated overnight (4 oC)30 to induce 
crystallization of excess of ammonium penicillin. Then ammonium penicillin crystals 
were filtered from the solution, the solution was evaporated and the rest dried in 
vacuum for 24 h to provide the desired product as a yellow solid (0.799 g; 85.6 %). m.p. 
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48-50 oC; [α]D25 = 41.3  6.0 (c = 2 mgmL-1 in methanol); 1H-NMR (400.13 MHz, CD3OD) 
 = 8.98, (s, 1H), 7.61 (s, 1H), 7.54 (s, 1H), 7.33-7.21 (m, 5H), 4.94 (d, 1H, J = 7.1 Hz), 4.36 
(d, 1H, J = 7.1 Hz), 4.29 (t, 2H, J = 4.9 Hz), 3.92, (s, 3H), 3.86 (t, 2H, J = 4.9 Hz), 3.59 (d, 
2H, J = 7.1 Hz), 3.50 (s, 1H), 1.55 (s, 3H), 1.24 (s, 3H) ppm; 13C-NMR (100.62 MHz, 
CD3OD)  = 175.04, 174.82, 174.00, 136.78, 130.63, 130.51, 130.40, 129.61, 129.85, 129.61, 
127.91, 124.68, 124.00, 76.50, 66.76, 61.10, 60.12, 59.53, 53.26, 43.65, 36.45, 27.84 ppm; IR 
(KBr):  = 3418, 2965, 2931, 2108, 1644, 1585, 1499, 1455, 1398, 1356, 1260, 1167, 1127, 
1076, 1034, 879, 798, 734, 704, 668, 619, 464, 445, 432, 424 cm-1; (ESI+) m/z calcd for 
C6H11N2O+: 127.2, found 127.0; (ESI-) m/z calcd for C16H18N3O4S-: 333.4, found [M+OH]- 
349.9.  
 
Figure 3.48. [C2OHMIM][Pen] 1H-NMR spectrum in CD3OD. 
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Figure 3.49. [C2OHMIM][Pen] 13C-NMR spectrum in CD3OD. 
 
Figure 3.50. [C2OHMIM][Pen] IR spectrum in KBr. 
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Figure 3.51. a) Sulphoxide Penicillin2 1H-NMR spectrum in CD3OD. b) Potassium Penicillin 1H-
NMR spectrum in CD3OD. 
 
3.1.3 Synthesis of Amoxicillin ILs 
3.1.3.1 Preparation of 1-Ethyl-3-methyl-1H-imidazol-3-ium (2S,5R,6R)-6-((R)-
2-amino-2-(4-hydroxyphenyl)acetamido)-3,3-dimethyl-7-oxo-4-thia-1-
azabicyclo[3.2.0]heptane-2-carboxylate [EMIM][Amx] 
 
Figure 3.52 Struture of [EMIM][Amx]. 
1-Ethyl-3-methyl-1H-imidazol-3-ium chloride (0.385 g; 2.01 mmol) was dissolved in 
methanol and passed through an ion-exchange column Amberlite IRA-400-OH26,30 (5 
eq., flux rate 0.133 mLmL-1min-1 = 8 BVh-1). Then the hydroxide solution formed was 
slowly added to amoxicillin trihydrate (0.930 g; 2.22 mmol) dissolved in 1.0 M 
                                                     
2 Sulphoxide Penicillin was prepared according Lim et al.( Y.-H. Lim, D.-H. Park, Y.-Y. Youn, K.-
H. Kim and H.-S. Cho, Mass Spectrometry Letters, 2011, 2, 16.  
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ammonium solution (50 mgmL-1). The mixture was stirred at room temperature for 1 h. 
After solvent evaporation, the residue was dissolved in 20 mL solution 
(methanol/acetonitrile 1:9)26,30 and left refrigerated overnight (4 oC)30 to induce 
crystallization  of excess of amoxicillin. Then amoxicillin crystals were filtered from the 
solution, the solution was evaporated and the rest dried in vacum for 24 h to provide 
the desired product as a yellow solid (0.768 g; 80.2 %). m.p. 84-86 oC; [α]D25 = 48.3  5.0 
(c = 2 mgmL-1 in methanol); 1H-NMR (400.13 MHz, CD3OD)  = 7.64 (s, 1H), 7.56 (s, 1H), 
7.27 (d, 2H, J = 8.2 Hz), 6.74 (d, 2H, J = 8.4 Hz), 5.00 (d, 1H, J1 = 5.9 Hz), 4.74 (s, 1H), 4.30 
(d, 1H, J1 = 5.9 Hz), 4.25 (1, 2H, J =  7.3 Hz), 3.77 (bs, 1H), 3.92 (s, 3H), 3.73, (bs, 1H), 3.43 
(bs, 1H), 3.35 (s, 1H, s), 1.55-1.48 (m, 6H); 1.22 (s, 3H) ppm; 13C-NMR (100.62 MHz, 
CD3OD)  = 175.57 , 175.15, 174.84, 141.24, 129.83, 129.12, 128.50, 124.96, 123.31, 77.12, 
66.67, 60.18, 60.11, 59.54, 46.03, 36.46, 27.78, 27.47, 15.63 ppm; IR (KBr):  = 3461, 2921, 
2852, 1706, 1688,1656, 1636, 1560, 1541, 1508, 1461, 1403, 1348, 1260, 1170, 1130, 673, 620, 
474, 422 cm-1; (ESI+) m/z calcd for C6H11N2+: 111.1, found 111.0; (ESI-) m/z calcd for 
C16H18N3O5S-: 364.4, found [M+OH]- 380.8. 
 
Figure 3.53. [EMIM][Amx] 1H-NMR spectrum in CD3OD. 
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Figure 3.54. [EMIM][Amx] 13C-NMR spectrum in CD3OD. 
 
Figure 3.55. [EMIM][Amx] IR spectrum in KBr. 
Chapter 3 Material and Methods 
80 
3.1.3.2 Preparation of Trihexyl(tetradecyl)phosphonium (2S,5R,6R)-6-((R)-2-
amino-2-(4-hydroxyphenyl)acetamido)-3,3-dimethyl-7-oxo-4-thia-1-
azabicyclo[3.2.0]heptane-2-carboxylate [P6,6,6,14][Amx] 
 
Figure 3.56 Struture of [P6,6,6,14][Amx]. 
Trihexyl(tetradecyl) chloride (1.042 g; 2.01 mmol) was dissolved in methanol and 
passed through an ion-exchange column Amberlite IRA-400-OH26,30 (5 eq., flux rate 
0.133 mLmL-1min-1 = 8 BVh-1). Then the trihexyl(tetradecyl)phosphonium hydroxide 
solution formed was slowly added to amoxicillin (0.988 g ; 2.36 mmol) dissolved in 1.0 
M ammonium solution (50 mgmL-1). The mixture was stirred at room temperature for 1 
h. After solvent evaporation, the residue was dissolved in 20 mL solution 
(methanol/acetonitrile 1:9)26,30 and left refrigerated overnight (4 oC)28 to induce 
crystallization of excess of amoxicillin. Then amoxicillin crystals were filtered from the 
solution, the solution was evaporated and the rest dried in vacuum for 24 h to provide 
the desired product as a yellow viscous liquid (1.586 g; 93.5%). [α]D25 = 22.0  5.8 (c = 2 
mgmL-1 in methanol); (400.13 MHz, CD3OD)  = 7.28 (d, 2H, J = 8.4 Hz), 6.76 (d, 2H, J = 
8.4 Hz), 5.00 (d, 1H, J = 5.9 Hz), 4.53 (s, 1H), 4.31 (d, 1H, J = 5.9 Hz), 3.42 (s, 1H), 2.23-
2.16 (m, 8H), 1.60-1.22 (m, 54H), 0.95-0.88 (m, 12H) ppm; 13C-NMR (100.62 MHz, 
CD3OD)  = 175.35, 174.22, 142.01, 129.62, 128.92, 116.59, 77.12, 66.57, 60.17, 54.94, 43.76, 
33.18, 32.27, 31.93, 31.56, 30.89, 30.58, 30.01, 27.96, 23.85, 23.57, 22.45, 19.62, 19.15, 14.58, 
14.46 ppm; IR (KBr): ν = 3419, 3921, 2107.38, 1638, 1560, 1506, 1459, 1398, 1270, 1130, 
1000, 668, 619, 570, 476, 456, 433, 412 cm-1; (ESI+) m/z calcd for C32H68P+: 483.85 found 
483.58; (ESI-) m/z calcd for C16H18N3O5S-: 364.40, found [M+OH]- 380.98. 
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Figure 3.57. [P6,6,6,14] [Amx] 1H-NMR spectrum in CD3OD. 
 
Figure 3.58. [P6,6,6,14] [Amx] 13C-NMR spectrum in CD3OD. 
 
Figure 3.59. [P6,6,6,14][Amx] IR spectrum in KBr. 
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3.1.3.3 Preparation of 1-Hexadecylpyridin-1-ium 6 (2S,5R,6R)-6-((R)-2-amino-
2-(4-hydroxyphenyl)acetamido)-3,3-dimethyl-7-oxo-4-thia-1-
azabicyclo[3.2.0]heptane-2-carboxylate [C16Pyr][Amx] 
 
Figure 3.60 Struture of [C16Pyr][Amx]. 
Cetylpyridinium chloride (0.456 g; 1.28 mmol) was dissolved in methanol and passed 
through an ion-exchange column Amberlite IRA-400-OH26,30 (5 eq., flux rate  
0.133 mLmL-1min-1 = 8 BVh-1). Then the cetylpyridinium hydroxide solution formed was 
slowly added to amoxicillin (0.587 g; 1.40 mmol) dissolved in 1.0 M ammonium solution 
(50 mgmL-1). The mixture was stirred at room temperature for 1 h. After solvent 
evaporation, the residue was dissolved in 20 mL solution (methanol/acetonitrile 1:9)26,30 
and left refrigerated overnight (4 oC)30 to induce crystallization  of excess of amoxicillin. 
Then amoxicillin crystals were filtered from the solution, the solution was evaporated 
and the rest dried in vacuum for 24 h to provide the desired product as a yellow solid 
(0.402 g; 47.0 %). m.p. 96-98 oC; [α]D25 = 77.0  5.8 (c = 2 mgmL-1 in methanol); 1H-NMR 
(400.13 MHz, CD3OD)  = 8.98 (d, 2H, J = 5.8 Hz), 8.58 (t, 1H, J = 7.74 Hz), 8.10 (t, 2H, J = 
6.7 Hz ), 7.26 (d, 2H, J = 8.5 Hz), 6.73 (d, 2H, J = 8.4 Hz), 5.01 (d, 1H, J = 6.0 Hz), 4.62 (t, 
2H, J = 7.5 Hz), 4.46 (s, 1H), 4.30 (d, 1H, J = 6.0 Hz), 3.44 (s, 1H), 2.02, (t, 2H, J = 6.9 Hz), 
1.48 (s, 3H), 1.38 -1.26 (m, 28H), 1.22 (s, 3H) 0.90 (3H, t, J = 6.7 Hz) ppm; 13C-NMR (100.62 
MHz, CD3OD)  =176.32, 175.60, 174.94, 158.32, 150.28, 146.87, 145.91, 132.86, 129.54, 
116.55, 77.13, 66.61, 63,17, 60.14, 33.11, 32.53, 30.80, 30.67, 30.52, 30.16, 27.24, 23.77, 14.49 
ppm; IR (KBr):  = 3440, 2914, 2849, 1685, 1651, 1636, 1560, 1488, 1472, 1400, 1384, 1260, 
1175, 1128, 847, 778, 720, 687, 621, 498, 476 cm-1; (ESI+) m/z calcd for C21H38N+: 304.30 
found 304.38; (ESI-) m/z calcd for C16H18N3O5S- 364.10, found [M+OH]- 380.93. 
Chapter 3 Material and Methods 
83 
 
 
Figure 3.61. [C16Pyr][Amx] 1H-NMR spectrum in CD3OD. 
 
Figure 3.62. [C16Pyr][Amx] 13C-NMR spectrum in CD3OD. 
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Figure 3.63. [C16Pyr][Amx] IR spectrum in KBr. 
3.1.3.4 Preparation of 3-(2-Hydroxyethyl)-1-methyl-1H-imidazol-3- (2S,5R,6R)-
6-((R)-2-amino-2-(4-hydroxyphenyl)acetamido)-3,3-dimethyl-7-oxo-4-thia-1-
azabicyclo[3.2.0]heptane-2-carboxylate [C2OHMIM][Amx] 
 
Figure 3.64 Struture of [C2OHMIM][Amx]. 
3-(2-Hydroxyethyl)-1-methyl-1H-imidazol chloride (0.456 g; 1.28 mmol) was dissolved 
in methanol and passed through an ion-exchange column Amberlite IRA-400-OH26,30 (5 
eq., flux rate 0.133 mLmL-1min-1 = 8 BVh-1). Then the hydroxide solution formed was 
slowly added to amoxicillin (0.525 g; 1.44 mmol) dissolved in 1.0 M ammonium 
solution (50 mgmL-1). The mixture was stirred at room temperature for 1 h. After 
solvent evaporation, the residue was dissolved in 20 mL solution 
(methanol/acetonitrile 1:9)26,30 and left refrigerated overnight (4 oC)30 to induce 
crystallization of excess of amoxicillin. Then amoxicillin crystals were filtered from the 
solution, the solution was evaporated and the rest dried in vacuum for 24 h to provide 
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the desired product as a yellow solid (0.359 g; 62.1 %). m.p. 109-111 oC; [α]D25 = 47.3  
3.6 (c = 2 mgmL-1 in methanol); 1H-NMR (400.13 MHz, CD3OD)  = 7.61 (s, 1H), 7.55 (s, 
1H), 7.27 (d, 2H, J = 8.4 Hz), 6.74 (d, 2H, J = 8.4 Hz), 5.00 (d,1H, J = 6.0 Hz), 4.47 (s, 1H), 
4.30-4.27 (m, 3H), 3.92 (s, 3H), 3.86 (t, 2H, J = 4.86 Hz), 3.43 (s, 1H), 1.48 (s, 3H), 1.22 (s, 
3H) ppm; 13C-NMR (100.62 MHz, CD3OD)  = 176.33, 175.62, 174.95, 158.34, 132.89, 
129.54. 124.75,124.04, 116.56, 77.17 66.64, 61.11, 60.15, 59.83, 59.50, 53.81, 36.45, 27.78, 
27.47 ppm; IR (KBr):  = 3420, 2970, 2921, 1722, 1690, 1655, 1599, 1577, 1545, 1509, 1436, 
1386, 1322, 1251, 1170, 1132, 1108, 1067, 877, 840, 820, 778, 652, 621, 535, 474 cm-1; (ESI+) 
m/z calcd for C6H11N2O+: 127.2, found 127.0; (ESI-) m/z calcd for C16H18N3O5S- 364.10, 
found [M+OH]- 380.9. 
 
Figure 3.65. [C2OHMIM][Amx] 1H-NMR spectrum in CD3OD. 
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Figure 3.66. [C2OHMIM][Amx] 13C-NMR spectrum in CD3OD. 
 
Figure 3.67. [C2OHMIM][Amx] IR spectrum in KBr. 
 
3.1.4 Synthesis of Amphotericin B ILs 
In order to minimize the impact from Grob fragmentation158,159 and ester hydrolysis, 
pure API-ILs based on Amphotericin B were prepared using dried solvents (water-free 
conditions at the beginning of the reaction). 
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3.1.4.1 Preparation of 1-Hexadecylpyridin-1-ium 
(1R,3S,5R,6R,9R,11R,15S,16R,17R,18S,19E,21E,23E,25E,27E,29E,31E,33R,35S,36
R,37S)-33-(((2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyltetrahydro-2H-
pyran-2-yl)oxy)-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-
dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-
carboxylate [C16Pyr][AmphB] 
 
Figure 3.68 Struture of [C16Pyr][AmphB]. 
Cetylpyridinium chloride (0.088g; 0.246 mmol) was dissolved in methanol and passed 
through an ion-exchange Amberlite IRA-400(OH)26,30 (5 eq., flux rate 0.133 mLmL-1min-1 
= 8 BVh-1). Then the hydroxide solution formed was slowly added to amphotericin B 
(0.250 g; 0.271 mmol) dissolved in 1.0 M dried triethylamine methanolic solution. The 
mixture was stirred at room temperature for 1 h. Then the solution was filtered and 
recrystallizes from methanol in order to remove the amphotericin crystalline impurities 
insoluble in methanol and then it was treated with calcium carbonate (3.0 g; 30.0 
mmol), to remove acid impurities. After solvent evaporation, it was dried in vacuum for 
24 h to provide the desired product as an orange solid (0.215 g; 71.3 %). [α]D25 = 49.7  
5.8 (c = 0.2 mgmL-1 in methanol); 1H-NMR (400.13 MHz, (CD3)2SO)  = 9.10 (d, 2H, J = 
5.6 Hz), 8.60 (t, 1H, J = 7.6 Hz), 8.16 (t, 2H, J = 6.7 Hz), 6.47-5.97 (m, 14H), 5.65 (bs, 1H), 
5.51-5.40 (m, 1H), 5.33-5.31 (m, 1H), 5.21-5.20 (m, 1H), 4.79-4.78 (m, 3H), 4.59 (t, 3H, J = 
7.4 Hz) 4.34 (bs, 1H), 4.24-4.23 (m, 2H), 4.17-4.12 (m, 1H), 4.07-4.05 (m, 1H), 3.74-2.81 
(m, 12H), 2.41-2.25 (m, 3H), 2.15 (d, 1H, J = 5.7 Hz), 1.91-1.89 (m, 2H), 1.82-1.37 (m, 
16H), 1.27-1.23 (m, 28H), 1.14 (d, 3H, J = 5.8 Hz), 1.11 (d, 3H, J = 6.1 Hz), 1.03 (d, 3H, J = 
5.9 Hz), 0.90 (d, 3H, J = 6.9 Hz), 0.85 (t, 3H, J = 6.7 Hz) ppm; 13C-NMR (150 MHz, 
(CD3)2SO)  = 170.45, 145.37, 144.64, 133.66, 133.63, 133.61, 133.47, 133.17, 132.70, 132.66, 
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132.25, 132.20, 131.99, 131.90, 131.84, 131.80, 127.99, 99.28, 96.65, 79.10, 78.88, 78.66, 
73.50, 72.87, 69.18, 68.75, 67.70, 66.15, 60.68, 44.65, 44.29, 44.27, 41.96, 35.08, 31.20, 30.61, 
28.95, 28.91, 28.81, 28.68, 28.61, 28.28, 25.31, 22.00, 18.41, 18.00, 16.91, 13.87, 11.99 ppm; 
IR (KBr):  = 3435, 3010, 2920, 2852, 1638, 1579, 1563, 1488, 1456, 1401, 1383, 1340, 1324, 
1272, 1181, 1130, 1108, 1069, 1037, 1009, 982, 908, 887, 853, 772, 719, 683 cm-1. MALDI-
TOF-MS analysis: m/z calcd for C21H38N+: 304.2999 found 304.3117; m/z calcd for m/z 
calcd for C47H72NO17- 922.4806, found [M-2H]- 920.5183. 
 
Figure 3.69. [C16Pyr][AmphB] 1H-NMR spectrum in (CD3)2SO. 
 
Figure 3.70. [C16Pyr][AmphB] 13C-NMR spectrum in (CD3)2SO. 
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Figure 3.71. [C16Pyr][AmphB] IR spectrum in KBr. 
 
3.1.4.2 Preparation of (2-Hydroxyethyl)-trimethylammonium 
(1R,3S,5R,6R,9R,11R,15S,16R,17R,18S,19E,21E,23E,25E,27E,29E,31E,33R,35S,36
R,37S)-33-(((2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyltetrahydro-2H-
pyran-2-yl)oxy)-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-
dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-
carboxylate [Cholin][AmphB] 
 
Figure 3.72 Struture of [Cholin][AmphB]. 
(2-Hydroxyethyl)-trimethylammonium chloride (0.0355g; 0.254 mmol) was dissolved 
in methanol and passed through an ion-exchange Amberlite IRA-400(OH)26,30 (5 eq., 
flux rate 0.133 mLmL-1min-1 = 8 BVh-1). Then the hydroxide solution formed was slowly 
added to amphotericin B (0.249 g; 0.269 mmol) dissolved in 1.0 M dried triethylamine 
methanolic solution. The mixture was stirred at room temperature for 1 h. Then the 
solution was filtered and recrystallizes from methanol in order to remove the 
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amphotericin crystalline impurities insoluble in methanol and then it was treated with 
calcium carbonate (3.0 g; 30.0 mmol), to remove acid impurities. After solvent 
evaporation, it was dried in vacuum for 24 h to provide the desired product as an 
orange solid (0.1335 g; 51.1 %). m.p. degradated.; [α]D25 = 50.0  5.8 (c = 1 mgmL-1 in 
methanol); 1H-NMR (400.13 MHz, (CD3)2SO)  = 6.47-5.97 (m, 14H), 5.68 (bs, 1H), 5.46-
5.40 (m, 1H), 5.35-5.32 (m, 1H), 5.24-5.20 (m, 1H), 4.98-4.74 (m, 1H), 4.63 (bs, 1H) 4.34 
(bs, 1H), 4.37-4.32 (m, 1H), 4.26-4.24 (m, 1H), 4.08-4.04 (m, 1H), 3.84-3.83 (m, 6H), 3.61-
3.64 (m, 4H), 3.60-3.38 (m, 10H), 3.10 (s, 9H), 2.33-2.27 (m, 3H), 2.15 (d, 1H, J = 5.8 Hz), 
1.91-1.70 (m, 1H), 1.65-1.31 (m, 10H), 1.23 (s, 3H), 1.14 (d, 3H, J = 5.6 Hz), 1.10 (d, 3H, J = 
6.1 Hz), 1.03 (d, 3H, J = 6.0 Hz), 0.91 (d, 3H, J = 7.0 Hz), 0.83 (t, 3H, J = 6.7 Hz) ppm; IR 
(KBr):  = 3398, 3018, 2917, 2077, 1638, 1577, 1559, 1506, 1460, 1401, 1387, 1324, 1270, 
1183, 1130, 1110, 1073, 1035, 982, 956, 851, 721 cm-1. MALDI-TOF-MS analysis: m/z calcd 
for C5H14NO+: 104.1070, found 104.1080; m/z calcd for C47H72NO17-  922.4806, found [M-
2H]- 920.6717. 
 
Figure 3.73. [Cholin][AmphB] 1H-NMR spectrum in (CD3)2SO. 
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Figure 3.74. [Cholin][AmphB] IR spectrum in KBr. 
 
3.1.4.3 Preparation of (3-(2-Hydroxyethyl)-1-methyl-1H-imidazol-3-ium 
(1R,3S,5R,6R,9R,11R,15S,16R,17R,18S,19E,21E,23E,25E,27E,29E,31E,33R,35S,36
R,37S)-33-(((2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyltetrahydro-2H-
pyran-2-yl)oxy)-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-
dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-
carboxylate [C2OHMIM][AmphB] 
 
Figure 3.75 Struture of [C2OHMIM][AmphB]. 
3-(2-Hydroxyethyl)-1-methyl-1H-imidazol-3-ium (0.040 g; 0.226 mmol) was dissolved 
in methanol and passed through an ion-exchange Amberlite IRA-400(OH)26,30 (5 eq., 
flux rate 0.133 mLmL-1min-1 = 8 BVh-1). Then the hydroxide solution formed was slowly 
added to amphotericin B (0.251 g; 0.272 mmol) dissolved in 1.0 M dried triethylamine 
methanolic solution. The mixture was stirred at room temperature for 1 h. Then the 
solution was filtered and recrystallizes from methanol in order to remove the 
amphotericin crystalline impurities insoluble in methanol and then it was treated with 
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calcium carbonate (3.0 g; 30.0 mmol), to remove acid impurities. After solvent 
evaporation it was dried in vacuum for 24 h to provide the desired product as orange 
solid. (0.1731 g; 72.8 %). m.p. degradated.; [α]D25 = 63.0  5.8 (c = 1 mgmL-1 in methanol); 
1H-NMR (400.13 MHz, (CD3)2SO)  = 9.10 (s, 1H), 7.72 (s, 1H), 7.69 (s, 1H), 6.48-5.96 (m, 
14H), 5.69 (bs, 1H), 5.53-5.40 (m, 1H), 5.32 (bs, 1H), 5.21-5.10 (m, 1H), 4.86-4.70 (m, 2H), 
4.65-4.57 (m, 2H), 4.44-4.33 (m, 2H), 4.21 (t, 3H, J = 4.9 Hz), 4.08-4.03 (m, 2H), 3.86 (s, 
3H), 3.72 (t, 3H, J = 4.9 Hz), 3.64-3.17 (m, 12H), 3.13-2.84 (m, 5H), 2.36-2.28 (m, 2H), 2.16 
(d, 1H, J = 5.9 Hz), 1.86- 1.23 (m, 16H), 1.14 (d, 3H, J = 5.9 Hz), 1.11 (d, 3H, J = 6.1 Hz), 
1.04-1.01 (m, 3H), 0.91 (d, 3H, J = 6.9 Hz) ppm; IR (KBr):  = 3436, 2924, 2856, 1637, 1567, 
1490, 1468, 1458, 1403, 1389, 1328, 1272, 1233, 1183, 1132, 1104,1071, 1009, 978, 905, 857, 
776, 721, 687 cm-1. MALDI-TOF-MS analysis: m/z calcd for C6H11N2O+: 127.0866, found 
127.0710; m/z calcd for C47H72NO17-  922.4806, found [M-2H]- 920.4689. 
 
 
Figure 3.76. [C2OHMIM][AmphB] 1H-NMR spectrum in (CD3)2SO. 
Chapter 3 Material and Methods 
93 
 
Figure 3.77. [C2OHMIM][AmphB] IR spectrum in KBr. 
 
 
3.1.4.4 Preparation of (3-(2-Methoxyethyl)-1-methyl-1H-imidazol-3-ium 
(1R,3S,5R,6R,9R,11R,15S,16R,17R,18S,19E,21E,23E,25E,27E,29E,31E,33R,35S,36
R,37S)-33-(((2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyltetrahydro-2H-
pyran-2-yl)oxy)-1,3,5,6,9,11,17,37-octahydroxy-15,16,18-trimethyl-13-oxo-14,39-
dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-
carboxylate [C3OMIM][AmphB] 
 
Figure 3.78 Struture of [C3OMIM][AmphB]. 
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(3-(2-methoxyethyl)--1-methyl-1-methyl-1H-imidazol-3-ium (0.041 g; 0.252 mmol) was 
dissolved in methanol and passed through an ion-exchange Amberlite IRA-400(OH)26,30 
(5 eq., flux rate 0.133 mLmL-1min-1 = 8 BVh-1). Then the hydroxide solution formed was 
slowly added to amphotericin B (0.251 g; 0.272 mmol) dissolved in 1.0 M dried 
triethylamine methanolic solution. The mixture was stirred at room temperature for 1 
h. Then the solution was filtered and recrystallizes from methanol in order to remove 
the amphotericin crystalline impurities insoluble in methanol and then it was treated 
with calcium carbonate (3.0 g; 30.0 mmol), to remove acid impurities. After solvent 
evaporation, it was dried in vacuum for 24 h to provide the desired product as orange 
solid. (0.1592 g; 59.5 %). m.p. degradated.; [α]D25 = 41.0  7.1 (c = 1 mgmL-1 in methanol); 
1H-NMR (400.13 MHz, (CD3)2SO)  = 9.11 (s, 1H), 7.73 (s, 1H), 7.70 (s, 1H), 6.51-5.96 (m, 
14H), 5.71 (bs, 1H), 5.53-5.40 (m, 2H), 5.35 (bs, 1H), 5.21-5.11 (m, 1H), 4.85-4.63 (m, 5H), 
4.57-4.56 (s, 2H), 4.36-4.34 (m, 4H), 4.26-4.22 (m, 2H), 4.19-4.14 (m, 2H), 4.07-4.04 (m, 
2H), 3.58-3.36 (m, 12H), 3.26 (s, 3H), 2.33-2.25 (m, 2H), 2.16 (d, 1H, J = 5.6 Hz), 1.91- 1.23 
(m, 16H), 1.15 (d, 3H, J = 5.7 Hz), 1.11 (d, 3H, J = 6.2 Hz), 1.04 (d, 3H, J = 5.9 Hz), 0.91 (d, 
3H, J = 6.9 Hz) ppm; IR (KBr):  = 3435, 2921, 2848, 1656, 1648, 1579, 1561, 1490, 1480, 
1456, 1385, 1322, 1262, 1179, 1130, 1106,1069, 1039, 1009, 901, 853, 776, 719, 685 cm-1 
MALDI-TOF-MS analysis: m/z calcd for C6H11N2O+: 127.0866, found 127.0710; m/z calcd 
for C47H72NO17-  922.4806, found [M-2H]- 920.4689. 
 
Figure 3.79. [C3OMIM][AmphB] 1H-NMR spectrum in (CD3)2SO. 
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Figure 3.80. [C3OMIM][AmphB] IR spectrum in KBr. 
 
Figure 3.81. 13CP-MAS NMR spectrum: a) TMS, b) [C16Pyr][AmphB], c) [C3OMIM][AmphB], d) 
[C2OHMIM][AmphB]. 
 
 
3.2 Antimicrobial Activity Studies 
3.2.1 Microorganisms and Growth Conditions 
All the bacteria cells studied were stored at -80 oC by Vibakstore cryopreservation 
systems. A total of 8 bacterial strains were used in this study. The following reference 
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strains were obtained from the American Culture Collection (ATCC): Escherichia coli 
ATCC 25922 and Staphylococcus aureus ATCC 25923. Klebsiella pneumonia, Staphylococcus 
epidermidis and Enterococcus fecalis and the resistant bacteria, E coli Tem CTX M9, E. coli 
CTX M2, E. coli AmpC Mox2 were clinical isolates from previous works27-29,50-52. These 
resistant strains were identified by Vitek2 systems from bioMérieux . Bacteria were 
grown on Trypticase soy agar (TSA) for 24 h at 37 oC prior to each test. The bacteria 
assays were made in Tryptic Soy Broth (TSB). 
The eukaryotic model used was Saccharomyces cerevisiae PYCC 4072 (from the 
Portuguese Yeast Culture Collection). This strain was stored at -80 oC in Yeast Extract 
Peptone Dextrose (YEPD) medium with 15% glycerol. The yeast cells were grown on 
YEPD with agar at 37 oC for 24 h prior to each test. The yeast assays were made in 
liquid YEPD. 
3.2.2 Culture Medium 
The composition and preparation of the different culture medium used in this work are 
described in this section. 
Trypticase Soy Agar (TSA) – TSA (CULTIMED) is a dehydrated culture medium quite 
common for growth and isolation of bacteria160. It is a solid medium and was used for 
the growth and isolation of Gram-positive and Gram-negative bacteria. This medium 
was prepared by suspending 40 g of dehydrated medium in 1 L of distilled water. 
Then it was heated to boiling point while constantly stirring and boiled for 1 minute 
more. Then it was sterilized at 121 °C for 15 minutes and distributed into sterile Petri 
dishes. The final composition per litre of the medium was: Soy Peptone (5.0 g), Casein 
Peptone (15.0 g), Sodium Chloride (5.0 g) and Agar (15.0 g). 
Tryptone Soy Broth (TSB) – TSA (CULTIMED) is a dehydrated culture medium. It is a 
liquid medium used for the micro dilution susceptibility testing160. This medium was 
prepared by suspending 30 g of dehydrated medium in 1 L of distilled water. It was 
heated to boiling point while constantly stirring and boiled for 1 minute more. Then it 
was sterilized at 121 °C for 15 minutes and distributed into test tubes ( 5 mL/tube) for 
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growth or distributed in 96-well microtiter plate for the micro dilutions susceptibility 
tests. The final composition per litre of the medium was: Soy Peptone (3.0 g), Casein 
Peptone (17.0 g), Sodium Chloride (5.0 g), di-Potassium Hydrogen Phosphate (2.5 g). 
Yeast Extract Peptone Dextrose (YEPD) – This medium is used for maintaining and 
developing yeast. This medium could be liquid or solid (with agar). It was prepared by 
dissolving the following components: yeast extract (10.0 g, (SIGMA)), peptone (20.0 g, 
(CULTIMED)), glucose (20.0 g, (MERCK)) in one litter. In the case of a solid medium, 
agar was added (15.0 g, LIOFILCHEM) to the liquid medium. After medium 
preparation it was autoclaved at 121 °C for 15 minutes and distributed into test tubes 
( 5 mL/tube) for growth or distributed in 96-well microtiter plate for the micro 
dilutions susceptibility tests. 
3.2.3 Minimum Inhibitory Concentration (MIC) 
The MIC values were determined in triplicate by the broth micro dilution method in a 
96-well microtiter plate using TSB, according to the methodology from Clinical 
Laboratory Standard Institute (CLSI)160. Prior to MIC determination, each inoculum 
density was adjusted in TSB to 0.5 McFarland standard by a photometric device160. This 
resulted in a suspension containing approximately 1  108 to 2  108 colony forming 
units CFUmL-1 for E. coli ATCC25922®160. A similar approach was used for the other 
strains. Following this step, 0.5 L of the suspension was added to each well in order to 
obtain 0.5 – 2.5 x 104 CFUmL-1 as final concentration. Bacteria were exposed to an IL 
concentration of 5.0 mM, 2.5 mM, 0.5 mM, 0.05 mM, 0.005 mM, 0.0005 mM and 0.00005 
mM. With the exception of [P6,6,6,14] cations that were diluted in 1 % 
dimethylsulphoxide all others were dissolved in water and these results were 
compared with bacteria that had grown in TSB broth in the presence of 1% DMSO as a 
control. The MIC for each Amp-IL was recorded as the lowest concentration that 
showed no turbidity after 24 h of incubation at 37 oC19,160. The presence of turbidity is 
an indication of microbial growth and the corresponding concentration is considered 
ineffective. 
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In the case of S. cerevisiae,  the method used to determine the MICs was the exact same 
procedure replacing the TSB medium by the YEPD liquid medium. 
3.2.4 Minimum Bactericidal Concentration (MBC) 
To study if the antimicrobial activity of the synthesized ILs was bacteriostatic 
(inhibited growth) or bactericidal,  the colorimetric assay (XTT method) was used161. 5 
μL of sodium salt of (2,3-bis[2-Methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-
carboxyanilide inner salt) (XTT) was added to the non-turbid wells of the MIC assay 
plate and incubated for 3 h at 37 oC for the bactericidal status determination161,162. In the 
case of viable cells with inhibited growth, mitochondrial dehydrogenases of viable cells 
cleave the tretrazolium ring of XTT yielding dark orange aqueous soluble formazan 
crystals. However, a solution containing non-viable cells would remain with the same 
colour162. In this case, MICs values were equal to MBC for each of the ILs used, so the 
antibacterial activities of these compounds were considered to be bactericidal. 
3.2.5 Relative Decrease of Inhibitory Concentration (RDIC) 
To better understand and compare the results obtained from MIC values studies, we 
calculated the relative decrease of inhibitory concentration (RDIC). This is the ratio 
between the MIC values of the API and the ILs synthesised [Cat][API]. In the case of 
resistant bacteria, RDIC values were calculated, assuming that it is 5 mM in all cases 
(the highest value that was measured) providing us with the possibility to estimate the 
minimum positive effect of [Cat][API]. 
3.2.6 Growth Rate Studies 
In order to complete the characterization of anti-bacterial activity, the Growth Rate 
(GR) when exposed to the MIC values was evaluated. Additionally, GR values in the 
presence of higher and lower concentration of the MIC previously found for each 
compound was also determined. 
The GR parameter was determined in triplicate by the broth micro dilution method in 
a 96-well microtiter plate using Tryptic Soy Broth (TSB)160,163,164. Approximately 5000-
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25000 CFUmL-1 of bacteria was exposed to an IL concentration superior, equal or 
inferior value of the determined MIC, making periodical readings of the optical density 
(OD) at 620 nm to establish the bacterial population growth curve and then 
determining the curve’s slope. The GR was determined by fitting a linear function to 
the Exponential (log) phase curve. 
3.3 Cell Line Culture Studies 
All human cell lines (MG63, RKO, PC3 and T47D) were purchased from the American 
Type Culture Collection (ATCC). Skin and gingival fibroblasts were obtained from 
explants collected from healthy 25 to 35 year-old donors with, after informed consent. 
Cells were maintained in α-minimal essential medium (α-MEM) containing 10% fetal 
bovine serum, 100 IUmL-1 penicillin, 2.5 gmL-1 streptomycin, 2.5 gmL-1 amphotericin 
B and 50 gmL-1 ascorbic acid. At about 70-80 % confluence, cells were enzymatically 
detached with 0.05 % trypsin and 0.5 mM EDTA and seeded at 104 cellscm-2. After an 
attachment period of 24 h, the culture medium was renewed, and supplemented with 
different concentrations (0.005-500 mM) of the ampicillin-derived ILs. Cell cultures 
were maintained in a 5 % CO2 humidified atmosphere at 37 oC. Cellular 
viability/proliferation was assessed by the 3-(4,5- dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) (MTT) assay at days 1, 3 and 5 of culture, as described 
before165,166. This assay is based on the reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide to a purple formazan product by viable cells. Shortly, 
cultured cells were incubated at 37 oC with 0.5 mgmL-1 of MTT during 4 h. After that 
the culture medium was removed. Then the stained product was dissolved with 
dimethylsulfoxide. Finally the absorbance determination was conducted at 550 nm in 
an ELISA plate reader. Results were expressed as absorbance per square centimetre 
(Acm-2)165,166.  
The values of the half maximal inhibitory concentration (IC50) and the median lethal 
dose (LD50) were obtained from nonlinear regression analysis of concentration-effect 
curves using the GraphPad Prism software167,168. The definition of the IC50 is given  by 
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Sebaugh169 as  “the response corresponding to the 50% control (the mean of the 0% and 
100% assay controls)” and is used to measure the efficacy of a compound in inhibiting 
any biochemical or biological function. The term LD50 means the median lethal dose 
and is the amount of material which causes the death of 50% of a population170. 
3.4 Statistical Analysis 
In order to evaluate the significance of the growth curves of the selected 
microorganisms with and without the ILs, and the LD50 and IC50 of the ILs on the 
selected human cell lines, it was used the statistical software SPSS 15.0 (SPSS Inc., 
EUA). The sample distribution followed a non-normal distribution and therefore, 
verified by the Kolmorogov-Smirnov test and the variance analysis was studied by the 
Levene’s test. 
The influence of ILs of both microorganisms and human cells lines was evaluated by 
Mann-Whitney U with a significance level of 0.005. 
IC50 and LD50 were calculated using Graphpad software.  
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Development of Novel Ionic Liquids Based 
on Ampicillin 
 
4.1 Abstract 
Novel ionic liquids containing ampicillin as active pharmaceutical ingredient anion 
were prepared with good yields by using a new, efficient synthetic procedure based on 
the neutralization of a moderately basic ammonia solution of ampicillin with different 
organic cation hydroxides. The relevant physical and thermal properties of these novel 
ionic liquids based on ampicillin were also evaluated. 
4.2 Introduction 
Ionic liquids (ILs) are generally defined as organic salts with melting points below 100 
oC (some of them are liquid at room temperature) and composed entirely of ions9,95. 
The large number of possible cation/anion combinations allows for great variety of 
tuneable interactions and subsequent applications9,137,171. Ionic liquids were initially 
used as greener alternatives to conventional, toxic and volatile organic solvents3,9. Some 
properties generally attributed to ILs, such as high thermal and electrochemical 
stability, negligible vapour pressure171,172, high ionic conductivity171, non-flammability 
and a tuneable solvation capacity, encouraged their application across a wide range of 
areas, including organic chemistry9,137, chemical engineering9,171, material science171,173, 
physical chemistry171,174,175, analytical chemistry171,176, and biotechnology2,9,107,171. 
Recently, ILs have been combined with active pharmaceutical ingredients (APIs), and a 
so-called third generation of ILs has emerged8. These ILs-APIs compounds offer new 
and improved properties, such as stability, solubility, permeability and drug delivery, 
as compared to the corresponding solid pharmaceutical forms. The use of an active 
drug in the liquid form (at room temperature) can avoid some of the issues of 
polymorphism associated with crystalline solids and, thus, dramatically influence the 
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drug’s solubility and dosages9,71,150. However, the entrance of ILs into the biosciences 
has been delayed mainly because of the toxicity of the counterions9. Most recent 
communications and reviews refer to the toxicity and activity of ILs against 
microorganism and cell cultures, especially their antimicrobial activity as well as drug 
delivery performance9,71,133-135. ILs have recently been tested in the fight against multi-
drug resistance21,135 and even against microbial biofilms, showing a broad and powerful 
spectrum of activity against several microbial pathogens, including Methicillin-
resistant Staphylococcus aureus. The recent outbreak of E. coli O10453,54 in Germany as 
well as the appearance of multi-drug-resistant organisms such as Gram-negative 
Enterobacteriaceae given by the New Delhi metallo β-lactamase55-57 are becoming 
increasingly serious public health problems worldwide. Thus, the discovery of 
alternative and efficient pathways for the treatment of infections is one of the most 
urgent challenges of this century. Novel therapies using ILs as a drug delivery device9 
offer interesting avenues for exploration. 
From the pharmaceutical point of view, the possibility of eliminating the negative side 
effects of a given active compound by delivering it as an ILs-APIs is extremely 
attractive. Taking advantage of the ILs building up platform, the counter-ion can be 
meticulously selected in order to minimize those undesirable side effects or to open up 
novel treatment therapies in which two active ions are paired.  
4.3 Results and Discussion 
This work intended to develop an efficient, synthetic methodology for preparing 
several ILs-APIs based on ampicillin [Amp]. Ampicillin has always been used as anion 
combined with the following organic cations 1-ethyl-3-methylimidazolium, [EMIM], 1-
hydroxy-ethyl-3-methylimidazolium, [C2OHMIM], choline, [Cholin], 
tetraethylammonium, [TEA], cetylpyridinium, [C16pyr] and trihexyltetradecyl-
phosphonium [P6,6,6,14]. These anions were chosen due to their low toxicity, except in the 
case of [P6,6,6,14] which was chosen to ensure that a ILs-APIs in the liquid form could be 
obtained. The combination of the adequate anion or cation with a specific drug can 
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lead to an alteration in the compound’s biopharmaceutical drug classification32 as well 
as their drug formulation process. 
The most conventional synthetic preparation of ILs involves a metathesis reaction of 
anion halide with an adequate anion and it was also used in the preparation of ILs 
containing ampicillin anion19. The pure IL can be obtained by eliminating undesirable 
inorganic salts (mainly sodium, potassium or lithium chloride or bromide) using 
precipitation followed by filtration177. The need to obtain pure ILs, especially halide-
free ones, has been one of the central concerns within the IL community. The use of 
inorganic acids instead of salts is a potential approach to reducing these inorganic 
contaminations178. In the case of a large number of inorganic or organic anions, 
alternatives need to be considered, due to the fact that an anion exchange by weaker 
acids than hydrohalic acids91 cannot be efficiently performed. In the case of 
imidazolium cations, Earle and Seddon proposed the use of imidazole carbenes84 as 
strong bases. Nevertheless, this process is restricted to imidazolium cations, due to the 
high reactivity and low stability of the carbene intermediate178.  
Ion exchange resins methods recently developed by Ohno et al.26 are being successfully 
used as alternative anion exchange processes and they have been extended to other 
reactions. Amberlite resin (in the OH form) has been used in order to exchange halides 
(bromide or chloride) to the hydroxide form and then this basic solution is neutralized 
by the addition of an adequate acid solution. The acid-base reaction yields the desired 
salt or IL26,91,178. Our first attempt to use this anion exchange method failed due to 
ampicillin´s poor solubility in most common organic solvents (with the exception of 
DMSO), as well as the instability of the β-lactam ring in the presence of strong bases. 
The decomposition of ampicillin was always detected by NMR analysis after several 
attempts. 
The initial synthetic procedure was modified by dissolving ampicillin in a moderately 
basic ammonia solution and then neutralizing it with different hydroxides prepared 
with the Ohno method. Using an ammonia solution buffer (pH = 11.6), the hydrolysis 
of the sensitive β-lactam ring from a possible hydroxide attack was avoided. Pure ILs-
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APIs based on ampicillin structure were obtained after eliminating the excess ammonia 
and/or ampicillin by evaporation and crystallization respectively. The organic cations 
were selected from substituted ammonium, phosphonium, pyridinium and 
methylimidazolium salts which were first transformed into hydroxides by the use of an 
ionic exchange column (Amberlite IRA-400 OH) in methanol26. The prepared 
hydroxides were then neutralized with the beta-lactam antibiotic (Scheme 4.1). 
 
Scheme 4.1 Schematic synthetic procedure for the preparation of ampicillin-based ILs. 
The structure of the cations synthesised and studied in this work appears in Figure 4.1.  
 
Figure 4.1 Structure of cations used. 
All isolated products were completely characterized by 1H and 13C-NMR, FTIR and ESI 
mass spectra in order to check their expected structures and final purities. NMR 
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studies also elucidate about the expected cation/anion correlations by a quantitative 
integration of their characteristic 1H resonance peaks.  
4.3.1 Physical Properties 
Table 4.1 summarizes some properties of the synthesized ILs-APIs based on 
Ampicillin. Our optimized synthetic procedure allowed us to obtain pure compounds 
in high yields (71 to 95%). All compounds are soluble in methanol, ethanol and water 
(except [P6,6,6,14][Amp]). It is important to emphasize that the use of appropriate 
ammonium and imidazolium cations can effectively change the initial trihydrate 
ampicillin water solubility (6 mgmL-1) and consequently their potential membrane 
permeability. 
Table 4.1 Physical Properties of ILs-APIs based on ampicillin. 
Compound Yield [%][a] [α]D27 [o] [b] 
Solubility 
Miscible[c] Immiscible[c] 
[TEA][Amp] 76.0 +48.72.5 
MeOH, EtOH, 
iPrOH, H2O 
Ac, AcOEt (pm) 
[P6,6,6,14][Amp] [d] 80.0 +23.31.5 
MeOH, EtOH, 
iPrOH, Ac, AcOEt 
H2O 
[C16Pyr][Amp] 76.4 +51.70.9 
MeOH, EtOH, 
iPrOH 
Ac, AcOEt, H2O 
(pm) 
[Cholin][Amp] 70.7 +52.30.8 
MeOH, EtOH,  
H2O 
iPrOH, Ac, AcOEt 
[EMIM][Amp] 94.6 +89.35.5 
MeOH, EtOH, 
iPrOH, H2O 
Ac, AcOEt (pm) 
[C2OHMIM][Amp] 86.8 +86.34.5 
MeOH, EtOH, 
H2O 
iPrOH (pm), Ac, 
AcOEt (pm) 
[a] Isolated yields. [b] Optical rotation values measured in methanol (2 mgmL-1) by polarimetry at 27 oC. 
[c] Observed complete solubilisation (miscible), partial miscible (pm) or non-solubilisation (immiscible) by 
adding solvent to a small amount of ionic liquid, MeOH (methanol), EtOH (ethanol), iPrOH (iso-
propanol), Ac (acetone) and AcOEt (ethyl acetate). [d] The water content of [P6,6,6,14][Amp] was 14.7 ppm 
(determined by Karl Fisher titration). 
 
[Cholin][Amp] and [C2OHMIM][Amp] are immiscible in isopropanol contrarily to 
other  ILs-APIs. [P6,6,6,14][Amp] is the only IL-API completely miscible in acetone and 
ethyl acetate.  
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Optical rotations values of the prepared ILs-APIs based on ampicillin (+23.3o  1.5 to 
+89.3o  4.5 in methanol, Table 4.1) are significantly lower compared with the initial 
trihydrate ampicillin (+163.0 o  2.0 in water) but are of the same order of magnitude as 
commercial sodium ampicillin (+40.0º  4.0). The highest optical rotations of the 
prepared compounds were observed when imidazolium cation structures were used.  
 
4.3.2 Thermal Properties 
The thermal properties of synthesized ILs-APIs based on ampicillin are summarized in 
Table 4.2.  
All the ILs-APIs were obtained as pale yellow solids (melting temperature, ™, between 
58 oC and 86 oC) except in the case of [P6,6,6,14][Amp] (viscous yellow liquid). 
[C2OHMIM][Amp] was obtained as a yellow molten salt (Tm = 117 oC). Particularly 
relevant is the successful reduction of the initial melting point of commercial ampicillin 
or sodium ampicillin (higher than 300 oC) by the appropriate selection of organic 
cations. The glass transition temperature (Tg) was determined at a heating/cooling rate 
of 1 oCmin-1 for all compounds. Similar values of glass transition temperatures were 
detected for all ILs-APIs (-17.86 oC to -20.84 oC) except in the case of [P6,6,6,14][Amp].  
In the case of [P6,6,6,14][Amp], DSC curves showed two transition peaks at low 
temperature which can be attributed to crystallization (-80.07 oC) and melting (-23.01 
oC) processes, respectively.  
Decomposition studies were performed by TGA analysis for all the synthesized 
compounds. As expected, these studies indicated that the selection of the organic 
cation influences the thermal stability of ILs-APIs based on ampicillin. [P6,6,6,14][Amp] 
and [C16Pyr][Amp] presented higher thermal stability than those ILs-APIs based on 
imidazolium and ammonium cations. 
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Table 4.2 Thermal Properties (Tm, Tg and Tdec) of ILs-APIs based on ampicillin. 
Compound Physical State Tm[a] [oC] Tg[b] [oC] Tdec[c] [oC] 
[TEA][Amp] Pale yellow Solid 79.0 -18.64 214.75 
[P6,6,6,14][Amp] Yellow Viscous Liquid - - 297.65 
[C16Pyr][Amp] Pale yellow Solid 86.0 -19.64 269.39 
[Cholin][Amp] Pale yellow Solid 58.0 -20.12 221.29 
[EMIM][Amp] Pale yellow Solid 72.0 -17.86 239.64 
[C2OHMIM][Amp] Pale yellow Solid 117.0 -20.84 246.40 
[a] Melting temperature ™ was determined by a melting point apparatus (Stuart Scientific). [b] Glass transition 
temperature (Tg) was determined by DSC measurements at a heating/cooling rate of 1 oC.min-1 for all ILs. [c] 
Decomposition temperature (Tdec) was determined by TGA studies. 
 
4.3.3 NMR Studies 
A preliminary 1H-NMR study was performed in the case of IL [Cholin][Amp] for 
different temperatures (25 oC to 85 oC). Figure 4.2 illustrates a comparative 1H-NMR 
study of [Cholin][Amp] at four temperatures (25, 45, 65 and 85 oC) in d-DMSO. Two 
different regions of the 1H-NMR spectra between 1 to 2 ppm and 6.5 to 8.8 ppm were 
particularly selected to check the aliphatic (methyl peaks) and aromatic (phenyl peaks) 
signals of ampicillin anion, respectively. 
In the case of two methyl peaks (1.10 and 1.41 ppm) of ampicillin, a chemical shift to 
the left was observed between 25 oC and 85 oC. This variation of the chemical shift (at 
least 0.4 ppm of difference between 25 oC to 85 oC) can be explained by the possible 
interaction of the carboxylate group of the ampicillin anion with the choline cation. 
In the case of the aromatic peaks from ampicillin (7.20 to 7.50 ppm), no significant 
variation of chemical shift was observed, indicating that the phenyl ring of ampicillin 
does not interact with the choline cation.  
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Figure 4.2 Comparative 1H-NMR study of [Cholin][Amp] for four temperatures (25, 45, 65 and 
85 oC) and two NMR regions (1 to 2 ppm and 6.5 to 8.8 ppm) in DMSO. 
4.4 Conclusions 
The present work reports a new and efficient method for the synthesis of beta-lactam 
antibiotics like ampicillin, which may prove useful for the development of new 
bioactive materials [1] (antiseptics and anti-biofilm, for example) or to reduce drug 
resistance in microorganisms. With the careful selection of the organic cation, it is 
possible to provoke important physical and thermal properties of ILs-APIs based on 
ampicillin, such as water solubility, melting point and thermal stability. [Cholin][Amp] 
is the most interesting example of a prepared API-IL in what concerns their particular 
IL properties (low melting point, high water solubility) as well as the biocompatibility 
and low toxicity of the choline cation. 
 
 
 
 
 
 
 
 
 
 
 
Chapter 5.  
Antibacterial Activity of Ionic 
Liquids Based on Ampicillin 
Against Resistant Bacteria 
 
 
This chapter is a reproduction of a submitted article to the RSC 
advances (RA-ART-08-2013-044286): 
Antibacterial activity of Ionic Liquids based on ampicillin against 
resistant bacteria 
Ricardo Ferraz, Vânia Teixeira, Débora Rodrigues, Rúben Fernandes, 
Cristina Prudêncio, João Paulo Noronha, Željko Petrovski and Luís C. 
Branco 
 
 
  
Chapter 5 Antibacterial Activity of Ionic Liquids Based on Ampicillin Against Resistant Bacteria 
113 
5 
 
Antibacterial Activity of Ionic Liquids Based 
on Ampicillin Against Resistant Bacteria 
 
5.1 Abstract 
Antibacterial activity of novel Active Pharmaceutical Ingredient Ionic Liquids (API-
ILs) based on ampicillin anion [Amp] have been evaluated. They showed growth 
inhibition and bactericidal properties on some sensitive bacteria and especially some 
Gram-negative resistant bacteria when compared to the [Na][Amp] and the initial 
bromide and chloride salts. For these studies, minimum inhibitory concentration (MIC) 
and minimum bactericidal concentration (MBIC) were analysed against sensitive 
Gram-negative bacteria Escherichia coli ATCC 25922 and Klebsiella pneumonia (clinically 
isolated). Sensitive Gram-positive Staphylococcus. Aureus ATCC 25923, Staphylococcus 
epidermidis and Enterococcus faecalis were also analysed. This was completed with MIC 
and MBIC evaluation of clinically isolated resistant strains such as E. coli TEM CTX M9, 
E. coli CTX M2 and E. coli AmpC Mox. From the obtained MIC values of studied  
APIs-ILs and standard [Na][Amp], RDIC (relative decrease of inhibitory concentration) 
values were calculated. High RDIC values of [C16Pyr][Amp] especially against two 
resistant Gram-negative strains E. coli TEM CTX M9 (RDIC > 1000) and E. coli CTX M2 
(RDIC > 100) point clearly to a potential promising role of APIs-ILs as antimicrobial 
drugs, particularly against resistant bacterial strains. 
5.2 Introduction 
Ionic Liquids (ILs) are usually defined as organic salts with melting points lower than 
100 oC (several of them are liquid at room temperature)3. They became popular due to 
large number of possible cation/anion combinations allowing different tuneable 
interactions and potential applications. Some ILs properties, such as their high thermal 
and chemical stability, negligible vapour pressure172,179, high ionic conductivity, lack of 
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inflammability and adjustable solubility have attracted numerous applications across 
an extensive variety of research areas2,107,174,176, in particular related to organic 
chemistry, chemical engineering, material science, physical chemistry, analytical 
chemistry and biotechnology, among others. 
One of the most promising applications of ILs seems to be the so-called third 
generation of ILs (their arrangement with active pharmaceutical ingredients, APIs) or 
APIs-ILs9. It is suggested that these compounds can solve problems associated to the 
pharmaceutical industry related with polymorphism and drug solubility8,9,30,71,151. At the 
beginning, the uses of ILs in biosciences was difficult because of ILs’ toxicity136,180. 
However, more recently lower inherent toxicity was shown and thus a lower impact on 
human health and the environment from some hydrophobic ILs derived from toxic 
herbicides136,180. Presently, biocidal properties of large cations, such as benzalkonium 
and imidazolium species, have also been largely used as an advantage to kill or inhibit 
bacteria18,97 or yeast181,182 growth. In respect to this area, different publications have 
reported antimicrobial activity studies using microorganisms or cell culture for long 
alkyl chain quaternary ammonium133,183. Recently, Cole and co-workers19 reported the 
use of metathesis reaction to produce ILs with long alkyl chain quaternary ammonium 
and ampicillin anion. Some ILs have been efficiently tested with clinically significant 
microbial pathogens, including Methicillin-resistant Staphylococcus aureus (MRSA)135. 
Bacterial resistance to different antibiotics, commercially available, is one of the major 
public health problems27,50,51. Recent outbreaks of E. coli O10453,54 in Germany as well as 
the emergence of multi-drug resistant organisms such as Gram-negative 
Enterobacteriaceae associated to the New Delhi metallo β-lactamase55,80 confirm that 
this is a serious problem for public health, but also from an economic and social point 
of view. Besides the fact that bacterial resistance increases mortality and morbidity, 
some recent publications have reported the financial burden of health care-associated 
infections (HAIs) in the USA60,61. 
Innovative therapies involving the use of ILs as a drug delivery platform suggest other 
attractive opportunities for exploration. The possibility to eliminate or reduce the 
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negative side effects of a given active compound by delivering it as an API-IL is 
extremely attractive for pharmaceutical, environmental technologies and other medical 
applications. It is suggested that the appropriate combination of counter ion and a 
specific drug as API-IL can influence the final biopharmaceutical drug classification 
(BCS), toxicity and biodegradability behavior32,181,182, water solubility, permeability as 
well as the drug formulation process. Besides, it can changes some biological 
properties. 
As mentioned before, the bacterial resistance to antibiotics is a serious public health 
threat and needs novel and urgent action. In this context, we studied the bacterial 
activity of different API-ILs based on Ampicillin30 against a panel of sensitive Gram-
negative and Gram-Positive bacteria as well as a panel of resistant bacteria. In 
particular, we selected sensitive Gram-negative bacteria Escherichia coli ATCC 25922 
and Klebsiella pneumonia (clinically isolated); sensitive Gram-positive S. Aureus ATCC 
25923, Staphylococcus epidermidis (clinically isolated) and Enterococcus faecalis (clinically 
isolated) and the resistant bacteria (clinically isolated strains) E. coli TEM CTX M9, E. 
coli CTX M2, E. coli AmpC Mox227,29,50-52. 
5.3 Results and Discussion 
In this work, API-ILs or pharmaceutical organic salts were produced by the 
neutralization method30 from ampicillin. The toxic effect of cationic counter ion of API-
ILs should not be neglected156. All prepared Ampicillin based ILs are considered non-
toxic, except in the case of [P6,6,6,14] cation, which is toxic according to standard toxicity 
test against human colon carcinoma cell line (CaCo-2)25. Contrarily, Choline cation 
([Cholin]+) is used as an essential nutrient; low molecular substituted ammonium or 
imidazolium cations ([TEA]+ or [CnMIM]+ ) as alternative low-toxic cations and 
cetylpyridinium cation ([C16Pyr]+ ) have already been applied in pharmaceutical 
applications184. For comparative studies, the activity tests were also performed using 
starting materials (bromide and chloride salts) while ampicillin sodium salt was 
always used as the standard API. The purity of compounds was checked by 1H and 
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13C-NMR and mass spectra analysis. Figure 5.1 summarizes all prepared API-ILs based 
on Ampicillin anion ([Amp]).  
 
Figure 5.1 Representation of the prepared API-ILs based on ampicillin anion. 
Table 5.1 shows the MICs for the API-ILs based on ampicillin sensitive bacteria and 
Table 5.2 presents the MICs for resistant strains. The analysis from Table 5.1 suggests 
that in the case of sensitive bacteria, the [C16Pyr][Amp] exhibits the highest activity and 
significantly lower MIC values when compared to [Na][Amp]. In the case of K. 
pneumonia, S. epidermidis and E. fecalis suggest that this could be a promising 
antibacterial compound for this kind of bacteria. 
Some toxicity studies indicated that the least toxic anions are Cl- and BF4-185 and a there 
is a possible relation between toxicity and the length of alkyl chains in the case of 
imidazolium, pyridinium and quaternary ammonium cations for several 
microorganisms such as rods, cocci and fungi157. 
In our work, the combination effect of ampicillin anion (API) with selected organic 
cation has been evaluated. Also, the cation’s own contribution or synergetic effect from 
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cation/anion were checked by measuring MIC values of [Cat][Cl] and [Cat][Br] (shown 
in Table 5.1 and Table 5.2) that were used in the synthesis of [Cat][Amp]30. 
Table 5.1 Minimum inhibitory concentrations (mM) on the ampicillin sensitive bacterial strains 
tested. 
Strains  
Comp. 
Gram-negative  Gram-positive 
E. coli ATCC 25922 K. pneumoniae  S. aureus ATCC 25923 E. fecalis S. epidermis 
[Na][Amp]a) 0.05 2.5  0.005 0.05 0.05 
[TEA][Amp] >5 >5  >5 >5 >5 
[TEA][Br] >5 >5  2.5 >5 >5 
[P6,6,6,14][Amp] 2.5 5  0.05 0.05 0.05 
[P6,6,6,14][Cl] 2.5 2.5  2.5 >5 2.5 
[C16Pyr][Amp] 0.5 0.05  0.005 0.005 0.005 
[C16Pyr][Cl] 0.5 2.5  0.5 0.5 2.5 
[Cholin][Amp] >5 >5  >5 >5 >5 
[Cholin][Cl] >5 >5  2.5 >5 >5 
[EMIM][Amp] >5 >5  >5 >5 >5 
[EMIM][Br] >5 >5  0.05 >5 5 
[C2OHMIM][Amp] 5 >5  >5 5 2.5 
[C2OHMIM][Cl] 5 >5  >5 5 5 
a) The [Na][Amp] was used as control. 
 
The results showed that the toxic effect of the chloride and bromide is almost negligible 
in diluted solutions as already described in the literature156,185. With the exception of 
[C2OHMIM][Cl] providing lower MIC value against resistant E. coli CTX M2 than 
[C2OHMIM][Amp]. 
MIC values of ionic liquids and salts containing highly polar cations in particular 
[Cholin][Amp] or [C2OHMIM][Amp] are always higher than [Na][Amp]. Contrarily, 
the ampicillin ILs containing apolar cations such as [P6,6,6,14][Amp] and [C16Pyr][Amp] 
presented lower MIC values than [Na][Amp].These observations can be explained with 
the fact that the highly polar cations are more prone to stay in aqueous solution instead 
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of  hydrophobic cell membranes and therefore anchor themselves to ampicillin anions 
(ion trapping effect)186. The correspondent ampicillin salts thus stay trapped to aqueous 
solution which eventually becomes hydrolysed. 
Table 5.2 Minimum inhibitory concentrations (mM) on the ampicillin resistant bacterial strains 
tested. 
Strains 
Comp. 
E. coli TEM CTX M9 E. coli CTX M2 E. coli AmpC MOX2 
[Na][Amp]a) >5 >5 >5 
[TEA][Amp] >5 >5 >5 
[TEA][Br] >5 2.5 >5 
[P6,6,6,14][Amp] 0.5 0.5 >5 
[P6,6,6,14][Cl] 2.5 5 >5 
[C16Pyr][Amp] 0.005 0.05 0.05 
[C16Pyr][Cl] 0.5 >5 >5 
[Cholin][Amp] >5 >5 >5 
[Cholin][Cl] >5 >5 >5 
[EMIM][Amp] >5 >5 >5 
[EMIM][Br] 5 >5 >5 
[C2OHMIM][Amp] >5 >5 5 
[C2OHMIM][Cl] >5 2.5 5 
a) The [Na][Amp] was used as control. 
Unlike penicillin G, which is active only against Gram-positive bacteria, ampicillin 
possesses an additional amino group and is active against both Gram-positive and 
some Gram-negative bacteria. Bacteria may be resistant (or develop) resistance on β-
lactam antibiotics by developing very efficient β-lactamase enzymes (“penicillinases”), 
by developing change (resistance gene) in penicillin-binding proteins (PBPs) and 
therefore providing poor affinity for antibiotic or development of porin channel 
blockage (in case of Gram-negative bacteria)187-189. 
As observed from Table 5.3 and Table 5.4, [C16Pyr][Amp] exhibits the most noticeable 
Relative Decrease of Inhibitory Concentration (RDIC). Among sensitive Gram-positive 
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bacteria [C16Pyr][Amp] shows no effect on S. aureus ATCC 25923 (RDIC = 1) or mild 
positive effect against E. fecalis and S. Epidermis (RDIC=10 for each). Among sensitive 
and resistant Gram-negative strains (Table 5.3 and Table 5.4) [C16Pyr][Amp] IL presents 
a slight increase of the MIC value on E. coli ATCC 25922 (RDIC = 0.1). MIC decreases in 
the case of K. Pneumonia (RDIC = 50) and regarding the resistant strains E. coli TEM 
CTX M9 (RDIC > 1000) and E. coli CTX M2 (RDIC > 100) the decrease was remarkable. 
Table 5.3 Relative Decrease of Inhibitory Concentration (RDIC) of ampicillin anion in 
[Cat][Amp] (RDIC) comparing with sodium ampicillin for ampicillin sensitive 
bacteriaa). 
Strains  
Comp. 
Gram-negative Gram-positive 
E. coli ATCC 25922 K. pneumoniae  S. aureus ATCC 25923 E. fecalis S. epidermis 
[Na][Amp]a) 1 1  1 1 1 
[P6,6,6,14][Amp] 0.02 0.5  0.1 1 1 
[C16Pyr][Amp] 0.1 50  1 10 10 
[C2OHMIM][Amp] 0.01 -  - 0.01 0.02 
a) for explanation of RDIC values see Experimental section. 
Lehn et al. demonstrated that transport across biological membranes of highly polar 
anionic compounds can be facilitated if they are paired with lipophilic ammonium 
ions, which act as phase transfer190. We and others have recently suggested the 
application of the same principle for penetration and drug delivery in APIs-ILs with 
lipophilic counterions8,9,30,135,151. The results of [C16Pyr][Amp] on ampicillin sensitive 
Gram-positive and both sensitive and resistant Gram-negative strains are according to 
this principle. [C16Pyr][Amp] usually does not influence the RDIC values of sensitive 
strains as peptidoglycan of Gram-positive bacteria is already directly exposed to an 
aqueous solution while outer membrane of sensitive Gram-negative bacteria does not 
represent a physical barrier for [Na][Amp]. Regarding small fluctuations in the case of 
E. coli ATCC 25922 (RDIC = 0.1), K. pneumonia (RDIC = 50), E. fecalis and S. Epidermis 
(each RDIC = 10) all can be explained in morphological differences of the cell surface of 
these bacteria, peptidoglycans, outer lipid layers among others and their interaction 
with API-IL. However, the most remarkable effect of [C16Pyr][Amp] is observed 
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against resistant Gram-negative strains. For E. coli CTX M2 RDIC value is higher than 
100 and for E. coli TEM CTX M9 is even higher (RDIC > 1000). No activity (and 
consequently no RDIC value) has been found for E. coli AmpC Mox2. In the case of 
[P6,6,6,14][Amp] the MIC values decrease in resistant bacteria E. coli TEM CTX M9 and E. 
coli CTX M2. In this case the RDIC values are lower than for [C16Pyr][Amp]. However, 
the RDICs are in order of tens. These results clearly suggest that antibiotic APIs-ILs 
help in the deliver of antibacterial agent [Amp] to some Gram-negative bacteria that 
developed resistance against beta-lactam antibiotics187,189, most probably acting as 
lipophilic phase transfer agent across the outer membrane of the bacteria190. If this 
transportation mechanism is true, APIs-ILs obviously may solve some resistance 
problems – e.g. in the case of porin channel blockage, they should be fully effective 
against bacterial resistance but if mutation on Penicillin-binding proteins (PBPs) 
occurred, they would show no effect, while in the case of resistance based on the 
development of beta-lactamases, their success may depend on several factors. 
However, as bacteria frequently developed more than one resistance mechanism, the 
full effect of ILs-APIs on them should be further studied. Regarding sensitive strains, 
the MIC values of [P6,6,6,14][Amp] present an opposite effect. In this group of bacteria 
RDIC values were equal or lower than 1, indicating a more complex interaction. 
Table 5.4 Relative Decrease of Inhibitory Concentration (RDIC)a) of ampicillin anion in 
[Cat][AMP] comparing with Sodium Ampicillin for ampicillin resistant bacteriaa. 
Strains 
Comp. 
E. coli TEM CTX M9 E. coli CTX M2 E. coli AmpC Mox2 
[Na][Amp] 1 1 1 
[P6,6,6,14][Amp] >10 >10 - 
[C16Pyr][Amp] >1000 >100 >100 
a) for explanation of RDIC values see Experimental section. 
 
The Growth Rate (GR) studies were performed by exposing approximately 0.5 to 2.5 x 
104 CFUmL-1 of bacteria to an ampicillin based IL concentration. The selected 
concentrations were of superior, equal or inferior value of the determined MIC. 
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As expected, in the presence of concentrations equal and superior to MIC, no growth 
was observed. In the presence of inferior MIC values, a decrease was observed on GR 
in most of the cases (Table 5.5, Figure 5.2). These observations indicate that in the 
presence of an IL with an inferior concentration of MIC, a possible growth inhibition 
occurs in a similar way, especially in the case of pathogenic strains. These results point 
to a potential use of these compounds as antibacterial drugs mainly against resistance 
strains at very low concentrations. 
Table 5.5 Growing rates for the different organisms in the presence and absence of 
[P6,6,6,14][Amp].  
Organism 
MIC/ 
mM 
Conc. Tested/ 
mM 
Growing rate.min-1 
Decreasing rate 
With [P6,6,6,14][Amp] no compound 
E. coli ATCC 25922 2.5 0.5 0.0007  0 .0001 0.0020  0.0001 0.035 
S. aureus ATCC 25923 0.005 0.0005 0.0004  0 .0003 0.0052 0 .0007 0.077 
K. pneumonia 5.0 0.5 0.00045  0 .00007 0.0025  0.0005 0.18 
E. fecalis 0.05 0.005 0.0009  0.0004 0.0033  0.0001 0.28 
S. epidermis 0.05 0.005 0.0006  0.0000 0.0047 0 .0002 0.13 
E. coli TEM CTX M9 0.5 0.05 0.00067  0.00006 0.0033  0.0007 0.20 
E. coli AmpC Mox2 0.5 0.05 0.00077 0 .00006 0.0032  0.0004 0.24 
 
Figure 5.2 illustrates resistant Gram-negative strains bacteria E. coli AmpC Mox2 
(Figure5.2 a); E. coli TEM CTX M9 (Figure 5.2 b); E. coli CTX M2 (Figure 5.2 c) growth 
curves in the case of [C16Pyr][Amp] for different concentrations (0.5, 0.05 and 0.005 
mM). 
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Figure 5.2 Representation of growth curves (Log(optical density) vs Time) from resistant Gram-
negative strains bacteria E. coli AmpC Mox2 (a); E. coli TEM CTX M9 (b); E. coli CTX 
M2 (c) in the case of API-IL [C16Pyr][Amp] for different concentrations. For 
comparison no compound addition experiments were performed.  
0,000
0,200
0,400
0,600
0,800
1,000
1,200
1,400
1,600
0 500 1000 1500 2000
O
p
ti
ca
l 
D
en
si
ty
 
Time /min 
E. coli AmpC MOX 2 
[C16Pyr][Amp]  0.005 mM
[C16Pyr][Amp]  0.05 mM
[C16Pyr][Amp]  0.5 mM
1% DMSO
no compound
a) 
0,000
0,200
0,400
0,600
0,800
1,000
1,200
1,400
1,600
0 500 1000 1500 2000
O
p
ti
ca
l 
D
en
si
ty
 
Time /min 
E. coli TEM CTX M9 
[C16Pyr][Amp]  0.0005 mM
[C16Pyr][Amp]  0.005 mM
[C16Pyr][Amp]  0.05 mM
no compound
b) 
0,000
0,200
0,400
0,600
0,800
1,000
1,200
1,400
1,600
0 500 1000 1500
O
p
ti
ca
l 
D
e
n
si
ty
 
Time /min 
E. coli CTX M2 
[C16Pyr][Amp]  0.005 mM
[C16Pyr][Amp]  0.05 mM
[C16Pyr][Amp]  0.5 mM
no compound
c) 
L
o
g
 (
o
p
ti
ca
l 
d
en
si
ty
) 
L
o
g
 (
o
p
ti
ca
l 
d
en
si
ty
) 
L
o
g
 (
o
p
ti
ca
l 
d
e
n
si
ty
) 
Chapter 5 Antibacterial Activity of Ionic Liquids Based on Ampicillin Against Resistant Bacteria 
123 
5.4 Conclusion 
The present work suggested that ILs based on ampicillin can reverse the resistance in 
some clinical strains previously isolated and tested as resistant. With the appropriate 
selection of the organic cation, it is possible to provoke important biological variations 
in their antibacterial properties. This report also showed that the ion-pair effect is 
crucial in the ampicillin mechanism of action, being required a selection of 
hydrophobic ampicillin counterions. 
[C16Pyr][Amp] demonstrated the highest potential in reversion of resistance. 
[C16Pyr][Cl] is already used in some types of mouthwashes and toothpastes14 although 
it is irritant in higher concentrations15. The highest improvement of activity is obtained 
against Gram-negative resistant bacteria (E. coli TEM CTX M9 and E. coli CTX M2, 
RDIC >1000 and 100 respectively). These results are clearly promising and appoint to a 
beneficial effect of drug delivery assisted by API-IL through outer membrane of Gram-
negative bacteria, opening possibilities for new similar applications and explorations 
especially in reversing drug resistance. Drug delivery processes have never seemed to 
be a problem for Gram-positive and Gram-negative sensitive strains and therefore they 
showed more moderate oscillation in RDIC values (0.1-50), which are obviously 
connected to their morphology. RDIC values proved to be a good indicator for the 
measurement of the efficiency effectiveness of the process. In the future they can be 
used to quantify interaction of ILs-APIs and resistant bacteria in order to determine the 
influence of ILs-APIs on various bacterial resistance mechanisms. 
Our results also showed that future developments of novel APIs-ILs must been taken 
into consideration not only in the toxicity and hydrophobicity of the counter ion but 
also to be more focused on it. Example of [P6,6,6,14][Amp] which generally follows the 
trend of [C16Pyr][Amp], but with very low RDIC values (demonstrate that there may be 
more factors at stake to be considered). 
The reversion mechanism of the ampicillin based ILs should be further studied in 
order to improve infection control within the hospital environment and in the 
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community. Nevertheless, the use of ILs based antimicrobials will contribute to the 
decrease of nosocomial infections (in terms of morbidity and mortality) and costs 
associated with them. 
5.5 Experimental Section 
5.5.1 Reagents and Materials 
[Amp] has been used as anion combined with the following organic cations: 1-ethyl-3-
methylimidazolium, [EMIM]; 1-hydroxy-ethyl-3-methylimidazolium, [C2OHMIM]; 
choline, [Cholin]; tetraethylammonium, [TEA]; cetylpyridinium, [C16Pyr] and 
trihexyltetradecylphosphonium [P6,6,6,14]. In addition, in order to be accurate and make 
comparisons, activity tests were performed on starting materials (cation bromide and 
chloride salts). Sodium salt of ampicillin is always used as standard for comparison. 
5.5.2 Bacterial Strain 
A total of 10 bacterial strains were used in this study. The following reference strains 
were obtained from the American Culture Collection (ATCC): E. coli ATCC 25922 and 
S. aureus ATCC 25923. All other strains, including several resistant bacteria are 
clinically isolated from previous work: K. pneumonia, S. epidermidis and E. fecalis and the 
resistant bacteria, E coli Tem CTX M9, E. coli CTX M2, E. coli AmpC Mox2. These 
resistant strains were tested in Vitek2 systems from bioMérieux. 
5.5.3 Minimum Inhibitory Concentration (MIC) and 
Minimum Bactericidal Concentration (MBC) 
The MIC values were determined in triplicate by the broth micro dilution method in a 
96-well microtiter plate, using Tryptic Soy Broth (TSB), which is an adapted 
methodology from the Clinical Laboratory Standard Institute (CLSI)160 (Table 5.1 and 
Table 5.2). The organisms tested were grown individually on Tryptic Soy agar for 24 h 
at 37 oC prior to each antibacterial test. Prior to MIC determination, each inoculum 
density was adjusted in TSB to 0.5 McFarland standard by photometric device160. This 
resulted in a suspension containing approximately 1  108 to 2  108 colony forming 
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units CFUmL-1 for E. coli ATCC25922®. A similar approach was used for the other 
strains. Then 0.5 L of the suspension was added to each well to have 0.5-2.5x104 
CFUmL-1 as final concentration. Bacteria were exposed to an Ampicillin-IL salt using 
the following concentration: 5 mM, 2.5 mM, 0.5 mM, 0.05 mM, 0.005 mM, 0.0005 mM 
and 0.00005 mM. With the exception of [P6,6,6,14][Amp] that was diluted in 1% 
dimethylsulfoxide (DMSO), all others were dissolved in water and these results were 
compared with bacteria that had grown in TSB broth in the presence of 1% DMSO as a 
control. The MIC for each Amp-IL was recorded as the lowest concentration that 
showed no turbidity after 24 h of incubation at 37 oC160. The presence of turbidity is an 
indication of microbial growth and the corresponding concentration of an antibacterial 
agent is considered ineffective. To determine whether the Amp-ILs inhibited growth or 
had bactericidal activity, 5 μL XTT sodium salt of (2,3-bis[2-Methoxy-4-nitro-5-
sulfophenyl]-2H-tetrazolium-5-carboxyanilide inner salt) was added to the non-turbid 
wells of the MIC assay plate and incubated for 3 h at 37 oC for bactericidal status 
determination161,162. In the case of viable cells with inhibited growth, mitochondrial 
dehydrogenases of viable 100 cells cleave the tetrazolium ring of XTT yielding dark 
orange aqueous soluble formazan crystals. However, a solution containing non-viable 
cells would remain with the same colour162. In this case, MIC values were equal to MBC 
for each Ampicillin based ILs, so the antibacterial activities of these compounds were 
considered to be bactericidal. 
In order to obtain the ratio of MIC values for various sensitive bacteria they were 
grouped as ratio of MIC values of [Na][Amp] and [Cat][Amp] or so-called RDIC values 
(relative decrease of inhibitory concentration). 
As in the case of resistant bacteria, the MIC values of [Na][Amp] could not be found 
experimentally. RDIC values of resistant bacteria are calculated assuming that the MIC 
value of [Na][Amp] is at least 5 mM (>5 mM) in all cases (the highest value that can be 
measured experimentally), providing the numerical RDIC values for all [Cat][Amp] 
with MIC values (Table 5.4). 
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5.5.4 Growth Rate Studies 
In order to complete the characterization of anti-bacterial activity, the Growth Rate 
(GR) when exposed to the MIC value was evaluated. Additionally, GR values in the 
presence of higher and lower concentration of the MICs, previously found for each 
compound, was also determined (Table 5.5 and Figure 5.2). 
The GR parameter was determined in triplicate by the broth micro dilution method in 
a 96-well microtiter plate using Tryptic Soy Broth (TSB)160,163,164. Approximately 5000-
25000 CFUmL-1 of bacteria is exposed to an ampicillin based IL of concentration 
superior, equal or inferior value of the determined MIC, performing periodical 
readings of the optical density (OD) at 620 nm. The growing rate was determined by 
fitting a linear  function to the Exponential (log) phase curve. 
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6 
 
Anti-tumoral Activity of Ampicillin Ionic 
Liquids and Their Salts 
 
6.1 Abstract 
Ionic Liquids (ILs) are a peculiar class of organic salts with melting points below  
100 oC. They are finding increased interest from the scientific community and industry 
due to the large number of potential cation/anion combinations, which allows a variety 
of tuneable interactions and applications. These type of combinations can be an 
innovative solution to the polymorphism behaviour of several drugs as well as to their 
reduced bioavailability. The focus of this work is to study the anti-cancer activity of ILs 
based on the ampicillin antibiotic, using cell viability tests. We evaluated  
anti-proliferative activity against some human cancer cell lines and found an  
anti-proliferative effect against diverse tumour cell lines using innovative active 
pharmaceutical ingredients (APIs) as molten salts or ionic liquids. 
6.2 Introduction 
As said before, Ionic Liquids (ILs) are organic salts, generally with melting points 
below 100oC (in many cases they are liquid at room temperature)9,171 and which have 
been applied in several research areas. One of the most promising applications of ILs 
seems to be the so-called third generation of ILs (their arrangement with active 
pharmaceutical ingredients, APIs) or APIs-ILs8,9. Recently, we described the successful 
combination of API ampicillin as anion with six different organic cations.30 This type of 
combination can be an innovative solution in order to eliminate polymorphism, 
characteristic of a large number of drugs, as well as, to improve their solubility and 
permeability behaviour. 
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The compound [C2OHMIM][Amp] possess  relevant discriminative and strong anti-
proliferative activity against five different human cancer cell lines, in particular T47D 
(breast), PC3 (prostate), HepG2 (liver), MG63 (osteosarcoma) and RKO (colon). 
 
Figure 6.1 Structure of compounds prepared based on ampicillin. 
The relevant question of the toxicity of the active pharmaceutical ingredient counter-
ion in ILs has been the major cause for the delay of the entrance of ILs in biosciences.9 
The toxicities towards microorganisms and eukaryotic cell cultures cover the whole 
range of biocidal potencies, from rather inactive molecular solvents that are 
biocompatible up to high concentrations in aqueous solutions. This leads to the 
successful proposal of ionic liquids as wood preservatives as well as different 
pharmaceutical applications,9,142  and even as potential anticancer therapeutic 
agents23,31,71 (in vitro). Consequently, the development of novel anti-cancer drugs that 
decrease the toxicity associated with active chemotherapies4,5 can also be pursued 
within the ionic liquid framework. The focus of this work is to further explore the 
outstanding properties of the previously synthetized ampicillin compounds, in 
particular their anti-proliferative effect against diverse tumour cell lines and compare 
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to results obtained of the primary human cell lines. Figure 6.1 illustrates the ILs based 
APIs (or molten salts-APIs) used in this study. 
6.3 Experimental section 
6.3.1 Biological studies 
All compounds were prepared using an optimized and sustainable method described 
in a previous publication30. 
The synthesized compounds were then used in order to evaluate their anti-
proliferative activity against some human cancer cell lines, such as T47D (ductal breast 
epithelial tumour cell line), PC3 (prostate cancer cell line), HepG2 (hepatocellular liver 
carcinoma cell line), MG63 (osteosarcoma cell line) and RKO (colon cancer cell line). In 
addition, two primary human cell types, namely, skin and gingival fibroblasts (SF and 
GF, respectively) were also tested. 
6.3.1.1 Cell viability/proliferation  
Cells were maintained in α-minimal essential medium (α-MEM) containing 10% fetal 
bovine serum, 100 IumL-1 penicillin, 2.5 gml-1 streptomycin, 2.5 gmL-1 amphotericin 
B and 50 μgmL-1 ascorbic acid. At about 70-80% confluence, cells were enzymatically 
detached with 0.05% trypsin and 0.5mM EDTA and seeded at 104 cellscm-2. After an 
attachment period of 24 h, the culture medium was renewed, and supplemented with 
different concentrations (0.005-500 mM) of the ampicillin-derived ILs. Cell cultures 
were maintained in a 5% CO2 humidified atmosphere at 37 oC. Cellular 
viability/proliferation was assessed by the MTT assay at days 1, 3 and 5 of the culture, 
as described before165,166. This assay is based on the reduction of 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide to a purple formazan product by viable cells. 
Shortly, cultured cells were incubated at 37 oC with 0.5 mg mlL-1 of MTT for 4 h. The 
culture medium was then removed; the stained product dissolved with 
dimethylsulfoxide and absorbance determination was conducted at 550 nm in an 
ELISA plate reader. Results were expressed as absorbance per square centimetre  
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(A cm-2).165,166 The values of the half maximal inhibitory concentration (IC50) and the 
median lethal dose (LD50) were obtained from nonlinear regression analysis of 
concentration-effect curves using the GraphPad Prism software167,168. The definition of 
the IC50 is given  by Sebaugh169 as “the response corresponding to the 50% control (the 
mean of the 0% and 100% assay controls)” and is used to measure the efficacy of a 
compound in inhibiting any biochemical or biological function. The term LD50 means 
the median lethal dose and is the amount of material which causes the death of 50% of 
a population170. 
6.4 Results and discussion 
Table 6.1 summarizes the anti-tumoral (IC50 and LD50) activities of the prepared ILs 
and molten salts based on the ampicillin anion against two primary human cell types, 
namely, skin (SF) and gingival fibroblasts (GF). 
Table 6.1 IC50 and LD50 in µMof the ILs based on ampicillin against primary human cell lines. 
Compounds 
Cell lines 
SF GF 
[TEA][Amp] 
IC50/ µM nd nd 
LD50/ µM nd 58.040 
[P6,6,6,14][Amp] 
IC50/ µM 0.249 0.173 
LD50/ µM >0.249 0.176 
[C16Pyr][Amp] 
IC50/ µM 0.032 0.012 
LD50/ µM 0,815 45.510 
[Cholin][Amp] 
IC50/ µM 48.480 nd 
LD50/ µM 49.790 nd 
[EMIM][Amp] 
IC50/ µM 6.366 0.853 
LD50/ µM >6.366 9.357 
[C2OHMIM][Amp] 
IC50/ µM 5.084 0.462 
LD50/ µM 22.600 30.470 
[Na][Amp]* 
IC50/ µM nd 109.100 
LD50/ µM 8.104 >109.100 
nd – IC50 and LD 50 not detected in the concentration range used. SF (skin fibroblasts), gingival fibroblasts (GF). [Amp] 
Ampicillin anion, [TEA] tetraethylammonium, [P6,6,6,14] trihexyltetradecylphosphonium, [C16pyr] cetylpyridinium, 
[Cholin] choline, [EMIM] 1-ethyl-3-methylimidazolium, [C2OHMIM] 1-hydroxy-ethyl-3-methylimidazolium.  
* [Na][Amp] was used as a control. 
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The [Na][Amp] was used as a control and, as can be seen in Table 6.1, it is one of the 
least toxic. The IC50 was not detected in the concentration range used against SF and 
the value of the IC50 for the GF was 109.1 µM. Analysing the other synthesised 
compounds and comparing the values with [Na][Amp], we can say that the most toxic 
to the human cell lines are [P6,6,6,14][Amp] and [C16Pyr][Amp] (the lowest values of the 
IC50). [TEA][Amp] and [Cholin][Amp] are the least toxic. The ILs based on 
imidazolium [EMIM][Amp] and [C2OHMIM][Amp] have values in the middle. These 
results are according to the literature which says that the increase of hydrophobicity 
and the increase of the alkyl chain leads to the increase of the toxicity25,155,157,191,192. 
Table 6.2 IC50 and LD50 in µM of the ILs based on ampicillin against cancer cell lines.  
Compounds 
Cell lines 
MG63 HepG2 T47D PC3 RKO 
[TEA][Amp] 
IC50/ µM 0.030 nd 0.042 35.650 56.700 
LD50/ µM 1.368 0.0951 43.990 58.920 68.370 
[P6,6,6,14][Amp] 
IC50/ µM 0.312 0.322 0.264 0.354 0.180 
LD50/ µM >0.312 15.770 4.970 9.335 11.860 
[C16Pyr][Amp] 
IC50/ µM 0.011 nd 0.005 132.700 0.226 
LD50/ µM 183.200 nd nd >132.700 59.170 
[Cholin][Amp] 
IC50/ µM 0.017 1.619 110.900 0.982 nd 
LD50/ µM 738.000 15.030 >110.900 17.160 0.707 
[EMIM][Amp] 
IC50/ µM 1.122 24.270 nd 29.990 0.269 
LD50/ µM >1.122 >24.270 32.370 31.020 >209.700 
[C2OHMIM][Amp] 
IC50/ µM 0.738 0.319 0.146 0.297 0.359 
LD50/ µM 4.197 0.4040 0.498 >0.297 0.362 
[Na][Amp]* 
IC50/ µM nd nd nd 0.597 2.406 
LD50/ µM 506.600 0.720 47.790 560.900 920.800 
nd – IC50 and LD 50 not detected in the concentration range used. MG63 (osteosarcoma cell line), HepG2 
(hepatocellular liver carcinoma cell), T47D (ductal breast epithelial tumour cell line), PC3 (prostate cancer cell line), 
line) and RKO (colon cancer cell line). [Amp] Ampicillin anion, [TEA] tetraethylammonium, [P6,6,6,14] 
trihexyltetradecylphosphonium, [C16pyr] cetylpyridinium, [Cholin] choline, [EMIM] 1-ethyl-3-methylimidazolium, 
[C2OHMIM] 1-hydroxy-ethyl-3-methylimidazolium. * [Na][Amp] was used as a control. 
 
Table 6.2 shows the results of Ampicillin-ILs on five human cancer cell lines: 
osteosarcoma cell line (MG63), hepatocellular liver carcinoma cell (HepG2), ductal 
breast epithelial tumour cell line (T47D), prostate cancer cell line (PC3), line) and colon 
cancer cell line (RKO). Table 6.2 shows that each IL based on Ampicillin have very low 
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values of IC50 and LD50 for at least one of the cancer cell lines, which demonstrate the 
potential of these organic salts as selective anti-tumour agents. However, 
[C2OHMIM][Amp] has low values of LD50 and IC50, in particular T47D (breast), PC3 
(prostate), HepG2 (liver), MG63 (osteosarcoma) and RKO (colon), when compared to 
the results of IC50 and LD50 on primary human cell lines, SF and GF, (more than 5 
times lower). So, these results demonstrate that [C2OHMIM][Amp] possess relevant 
discriminative and strong anti-proliferative activity against five different human cancer 
cell lines. Additionally, the values of LD50 ([C2OHMIM][Amp]) for this salt are much 
lower than those of the Ampicillin Sodium salt [Na][Amp], with the exception of the 
HepG2 cell line. Considering these results and analysing the only variant that had been 
changed, the structure of the cation, [C2OHMIM] is a cation that could have 3 points of 
interactions with ampicillin (Figure 6.2). [C2OHMIM] has 2 protons that could make a 
hydrogen bond and a  system that could interact with the  system of the ampicillin 
that provides more ways of interaction between the cation and the anion. This could 
help the salt entering the cell. 
 
Figure 6.2. Struture of [C2OHMIM] cation. The circles is show the possible point of interactions 
with ampicillin. 
The results from Table 6.1 and Table 6.2 indicate that [TEA][Amp] is more toxic (LD50) 
for MG63 (osteosarcoma cell line) and T47D (human ductal breast epithelial tumor cell 
line). [P6,6,6,14][Amp] also reveals a higher toxicity for the cancer cell lines than for the 
two normal cell types, a very low value of IC50 when comparing Ampicillin Sodium 
salt [Na][Amp]. [C16Pyr][Amp] is only significantly toxic against skin fibroblasts and 
[Cholin][Amp] against RKO (colon cancer cell line). The lowest value of LD50 obtained 
for [EMIM][Amp] was for MG63 cell line. The high cytotoxic effect, but low selectivity 
of compounds containing the [P6,6,6,14]+ cation, is not surprising as the very high 
cytotoxicity of compounds with this cation towards other cell lines has already been 
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described.25 Regarding the compounds containing [C16Pyr]+ cation, although frequently 
applied in pharmaceutical formulations, are also proven as very potent skin irritants.15 
This fact is in line with the results obtained here for the skin fibroblasts, where a small 
LD50 was obtained. 
Regarding the IC50 values of Ampicillin-ILs, which is related to the anti-tumoral 
activity, [P6,6,6,14][Amp] seems to significantly inhibit the growth of all tested cells (low 
values of IC50 for all the cancer cell lines. The compound [TEA][Amp] displays a high 
activity against MG63 (osteosarcoma cell line) and HepG2 (hepatocellular liver 
carcinoma cell), while no effect was found in the remaining cell lines. [C16Pyr][Amp] 
has anti-proliferative activity against all of the tested cells, except for the cases of 
HepG2 and PC3 (prostate cancer cell line). 
For [Cholin][Amp], a significant anti-proliferative behaviour was only observed in the 
case of MG63 (osteosarcoma cell line). Contrarily to the other bulky cations, the high 
cytotoxicity of [Cholin][Amp] towards MG63 cancer cell lines and high selectivity 
towards non-cancerogeneous cells can only be attributed to the xenobiotic (ampicillin) 
and its facilitated transport to the cytosol of cancer cell (effect of the ionic liquid) as the 
cation [Cholin]+ is an essentially nutrient9,184. 
On the other hand, [EMIM][Amp] only shows activity against RKO (colon cancer cell 
line). The IC50 values for the molten salt [C2OHMIM][Amp] are quite satisfactory, with 
very low values of IC50 for 4 of the 5 tumour cell lines tested. The only exception was 
MG63 (IC50 = 0.7384 µM), which revealed an inhibition of proliferation lower than the 
gingival fibroblasts (IC50 = 0.4616 µM). For [Na][Amp], the lowest value of IC50 was 
obtained for PC3 cell line (IC50 = 0.5973 µM). 
6.5 Conclusions 
In conclusion, [C2OHMIM][Amp] presented low values of IC50 and LD50 against five 
different cell lines (T47D (breast), PC3 (prostate), HepG2 (liver), MG63 (osteosarcoma) 
and RKO (colon)) showing that it could be used against cancer cell lines. A very low 
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cytotoxicity against two primary cell lines (skin (SG) and gingival fibroblasts (GF)) 
shows that these compounds are not toxic to human cell lines. The IC50 values also 
indicated that [C2OHMIM][Amp] presents an anti-proliferative activity against several 
tumour cell lines and a lower activity against primary fibroblasts. The other ampicillin 
ILs also show anti-tumoral activity against specific cell lines. It is important to 
emphasize that the appropriate selection of the cations and anions could render salts 
(or the ILs) with specific activity against different tumour cell lines, and therefore allow 
the modulation of the final biological properties of the pharmaceutical salts. 
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Synthesis of ILs based on Penicillin G, 
Amoxicillin and Amphotericin B 
 
7.1 Introduction 
The use of ILs in pharmaceutical sciences has increased in recent years193. They have 
been used to solve the problems related to the solubilisation of some drugs30,193-197. They 
are being exploited as solvents and/or (co)solvents and/or reagents to synthetize active 
pharmaceutical ingredients (APIs)7-9,30,150,193,198. Besides these applications, many ILs 
show antimicrobial activity as presented in Chapter 5. This leads to the use of ILs as 
active pharmaceutical ingredients (APIs) or formulation preservatives9,30,193. 
One of the many challenges that the pharmaceutical industry is facing is the solid form 
administration of many drugs. The problems with solid forms could be there low 
solubility, polymorphic conversion and low bioavailability9,30,198. The properties 
inherent to ILs could be of extreme importance to overcome the difficulties of solid 
form drugs9,30. Recent works have shown that ILs-APIs prove to have many attractive 
properties when compared to conventional drugs69. Our group has recently evaluate 
their relevant pharmacological properties, such as water solubility, octanol–water 
partition coefficient, hexadecylphosphocholine (HDPC) micelle–water partition 
coefficient and critical micelle concentration of the  ampicillin-based pharmaceutical 
active ionic liquids synthesized by us30,199. In the work “Evaluation of solubility and 
partition properties of ampicillin-based ionic liquids”199 the result clearly confirms the 
great potential of the API-IL methodology, since ampicillin-based ILs enhances 
properties regarding solubility in water, as well as more adequate properties regarding 
membrane affinity and permeation. This work199 also confirms that an accurate 
selection of the organic cation allows the fine-tuning of some important physical and 
thermal properties, such as water solubility, membrane permeation, melting point and 
thermal stability199.  
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In this chapter we present a sustainable methodology to synthesize ILs from APIs such 
as the one used to synthesize ampicillin ILs. The IL-APIs synthesised here are not only 
beta-lactamics like amoxicillin and penicillin, but also an antifungal containing 
amphotericin B. Although these molecules are completely different, the same 
preparative methodology could be applied to all of them with minor adaptations. 
As said before, the classic methodology for the synthesis of ILs is the metathesis 
reaction. This is a reaction where cations and anions exchange partners. The 
purification of ILs is made by the elimination of undesirable inorganic salts (mainly 
sodium, potassium or lithium chloride or bromide) using precipitation followed by 
filtration177. This reaction has two major problems. One is the difficulty to obtain 
halide-free ILs. The other problem relies in the ion exchange. When there is an anion 
exchange with weaker acids than hydrohalic acids91, it cannot be efficiently done30. 
The methodology used here for the preparation of the ILs-APIs is the same as used in 
Chapter 4 to obtain pure ILs from ampicillin. It is an adaptation based in the ion 
exchange resins developed by Ohno et al.26 The Amberlite resin is in the OH form and 
is used to obtain the hydroxide form from the halide salts (bromide or chloride), then 
this basic solution is neutralized with the buffered API solution. 
7.1.1 Amoxicillin and Penicilin 
Amoxicillin [Amx] and Penicillin [Pen] are two antibiotics that belong to the beta-
lactamic group like Ampicillin [Amp] (Figure 7.1).  
 
Figure 7.1. Struture of Ampicillin [Amp], Amoxicillin [Amx] and Penicillin [Pen]. 
From the point of view of microbiological synthesis, antibiotics are the most important 
bioactive and chemotherapeutic compounds200. Penicillin was the first product from an 
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organism to allow the distinction between the toxicity to the bacterial cell and toxicity 
to the mammalian host. This allows its use in the general treatment of infections caused 
by Gram-positive and Gram-negative organisms in humans and animals. The structure 
of beta-lactamics antibiotics consists in a nucleus that includes a beta-lactam ring fused 
through nitrogen and adjacent tetrahedral carbon to a second heterocycle (five-
membered thiazolidine ring).200 
In this work, as well as in Chapter 4, we pretend to obtain ILs from amoxicillin and 
penicillin. For the synthesis of most of these compounds we used the recently 
developed method of Ohno et al.26 for the preparation of quaternary ammonium, 
phosphonium, imidazolium and pyridinium hydroxides, which were later neutralized 
by appropriate acids (amoxicillin and penicillin) in a buffer solution to avoid antibiotic 
decomposition. 
7.1.2 Amphotericin B 
Amphotericin B is also an antimicrobial agent. In this case it is a polyene used mainly 
against fungal infections and parasitic disease. The main problems with amphotericin 
B are its low solubility and the capacity to self-aggregate and therefore cause severe 
nephrotoxicity, which may lead to kidney failure43. This drug has different 
formulations, most of them have recently been discovered (AmBisome®, Abelcet®, and 
Amphotec®). Due to the low solubility drug delivery systems, such as liposome, 
developments on nanosolubility and microsphere are being done. These drug delivery 
systems have the advantage to increase the concentration in the liver and spleen, but 
decrease the concentration in the kidney resulting in low toxicity. An alternative to this 
drug delivery systems is ILs. The transformation of amphotericin B as ILs could lead to 
the increase of the solubility or even the decrease of the toxicity. 
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Figure 7.2 Ionic Liquids based on amphotericin B. 
7.2 Material and Methods 
7.2.1 General remarks 
Commercially available reagents were purchased from Aldrich, BDH – laboratory 
reagents and Solchemar and were used as received. The solvents were from Valente & 
Ribeiro and distilled before used. The basic anion-exchange resin Amberlite IRA-400-
OH (ion-exchange capacity 1.4 Eq.mL-1) was purchased from Supelco. 1H and 13C-NMR 
spectra in (CD3)2SO or CD3OD (from Euriso-Top) were recorded on a Bruker AMX400 
spectrometer at room temperature unless specified otherwise. Chemical shifts are 
reported downfield in parts per million (ppm). IR spectra were measured on a Perkin 
Elmer 683. Optical rotations were recorded on a Perkin Elmer 241MC.  
7.3 Results and discussion 
7.3.1 Chemistry 
This work proposed to show that it is possible to prepare ILs from several types of 
APIs and develop an efficient and sustainable synthetic methodology for that. The 
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APIs used in this work have been used as an anion combined with the several organic 
cations 1-ethyl-3-methylimidazolium, [EMIM], 1-hydroxy-ethyl-3-methylimidazolium, 
[C2OHMIM], choline, [Cholin], tetraethylammonium, [TEA], cetylpyridinium, [C16pyr], 
trihexyltetradecylphosphonium [P6,6,6,14], 1-methoxyethyl-3-methylimidazolium 
[C3OMIM], 1-(2-hydroxyethyl)-2,3-dimethyl-1H-imidazol-3-ium chloride [C2ODMIM]. 
The anions used in this work were chosen due to their low toxicity, except in the case 
of [P6,6,6,14] which was chosen to ensure that at least one of the ILs-APIs could be 
obtained in the liquid form. The several combinations made between the cations and 
the anion as a specific drug can lead to an alteration in the compound’s 
biopharmaceutical drug classification32 as well as their drug formulation process. 
The Table 7.1 presents the results for the synthesis of the ILs. 
Table 7.1 Yield for the synthesis of ILs based on APIs. 
Anion Cation Yield 
[Amx] 
[EMIM] 80 
[C2OHMIM] 62% 
[P6,6,6,14] 94% 
[C16Pyr] 55% 
[Pen] 
[EMIM] 84% 
[C2OHMIM] 86% 
[Cholin] 98% 
[P6,6,6,14] 99% 
[C16Pyr] 91% 
[TEA] 92% 
[AmphB] 
[C3OMIM] 53% 
[Cholin] 51% 
[C16Pyr] 71% 
[C2OHMIM] 90% 
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7.3.2 Isolation of the Products 
The isolation of the ILs based on amoxicillin and penicillin was made in the exact same 
way as for ampicillin. The excess of the antibiotics was removed by filtration after the 
crystallization with acetonitrile/methanol (9:1). 
Amphotericin B was the most problematic compound to work. This compound is very 
unstable and is insoluble in water and in most common solvents. Besides, the 
fragmentation starts easily from hemiacetal ring. As in the case of beta-lactam 
antibiotics it was also decided that buffered neutralization method (using 1.0 M 
ammonium solution) should be used. However this solution did not managed to 
protect amphotericin B from decomposition. After the reaction with the desired cation 
hydroxide we tried to analyse the final mixture by 1H-NMR. This spectrum was 
inconclusive and therefore it was analysed by MALDI-TOF-MS the desired peak of the 
amphotericin B was not found. One of the peaks found was 420.7 u.m.a (Figure 7.3). 
Trying to understand this result, we analysed the structure of amphotericin B and it 
looked as if amphotericin B could suffer Grob fragmention158,159.  
 
Figure 7.3 MALDI-TOF-MS mass spectrum of the reaction mixture after the first attemtp to 
synthesise ILs based.on AmphB. 
Grob fragmention is a heterolytic fragmentation reaction where a molecule with a 
certain carbon-heteroatom (N, O, S, P, Si, B, or halogen) combination is cleaved under 
specific mechanistic principles158 (Scheme 7.1).  
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Scheme 7.1 Grob fragmentation of a general 1,3-diheterosubstituted substrate (from Prantz et 
al.158). 
In the case of AmphB, the degradation could start in the labile hemiacetal point, 
obviously promoted by attack of an aqueous base. Attack of a base on hemiacetal will 
promote the opening of acetal ring and further Grob fragmentation with the separation 
of amino sugar. In addition elimination of beta-hydroxy group of the ester 
functionality will occur, a reaction similarly catalysed by aqueous base and finally 
proper ester hydrolysis is plausible in aqueous basic condition (Scheme 7.2)). So, in 
order to minimize impact from Grob fragmentation and ester hydrolysis, new 
preparative conditions had to be explored. We decided then to test conditions in the 
absence of large quantities of water in reagents at the beginning of the reaction (so-
called water-free condition).Then we decided to use 1.0 M triethylamine methanolic 
solution as the buffer solution. This buffer solution managed to dissolve amphotericin 
B  and did not helped its degradation The isolation of pure ILs based on AmphB was 
made by recrystallization from methanol in order to remove the amphotericin 
crystalline impurities, insoluble in methanol and then it was treated with calcium 
carbonate to remove acid impurities. 
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Scheme 7.2 AmphB degradation by Grob fragmention – a possible mechanism. 
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7.3.3 Biological Activity 
In the present study, a series of ILs-APIs based on amoxicillin and penicillin (Table 
7.2)30 was tested against sensitive Gram-negative bacteria Escherichia coli ATCC 25922 
and Gram-positive Staphylococcus aureus ATCC 25923, as well as against the yeast 
Saccharomyces cerevisiae, an eukaryotic model organism. 
The Minimum Inhibitory Concentration (MIC) values were determined in triplicate by 
the broth micro dilution method, in a 96-well microtiter plate, using Tryptic Soy Broth 
(TSB) and adapted methodology from the Clinical Laboratory Standard Institute 
(CLSI)160. The E. coli and the S. aureus strains were grown individually on Tryptic Soy 
agar for 24 h at 37 oC prior to each antibacterial test and the S. cerevisiae was grown in 
YEPD solid medium. Prior to MIC determination, each inoculum density was adjusted 
in TSB to 0.5 McFarland standard by photometric device160. This resulted in a 
suspension containing approximately 1  108 to 2  108 colony forming units CFUmL-1 
for E. coli ATCC25922®160. A similar approach was used for the other strains. Then 0.5 
L of the suspension was added to each well to have 5000-25000 CFUmL-1. Bacteria 
were exposed to an IL-API concentration of 5 mM, 2.5 mM, 0.5 mM, 0.05 mM, 0.005 
mM, 0.0005 mM and 0.00005 mM. With the exception of ILs with [P6,6,6,14], which were 
diluted in 1% dimethylsulphoxide, all others were dissolved in water and these results 
were compared with bacteria that had grown in TSB broth in the presence of 1% 
DMSO. The MIC for each IL was recorded as having lowest concentration, showing no 
turbidity after 24 h of incubation at 37 oC19,160. The presence of turbidity is an indication 
of microbial growth and the corresponding concentration of antibacterial agent is 
considered ineffective. To study whether the antimicrobial activity of the synthesized 
ILs was bacteriostatic (inhibited growth) or bactericidal (fungicidal for the S. cerevisiae), 
the colorimetric assay (XTT method) was used161. 5 μL of XTT sodium salt of (2,3-bis[2-
Methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxyanilide inner salt) was added 
to the non-turbid wells of the MIC assay plate and incubated for 3 h at 37 oC for the 
bactericidal status determination161,162. In the case of viable cells with inhibited growth, 
mitochondrial dehydrogenases of viable cells cleave the tretrazolium ring of XTT, 
yielding dark orange aqueous soluble formazan crystals; however, a solution 
Chapter 7. Synthesis of ILs based on Penicillin G, Amoxicillin and Amphotericin B 
148 
containing dead bacterial cells would remain with the same colour162. In this case, MIC 
values were equal to MBC for each amoxicillin and penicillin based ILs. Therefore, the 
antibacterial activities of these compounds were considered to be bactericidal. For 
Sacharamyces cerevisiae it was considered fungicidal. 
Table 7.2 shows that for ILs based on Amoxicillin have high or equal values of MIC for 
the bacteria and for the yeast used with the exception of [Amx][C2OHMIM], which has 
a Relative Decrease of Inhibitory Concentration (RDIC) of 10.  
Table 7.2 Minimum inhibitory concentrations (mM) of the new compounds produced on the 
microbial stains. 
Compounds Escherichia Coli Staphylococcus Aureus Saccharomyces cerevisiae 
[P6,6,6,14][Amx] 2.5 mM 5.0 mM >5.0 mM 
[C16Pyr][Amx] 5.0 mM 0.050 mM >5.0 mM 
[EMIM][Amx]  0.5 mM >5.0 mM 0.50 mM 
[C2OHMIM][Amx] 0.050 mM >5.0 mM 0.050 mM 
[Amx]* 0.005 mM 0.050 mM 0.500 mM 
[TEA][Pen] >5.0 mM >5.0 mM 2.5 mM 
[P6,6,6,14][Pen] >5.0 mM 0.005 mM 0.050 mM 
[C16Pyr][Pen] 5.0 Mm >5.0 mM >5.0 mM 
[Cholin][Pen]  >5.0mM >5.0mM >5.0 mM 
[EMIM][Pen] >5.0mM >5.0mM >5.0 mM 
[C2OHMIM][Pen] 0.050mM >5.0mM >5.0 mM 
[Pen][K]* 0.500mM 0.500mM >5.0 mM 
*[Amx] and [Pen][K] were used as controls. 
 
For the case of the ILs based on Penicillin, Table 7.2 shows that for each microorganism 
tested there is only one ILs that has decreased the MIC values of Penicillin. In the case 
of E. coli [C2OHMIM][Pen] has a RDIC value of 10. For S. aureus and S. cerevisiae the IL 
that lead to the decrease of MIC value was the one that has [P6,6,6,14], a cation whose 
toxicity is well known25. In the case of S. aureus [P6,6,6,14][Pen] lead to the decrease of the 
MIC value related to Penicillin (RDIC = 10). For the yeast S. cerevisiae, RDIC is bigger 
than 100 and shows that, when conjugated with right cation, penicillin anion  has the 
potential to be used as an anti-fungal drug. 
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7.4 Conclusions 
This chapter shows that the methodology developed to synthesise ampicillin ILs could 
be used as an efficient methodology for the synthesis of ILs based on APIs like other 
beta-lactamics (amoxicillin and penicillin G). It can also be used to synthesise more 
complex antimicrobial agents like amphotericin B. This could be of extreme importance 
for the development of new bioactive materials[1] (antiseptics and anti-biofilm, for 
example), to fight drug resistance in microorganisms or to improve the 
biopharmaceutical classification system (BCS)32,146 and, just like ampicillin, they may 
have the potential to be used as anti-cancer agents. The right selection of the organic 
cation can provoke important physical and thermal properties of ILs-APIs, such as 
water solubility, melting point and thermal stability.  
The MIC results show us that [C2OHMIM][Amx], [C2OHMIM][Pen] and [P6,6,6,14] [Pen] 
are the compounds that could lead to further studies.  These results show that [P6,6,6,14] 
[Pen] could be more efficient in fighting S. cerevisiae contaminations than traditional 
antimicrobial agents. Due to the fact that MIC values of [Pen][P6,6,6,14] for S. aureus are 
lower than MIC values of amoxicillin and penicillin G, we could say that [Pen][P6,6,6,14] 
in the S. aureus tested, could be an alternative to amoxicillin and penicillin G antibiotics 
and they can also be useful in other applications like surface decontamination and 
disinfectant/antiseptic in a diverse range of antimicrobial infections. 
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Discussion and Conclusion 
 
8.1 Discussion 
The following discussion focuses essentially on the data presented in the previous 
research chapters and on future perspectives. In this work, each chapter of results is 
presented as an accepted or submitted paper and already includes a comprehensive 
discussion and a conclusion of the work presented. 
8.1.1 Synthesis 
One of the first references to the Ionic Liquids as Active Pharmaceutical Ingredients 
(ILs-APIs) was in 2007 (“The third evolution of ionic liquids: active pharmaceutical 
ingredients”)8, where Hough-Troutman et al.8 describe the first generation of ILs. The 
first generation of ILs is characterized by the use of ILs as solvents. The second 
generation uses ILs as energetic materials and lubricants. In this work Hough-
Troutman et al8 produced ranitidine docusate, lidocaine docusate and 
didecyldimethylammonium ibuprofen and studied the physical properties and 
biological efficacy. Since then, many publications have appeared describing the 
applications of ILs in pharmaceutical sciences. Also in 2007, Rogers and co-workers 
patented “Preparation of ionic liquid composition, e.g. pesticide composition, involves 
combining cations and anions having bioactive property or cation precursors and 
anion precursors having bioactive property when ionized”10. In this patent10, they show 
the use of preparing an ionic liquid composition (e.g. pesticide, herbicide, cosmetic, 
food additive, or explosive) with the advantage to overcome “polymorphism, 
solubility and delivery problems to control release rates, add functionality, enhance 
efficacy and improve ease of use and manufacture”10. 
The study of ILs toxicity has led to the use of ILs as antimicrobial agents. There are 
some publications showing the antimicrobial activity of ILs18,21,60,134,135. Most of the ILs in 
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these publications are imidazolium and/or phosphonium halides. In spite of this, there 
is another work with ILs as antimicrobial agents, like the use of ammonium based salts 
with artificial sweetener anions, from Hough-Troutman133. More recently, in 2011 Cole 
produced biocidal ILs consisting of cationic imidazolium or pyridinium and an anionic 
beta-lactam antibiotic19. Pernak has developed, between 2011 and 2013, ILs based in 
herbicides136,154,201-203. Nevertheless, besides Hough-Troutman’s, Cole’s and Pernak ‘s 
works, there are not many study cases about ILs based on API and most ILs produced 
are by metathesis reaction. As a matter of fact, in “Ionic Liquids - New Aspects for the 
Future“149, as referred by Clarissa P. Frizzo and co-workers those alternative methods 
to metathesis reaction were used by us in the synthesis of beta-lactamic antibiotics and 
by Bica and co-workers in the synthesis in solvent-free conditions of salicylic acid 
ILs149. As referred before, metathesis reaction has some inconvenients24,85: 
contamination with a small amount of halide ions, which may react with solute 
materials, and the presence of water or silver residues as impurities. 
There is another problem with the metathesis reaction related to the synthesis of 
pharmaceutical compounds: the use of halide solvents (like chloroform) for the 
majority of the purification process204-206. The pharmaceutical industry avoids the use of 
halide solvents205,206.The advantage of the method presented in this work is that it uses 
methanol as an organic solvent, avoiding the use of halide solvents in the synthesis and 
in the purification. 
The method used to synthesize the ILs in this work is the neutralization method. As 
said before, this method solved the problem of contamination90. The only difficulty 
with this method is when we have weaker acids than hydrohalic acids91. This problem 
was solved using hydroxide quaternary cations30. In this work we adapted ion 
exchange resin methods developed by Ohno and co-workers26,91-93. Amberlite resin (in 
the OH form) has was used in order to exchange halides (bromide or chloride) into 
hydroxide form and then this basic solution was neutralized by the adding an 
adequate buffer solution of the API. Because the amberlite resin used is regenerated, it 
brings about another advantage, since  we could use the same resin for several 
syntheses without spending further resin. 
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When this method was applied to the synthesis of the ILs and salts based on  
beta-lactamic antibiotics and amphotericin B, some were detected: 
1) the beta-lactam ring strain, which promotes the opening of the ring,  
2) the low solubility and the low stability of the amphotericin B; 
3) the purification of the final compounds. 
1) the beta-lactam ring strain, which promotes the opening of the ring 
To avoid the opening of the ring and to give more stability to the antibiotics, we 
decided to dissolve the antibiotic in a buffer. This process worked very well and the 
beta-lactamic ring did not open as shown in the analysis. 
2) the low solubility and the low stability of the Amphotericin B; 
To solve this issue, we applied the same methodology as used in the antibiotics, where 
a buffer was needed. The first buffer we tried was ammonium solution in water, but it 
did not work. Amphotericin was degraded. It seemed that Amphotericin B suffered 
Grob fragmentation158 Then it was decided that dried triethylammonium should be 
used to avoid degradation. The 1H-NMR shows that the Amphotericin B anion was 
presented in the final product. Also the triethylammonium solution in methanol 
helped to dissolve the Amphotericin B. 
3) the purification of the final compounds 
These syntheses did not have any side product. Nevertheless, all the syntheses used a 
slight excess of the acid (antibiotics and Amphotericin B), so it was necessary to 
remove the excess in the end. 
To remove the excess of beta-lactamic antibiotics (Ampicillin, Penicillin G and 
Amoxicillin) it was used a similar method to the one Ohno and co-workers had used: a 
mixture of f acetonitrile and methanol (9:1) to induce the crystallization of the antibiotic 
excess and then, the crystals were removed by filtration. 
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In the case of Amphotericin B, it was necessary to modify the process. In this case, after 
2 h of reaction, in solution, it was observed that the solution had some undissolved 
powder. To remove these impurities, first the solution was filtered. After filtration in 
order to remove any residues of triethylammonium, dry calcium carbonate was added. 
Then we filtered the solution and evaporated the solvent. The analysis confirmed that 
ILs had been obtained ILs based on amphotericin B. 
8.1.2 Biological Studies 
In this work, the new synthesized ILs based on Ampicillin were the most studied in 
terms of biological studies. The studies of the antibacterial activity against resistant 
strains and also their anti-tumoral activity were made for the first time with these 
ampicillin-ILs. 
The analysis of the results for the antibacterial activity demonstrated that the lowest 
MIC values of Ampicillin ILs used are for Ampicillin ILs containing apolar cations 
such as [P6,6,6,14][Amp] and [C16Pyr][Amp]. Probably because highly polar cations like 
[Cholin] or [C2OHMIM]  are more prone to stay in aqueous solution instead of in 
hydrophobic cell membranes and therefore anchor themselves to ampicillin anions (ion 
trapping effect)186. This could lead the correspondent ampicillin salts to stay in aqueous 
solution where they could eventually could be hydrolysed. These results are according 
to the literature which says that the increase of hydrophobicity and the increase of the 
alkyl chain increase the toxicity25,155,157,191. These studies describe the toxicity of 
imidazolium, pyridinium, quaternary ammonium and phosphonium cations in several 
microorganisms such as rods, cocci and fungi155,157,191 and on human colon carcinoma 
cell line25,192. 
These results suggest that antibiotic APIs-ILs help in the delivery of an antibacterial 
agent [Amp] to some Gram-negative bacteria that developed resistance against β-
lactam antibiotics187,189, most probably acting as a lipophilic phase transfer agent across 
the outer membrane of the bacteria as referred by Lehn et al.190 Many more studies are 
needed, in particular, to study the mechanism of action of the ILs. The understanding 
of this mechanism could be of extreme importance to fight bacterial resistance, because 
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it could lead to the finding of the right cation needed to conjugate with the antibiotic 
that could fight resistant bacteria. 
The study of the anti-tumoral activity was based on Kumar work23,31. Kumar had 
studied the anti-tumoral activity of imidazolium23, phosphonium31 and ammonium31 
ILs and because the ILs based on ampicillin have all kinds of these cations 
(imidazolium, phosphonium and ammonium), we decided to study these ILs in several 
cancer cell lines. The results obtained demonstrated the potential of these organic salts 
as selective anti-tumour agents. For example, [C2OHMIM][Amp] possesses relevant 
discriminative and anti-proliferative activity against five different human cancer cell 
lines, in particular T47D (breast), PC3 (prostate), HepG2 (liver), MG63 (osteosarcoma) 
and RKO (colon) and low or none anti-proliferative activity against two primary 
human cell types: skin fibroblasts (SF) and gingival fibroblasts (GF). As expected, 
Ampicillin ILs with the [P6,6,6,14]+ cation had very high cytotoxicity in all cell lines 
studied (cancer and non-cancer cell lines). Frade et al. had already studied several 
compounds based in this cation towards other cell lines, as has already been described 
showing its toxicity25. 
The biological characterization of the ILs based on Penicillin G, Amoxicillin, and 
Amphotoricin B are still being studied. In this work, we already presented some 
preliminary studies of the anti-microbial activity of Penicillin G and Amoxicillin ILs 
against E. coli, S. aureus and S. cerevisiae. The microorganisms were chosen because they 
are the classic study models of Gram-negative bacteria (E. coli), Gram-positive bacteria 
(S. aureus) and S. cerevisiaes, being the most common eukaryotic model organisms. 
These preliminary studies once again show that the presence of the cation [P6,6,6,14]+ (an 
apolar cation with large alkyl chain) led to a bigger antimicrobial activity.  
In the case of Amphotericin B ILs, studies are being prepared to study the activity 
against several strains of fungals Aspergillus fumigatus, Candida albicans and 
Sacharomyces cerevisiae. Because Amphotericin B is also the most important drug for the 
treatment of visceral and cutaneous leishmaniasis, studies on Leishmania (visceral and 
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cutaneous) will also be made in the future. Besides the solubility studies of ILs based 
on Amphotericin B are being prepared. 
8.2 Conclusion 
This Thesis is mainly focused on the synthesis of ILs based on APIs (Chapters 4 and 8) 
and their biological analysis (Chapter 5, 6 and 7). The use of ILs as solvents for 
synthesis is the major application of ILs. There is no doubt that ionic liquids are 
promising alternative solvents in synthesis, often improving the efficiency and 
sustainability of the synthesis. This work both anticipates and contributes to the 
interest of the pharmaceutical industry in ILs-APIS. It also demonstrates some new 
methods of preparing ILs-APIs and shows some of their potential applications. 
After the synthesis one of the focuses was on anti-bacterial activity on resistant strains. 
As said previously, the emergence of multi-drug resistant organisms has limited 
clinicians to the number of effective anti-infective agents available for treatment. 
Therefore, there is a need to reuse and find new applications for some of the drugs, not 
only for economic reasons but also to find new ways of therapy and treatment which 
will allow some drugs to be reconsidered. Based on Kumar work23,31, it was evaluated 
the anti-proliferative activity of this compounds on human cell line (cancer and non-
cancer) to find new alternative to chemotherapy. 
This work brings some new perspectives for the use of ILs. The main achievements are 
summarized in the following topics: 
a) Synthesis – A new sustainable strategic methodology was developed for the 
synthesis of ILs based APIs. This method is more useful when the exchange by acids 
weaker than hydrohalic acids91 cannot be efficiently performed. It is halogenated 
solvents free and the resin used can be recovered. In this work we have successfully 
synthesised the following ILs based on APIs with good yields, completely 
characterized (1H-NMR, 13C-NMR, IR and mass spectra): 
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 6 ILs based on ampicillin: [TEA][Amp], [P6,6,6,14][Amp], 
[C16Pyr][Amp], [Cholin][Amp], [EMIM][Amp], 
[C2OHMIM][Amp]. 
 4 ILs based on amoxicillin: [P6,6,6,14][Amx], [C16Pyr][Amx], 
[EMIM][Amx], [C2OHMIM][Amx]. 
 6 ILs based on penicillin G: [TEA][Pen], [P6,6,6,14][Pen], 
[C16Pyr][Pen], [Cholin][Pen], [EMIM][Amp], [C2OHMIM][Pen]. 
 4 ILs based on amphotericin B: [C16Pyr][AmphB], 
[Cholin][AmphB], [C2OHMIM][AmphB], [C3OMIM][Amp].  
The method of purification developed for each compound was efficient and proved to 
be appropriate. It showed to be efficient not only with antibiotics but also with anti-
fungal drugs, like amphotericin B. 
b) Antimicrobial activity – The biological activity for the ILs based on antibiotics 
showed us that ILs based on antibiotics could lead to alternative ways of fighting 
bacteria and even resistant bacteria. This proves that with a careful selection of the 
organic cation, it is possible to provoke important biological alterations in their 
antibacterial properties. In summary: 
 [C16Pyr][Amp] demonstrated the highest potential in reversion of 
resistance against Gram-negative resistant bacteria (E. coli TEM 
CTX M9 and E. coli CTX M2, RDIC > 1000 and 100 respectively); 
 [P6,6,6,14][Amp] with RDIC values > 10 against E. coli TEM CTX M9 
and E. coli CTX M2 was also able to fight the resistant bacteria 
presented. 
 The use of RDIC values allows a better understanding of the MIC 
values, as well as the evaluation of the real effect of ILs-APIs 
activity. 
The application of ILs based on antimicrobial agents in fighting infections may help to 
decrease the nosocomial infections (in terms of morbidity and mortality) and the costs 
associated to them. 
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a) Human cell line studies – besides the antimicrobial activity studies which were 
made for the ampicillin ILs, we also studied the toxicity effect of these 
compounds on two primary human cell types, namely, skin and gingival 
fibroblasts (SF and GF, respectively) and five cancer cell lines such as T47D 
(ductal breast epithelial tumour cell line), PC3 (prostate cancer cell line), HepG2 
(hepatocellular liver carcinoma cell line), MG63 (osteosarcoma cell line) and 
RKO (colon cancer cell line). In summary: 
 [C2OHMIM][Amp] showed the highest cytotoxicity against five 
different cell lines (T47D, PC3, HepG2, MG63  and RKO) and 
very low cytotoxicity against two primary cell lines (skin (SG) 
and gingival fibroblasts (GF); 
  [Na][Amp] mostly did not show activity; 
 [P6,6,6,14][Amp] was the most toxic; 
 [TEA][Amp] and [Cholin][Amp] were the least toxic. 
It is important to note that the correct choice of the cations and anions could render the 
salts or the ILs with specific activity against different tumour cell lines, and, in a 
broader way, modulate the final biological properties of the ILs9,23,31,142,155. This is in 
accordance with the recently proposed idea that neutral ionic liquids can modulate the 
biopharmaceutical drug classification system (BCS)1 of an active pharmaceutical 
ingredient and therefore enhance its membrane transport, as recently shown with 
protic ionic liquids, by other researchers15. 
This research also offers the groundwork for the application of this technology in other 
fields of the pharmaceutical industry. In addition to targeting drug-resistant or 
pathogenic bacteria, the consideration of ILs based on ampicillin as anti-tumour agents 
can be useful from this research. Likewise, this may be beneficial in designing new 
agents as anti-epileptic or anti-fungal drugs. The simple and rapid synthesis of ILs 
from active pharmaceuticals allows this flexible, pragmatic approach to lead to the next 
generation of combination drug therapy. 
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8.3 Future Work 
These methods of synthesis developed and studied in the present work seem to be 
suitable on what concerns the practical application for synthesis of ILs with other APIs, 
for example, for the synthesis of other anti-epileptics like valproic acid, anti-cancer 
drugs or any other kind of drugs. 
Bacteria resistance is a well-known problem. Therefore, these promising results could 
lead to further studies in order to better understand the resistance mechanism and how 
ILs based on antibiotics could act to eliminate or fight that resistance. First of all, it is 
necessary to study the bacteria activity of ILs based in amoxicillin and penicillin G 
against resistant bacteria. Then, it is necessary to study the mechanism of action of this 
ILs based on antibiotics in bacteria and resistant bacteria to better understand how they 
act. 
The biological activity of ILs based on Amphotericin B is already in progress, so there 
is a need to further understand their behaviour. ILs based on Amphotericin B are being 
analysed to study their mechanism of action in Aspergillus fumigatus, which could help 
to understand the fungicidal activity of these compounds.  
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